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Metoder for å måle utfall av behandling hos pasienter med prostatakreft uten 
spredning.
Prostatakreft uten påvist spredning kan behandles med operasjon, strålebehandling 
med eller uten hormonbehandling, eller hormonbehandling alene. Svært mange menn 
med nylig påvist prostatakreft vil imidlertid kunne leve i mange år uten plager av 
sykdommen også uten behandling, og en stor andel dør til slutt av helt andre årsaker 
enn prostatkreft. Man mangler imidlertid helt sikre metoder for å velge ut pasienter 
som ikke trenger behandling, men i noen tilfeller hvor sykdommen er i tidlig fase er et 
regelmessig kontrollopplegg hvor kurativ behandling iverksettes først hvis sykdomen 
viser tegn til utvikling, forsvarlig. Imidlertid kan prostatakreft også være en agressiv 
sykdom med stor risiko for spredning og forkortet levetid. Pasienter med nylig påvist 
prostatakreft uten spredning og intermediær til høy risiko for progresjon regnes derfor 
å være behandlingstrengende.
Det kan ta mange år før man merker symptomer på et tibakefall etter en 
behandling som ikke har gitt ønsket kurasjon. Da vil sykdommen ofte ha kommet for 
langt til å kunne helbredes. Påvisning av manglende behandlingseffekt før et 
tilbakefall av sykdommen gir symptomer er imidlertid kun viktig hvis det da finnes 
effektiv tileggsbehandling. Siden overlevelse vanligvis ansees som det viktigste 
effektmålet ved kurativ kreftbehandling, blir det også viktig å avklare om det å påvise 
et tidlig tilbakefall eller manglende behandlingseffekt virkelig kan forutsi om 
pasienten på sikt vil utvikle plager av kreftsykdommen og i verste fall dø av den. I 
tillegg er det også svært viktig at bivirkningene ved utredning og behandling er så lite 
plagsomme som mulig.  
Denne avhandlingen omhandler metoder for å måle effekt/utfall av behandling 
hos pasienter med prostatakreft uten spredning. Avhandlingen inbefatter 4 studier 
hvor hovedvekten er lagt på resultater av vevsundersøkelser av prostatkjertelen etter 
åpen radikal prostatectomi (operasjon) samt resultater i form av overlevelse og 
bivirkninger når kombinert strålebehandling og hormonbehandling sammenlignes 
med hormonbehandling alene. Videre undersøkes hvor hyppig det påvises kreftceller i 
systematiske vevsprøver fra prostata 3-4 år etter at de to sistnevne behandlingene ble 
iverksatt. Endelig undersøkes bivirkninger av vevsprøvetakning etter kombinert 
strålebehandling og hormonbehandlig sammenlignet med hormonbehandling alene.  
Resultatene av studiene viser at andel pasienter som fikk prostatakreften 
fullstendig fjernet ved operasjon bedømt ut fra kirurgiske marginer gradvis økte de 
første årener etter at operasjonsmetoden ble innført. Det gir en indikasjon på at 
operasjonsteknikken bedret seg vesentlig i samme periode.  
Strålebehandling kombinert med hormonbehandling ga vesentlig bedre 
totaloverlevelse enn hormonbehandling alene. Kombinasjonsbehandlingen ga en lett 
øktning av bivirkninger, men bivirkningene var akseptable.
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De pasientene som fikk denne kombinasjonsbehandlingen hadde vesentlig 
skjeldnere gjenværende kreftceller i vevsprøvene sammenlignet med de som bare fikk 
hormonbehandling. Videre hadde pasienter med gjennværende kreftceller i 
prostatakjertelen vesentlig høyere risiko for tilbakefall påvist med blodprøve (stigende 
PSA) .
Bivirkningene ved å ta systematiske vevsprøver fra prostata etter 
hormonbehandling med eller uten stråleterapi var små og gikk stort sett over i løpet av 
en uke.
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INTRODUCTION 
 
Prostate cancer is the most common malignancy in Norwegian males with 4168 new cases 
diagnosed in 2008. The annual incidence in Norway has been rapidly increasing since 1990 
coinciding with the introduction of the serum Prostate specific antigen (PSA) test. The majority 
of patients are now diagnosed with non-metastatic disease whereas regional and/or distant 
metastases are diagnosed in approximately 15%. Moreover, the incidence increases rapidly 
with age from the fifth decade, and approximately one in eight Norwegian men will be diagnosed 
with prostate cancer before the age of 75 (figure 1). 
 
Figure 1. Cumulative risk (%) of developing cancer in Norwegian males by the age of 
75 for selected cancers - 2004-2008 [1] 
  
 
Although prostate cancer is the second most frequent cause of cancer death responsible 
for 1090 of 5655 male cancer deaths in 2008, the prevalence in Norway is doubled in the last 
decade. As of December 31st 2008, 27570 patients diagnosed with the disease were alive. The 
5 years relative survival in localised disease exceeded 95% in 2004-08 as compared to 70% in 
1988-93.  In patients with distant metastasis, the trend was relatively stable with only a few 
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percentage points increase in 5 years relative survival, reaching 30% in 2004-08. Whereas the 
prostate cancer mortality rate increased steadily from the 1970s until 1996, there is now 
evidence that the rate is declining [1]. The increasing prostate cancer incidence seems to be 
closely related to measurement of PSA in serum (s-PSA), and the improved survival can in part 
be explained by a stage migration towards localised disease with more indolent and slowly 
progressing tumours (“insignificant cancers”) at diagnosis. On the other hand, it is likely that 
curative therapy contributes to the favourable trend observed in the recent years [2]. 
Etiology  
 
Huggins and Hodges demonstrated the testosterone dependent nature of prostate cancer in the 
early 1940s [3]. In benign prostatic stromal and epithelial cells as well as in cancer cells, 
testosterone entering from circulation is reduced to dihydrotestosterone (DHT) and act as a 
growth factor forming a complex with the androgen receptor (AR) which enters the nucleus 
(figure 2). The modified DHT-AR complex combines with specific parts of the DNA and 
stimulates m-RNA formation, successive protein synthesis (e.g. PSA) and cell proliferation [4-
6], whereas androgen depletion leads to apoptosis [7, 8]. 
 
Figure 2. The physiological mechanism of androgenic stimulation of prostate cancer cells [9]. 
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A positive family history is identified as the strongest prostate cancer risk factor with a 
11-fold higher risk in men with three first-degree relatives previously diagnosed with the 
disease [10]. Moreover, American men of African origin has an almost 60% increased relative 
risk of developing prostate cancer and a doubled risk of prostate cancer death as compared to 
those of European origin [11]. Although the genetic mechanisms in hereditary prostate cancer 
are not fully understood, several prostate cancer tumour suppressor genes have been identified 
[12-15]. 
In addition, there is some evidence from observational studies that diet and lifestyle 
may contribute to prostate cancer development. However, the associations seems to be weak, 
especially in localized disease [16]. In a recent meta-analysis, a relative risk of 1.05 per 
5 kg/m2 increment of body mass index was found [17], suggesting that obesity may be a 
prostate cancer risk factor. Although a high intake of n-6 fatty acids is proposed to increase 
prostate cancer risk [16], the association between diet and prostate cancer remains unclear. 
For instance, supplemental and dietary calcium was found to be associated with an increased 
risk in two observational studies [18, 19], whereas a possible protective effect was found in a 
randomized controlled trial (RCT) in which patients were allocated to a daily intake of 
supplementary calcium or placebo [20]. A high dietary or supplemental intake of several 
nutrients such as vitamin E, selenium as well as lycopene which is found in tomatoes is 
suggested to be associated with prostate cancer risk reduction [21-23].  
Diagnosis 
 
Localised prostate cancer is most commonly asymptomatic, but some men may experience 
lower urinary tract symptoms. In Norwegian men, the diagnosis of non-metastatic prostate 
cancer is most commonly established following s-PSA measurement and/or digital rectal 
examination (DRE) due to concern about prostate cancer, and rarely due to urinary symptoms 
[24]. 
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Prostate specific antigen 
The serine protease PSA is secreted from the prostate glands into the seminal fluid. PSA is 
responsible for semen liquefaction, and was characterized and detected in serum around 1980 
[25, 26]. Measurement of s-PSA has become an important diagnostic tool as an elevated serum 
level is strongly associated with prostate cancer [27]. On the other hand, benign prostatic 
disorders such as benign prostatic hyperplasia and prostatitis are also associated with elevated 
s-PSA [28]. Moreover, there is no distinct s-PSA cut-off value below which the prostate cancer 
diagnosis can be excluded. In the US Prostate Cancer Prevention Trial, Thompson et al. found 
prostate cancer in 15% of men with a s-PSA value of <4 ng/ml, of which 15% had histological 
aggressive tumours (Gleason score of >7) [29]. In attempt to increase the sensitivity and 
specificity of the s-PSA test as well as its ability to predict prognosis, several modifications 
have been introduced. A PSA velocity (increasing PSA over time) of >0.75 ng/ml/year is 
predictive of prostate cancer in undiagnosed patients [30], whereas a PSA doubling time 
(PSADT) >4 years indicates a favourable prognosis in diagnosed patients [31]. Moreover, a low 
percentage of free s-PSA (%fPSA) is shown to be predictive of cancer diagnosis and 
histological aggressiveness [32]. However, the sensitivity, specificity and predictive properties 
of these tests are restricted [33], and the cancer diagnosis cannot be based solely on s-PSA 
testing.  
The issue of PSA-screening in healthy men has been a matter of debate since the 
introduction of the test. Recently, the European Randomized Study of Screening for Prostate 
Cancer demonstrated a 20-30% reduced relative risk of dying from prostate cancer in men 
randomized to PSA-screening with a cut-off value of 3-4 ng/ml [34, 35]. However, PSA-
screening resulted in substantial overdiagnosis and overtreatment in patients with insignificant 
cancer. More than 1000 men had to be screened to prevent one prostate cancer death, and a 
total of 48 men had to undergo radical treatment. Furthermore, no difference in prostate cancer 
mortality was found in the North American randomized Prostate, Lung, Colorectal, and 
Ovarian (PLCO) Cancer Screening Trial in which a PSA cut-off level of 4.0ng/ml was used 
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[36]. By contrast, a much lower number needed to screen (293) and number needed to treat (12) 
to prevent one prostate cancer death was found in the recently published Göteborg randomised 
population-based prostate-cancer screening trial [37] 
According to the recently published Norwegian Directory of Health’s guidelines on 
diagnosis, treatment and monitoring of prostate cancer, the PSA test can be offered on an 
individual basis, but should not be taken unless the patient is fully informed about the 
consequences. Population based PSA-screening is not implemented in the official Norwegian 
health care program [38] .  
 
Trans rectal ultrasound-guided prostate biopsy 
The suspicion of prostate cancer should be verified by a histopathological diagnosis. In order 
to decrease the false-negative rate following prostate biopsy, systematic trans rectal 
ultrasound (TRUS)-guided biopsy (sextant biopsy) was introduced in the 1980s [39]. 
Currently, dependent on prostate volume, 10-12 biopsy cores are usually taken as a higher 
number of biopsy cores is shown to increase the detection rate. In a series of 1051 men with a 
serum-PSA of 4-10 ng/ml that underwent sextant biopsy and 2 additional transition zone 
biopsies the detection rate of cancer was 22%. In patients with negative biopsies, the detection 
rates in successive biopsies were 10, 5 and 4%, respectively [40]. Moreover, repeated biopsy 
with up to 40 cores (saturation prostate biopsy) in previously biopsy-negative men with a high 
suspicion of cancer yield detection rates of 13.5-41% [41-48]. In men with an elevated s-PSA 
and negative random biopsies, magnetic resonance spectroscopic imaging as well as dynamic 
contrast-enhanced magnetic resonance imaging may be used to localise tumour foci as targets 
for successive TRUS-guided biopsies  [49]. 
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Histopathology 
The vast majority of malignant prostate tumours are adenocarcinomas arising from the 
glandular epithelium, and histological tumour grade is shown to be a significant prognostic 
factor [50]. In the World Health Organisation (WHO) system, the tumour is graded on a 3-
point scale based on evaluation of nuclear anaplasia and glandular differentiation. A higher 
tumour grade corresponds with increasingly malignant morphologic appearance, and WHO-
grade 1-3 denotes well, intermediate and poorly differentiated tumours, respectively [51]. The 
Gleason grading system is based on the histological architecture of the tumour in which the 
growth pattern is graded on a scale from 1 to 5. Increasing grade corresponds to increasing 
infiltrative growth and loss of glandular formation, and grade 5 denotes the most malignant 
histopathological pattern (Table 1, Figure 3). [52]. Finally, the tumour is assigned a Gleason 
score defined as the sum of the two most commonly occurring grade patterns [51, 53]. The 
Gleason system appears to be superior to the WHO system in assessing the prognostic impact 
of tumour grade, and is internationally accepted as the reference grading system [54, 55].  
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Figure 3. Schematic diagram of the modified Gleason grading system [52] 
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Staging  
Patients diagnosed with prostate cancer should undergo a staging procedure according to the 
Tumour Node Metastasis (TNM) classification system of malignant tumours (Table 2) in 
order to select those eligible for curative treatment, and to exclude patients with metastasis 
from inappropriate local therapy [56]. 
 15
 The clinical tumour (cT) stage is usually assessed by a DRE and transrectal 
ultrasonography (TRUS) [57]. Pathological tumour (pT) stage as assessed following radical 
prostatectomy resembles cT-stage, although the cT1 categories are excluded. Localised 
disease include non-metastatic T1 and T2 (organ confined) and locally advanced tumours that 
penetrate beyond the prostatic capsule into adjacent tissues (>T3) [56].
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Table 2. TNM clinical classification for tumours of the prostate 
T - Primary Tumour 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
T1 Clinically inapparent tumour not palpable or visible by imaging 
T1a Tumour incidental histological finding in 5 % or less of tissue resected 
T1b Tumour incidental histological finding in more than 5 % of tissue resected 
T1c Tumour identified by needle biopsy (e.g., because of elevated PSA) 
T2 Tumour confined within prostate1
T2a Tumour involves one half of one lobe or less 
T2b Tumour involves more than one half of one lobe, but not both lobes 
T2c Tumour involves both lobes 
T3 Tumour extends throughout the prostatic capsule2
T3a Extracapsular extension (unilateral or bilateral) 
T3b Tumour invades seminal vesicle(s) 
T4 Tumour is fixed or invades adjacent structures other than seminal vesicles: Bladder 
neck, external sphincter, rectum, levator muscles, or pelvic wall 
N - Regional Lymph Nodes 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
M - Distant Metastasis 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
1. Tumour found in one or both lobes by needle biopsy, but not palpable or visible by imaging, is classified as T1c 
2. Invasion into the prostatic apex or into (but not beyond) the prostatic capsule is not classified as T3, but as T2 
 
 The regional lymph nodes lie within the confines of the true pelvis [56]. Imaging 
techniques such as magnetic resonance imaging (MRI) and computer tomography (CT) are 
frequently used in lymph node staging. Although the relatively low sensitivity and specificity 
of these techniques may be improved with contrast-enhanced MRI and positron emission 
tomography (PET) [58, 59], a pelvic lymph node dissection (PLND) is regarded to be the gold 
standard of nodal staging [60]. The PLND may be performed as an open or laparoscopic 
procedure, either prior to definitive local therapy (e.g. radiotherapy) or simultaneously with 
prostatectomy [61-63]. The majority of lymph node metastases are found outside the obturator 
fossa. Thus, according to recent guidelines, the PLND should be extended to include the area 
up to the bifurcation of the common iliac artery and down to the epigastric artery [60, 61]. 
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As haematogenous prostate cancer dissemination most frequently affects the skeleton, 
a bone scan has traditionally been used to determine the M-stage. Although the sensitivity is 
high, the specificity may be further improved using MRI as a supplement [64, 65].  
 
Risk assessment in presumed non-metastatic prostate cancer  
Several models and nomograms combining s-PSA, clinical tumour (cT) stage and Gleason 
score have been developed in order to predict likelihood of organ confined disease, 
extraprostatic tumour extension, seminal vesicle involvement, lymph node metastasis as well 
as relapse following radical therapy. The risk of an unfavourable pT and pN stage and 
outcome increases with serum level of PSA, higher Gleason score and advanced cT-stage [66-
70]. Moreover, 3 risk categories for treatment failure following curative therapy have been 
identified (Table 3) [71]. All three criterions must be fulfilled in the low risk group, whereas 
one criterion is sufficient in the intermediate and high risk groups. 
 
Table 3. Risk group categories in presumed localised prostate cancer, according to D’Amico 
[71]. 
   
Risk group PSA GS cT-stage 
Low  < 10 ng/ml < 6 < T2a 
Intermediate  >10 and < 20 ng/ml 7 T2b 
High  > 20 ng/ml 8-10 > T2c 
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Measures of outcome in non-metastatic prostate cancer  
 
Survival is commonly regarded to be the most important time-dependent end-point in curative 
cancer therapy [72]. In general, modeling of time to event data is done using various methods 
of survival analysis. The event of interest in overall survival (OS) is death of any cause. All 
other patients are censored at the time of last follow-up. When cancer specific survival (CSS) 
is estimated, patients who died from other causes are censored at the time of death [73]. Other 
commonly reported outcomes are disease-free survival (DFS), progression-free survival 
(PFS) and recurrence free-survival (RFS) in which the events of interest are lack of cure, 
progression and recurrence, respectively. In these instances, also death of any cause is defined 
as an event. Moreover, in prostate cancer, biochemical DFS, PFS and RFS relates to a 
threshold PSA-value above which the event is defined to have occurred [74]. Clinical DFS, 
PFS and RFS denote survival without local recurrence or metastasis, whereas metastasis-free
survival (MFS) is an estimate of the probability of surviving without metastasis. Often, time-
dependent clinical outcomes in terms of probabilities of recurrence, progression and 
metastasis are reported in clinical trials using survival analysis. In these cases, only recurrence 
or progression are defined as events, and patients who die without the event are censored [75].  
However, otherwise healthy men with newly diagnosed prostate cancer may have a 
life expectancy of many years even without therapy [76], and a high proportion will 
eventually die from other causes without clinical symptoms of their cancer [77-79]. On the 
other hand, clinically apparent (symptomatic) relapse or disease progression may occur after 
several years following therapy [80, 81]. In these patients, an earlier diagnosis of treatment 
failure is beneficial only if effective therapy is available. Thus, a key question is how well 
surrogate outcome measures such as histopathological outcome and biochemical recurrence 
following therapy predict survival [75].  
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In patients with non-metastatic prostate cancer, morbidity may be caused by 
progressive disease as well as side-effects from diagnostic procedures and therapy. Thus, a 
survival benefit gained from diagnosis and successive therapy must always be weighed 
against adverse effects on quality of life (QOL). This is particularly important in non-
metastatic prostate cancer due to the long natural history of the disease [76].  
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therapy (flutamide, bicalutamide, nilutamide) [82]. The term total androgen blockade (TAB) 
denotes combinations of castration and a peroral antiandrogen. 
Several RCTs have explored the effect of immediate versus deferred ADT mono-
therapy (orchiectomy or LHRH-agonist) in locally advanced and/or metastatic prostate cancer 
[83-87]. In a meta-analysis including these studies, a modest OS benefit (estimated 10% 
relative risk reduction) in favour of immediate treatment was found [88]. 
Antiandrogen monotherapy yield equal survival as compared to castration therapy 
(LHRH-agonist) in M0 prostate cancer [89]. Furthermore, in the Scandinavian Prostate 
Cancer Group (SPCG) Study 6, patients with M0 prostate cancer were randomised to either 
antiandrogen (bicalutamide 150mg daily) or placebo.  Whereas a trend towards reduced OS 
was found in patients with organ confined disease on antiandrogen monotherapy, the opposite 
trend as well as an improved PFS (43% relative risk reduction in favour of bicalutamide) was 
observed in patients with locally advanced disease [90].  
Three RCTs have compared external beam radiotherapy (EBRT) with and without 3-6 
months neoadjuvant ADT (LHRH-agonist or TAB) [91-93]. In all studies, a biochemical and 
clinical DFS benefit was found in favour of neoadjuvant therapy. In a recent meta-analysis, 
the estimated relative risk reductions were 37 and 31%, respectively [94], whereas no 
difference in survival was found in a recently published RCT comparing 3 and 8 months 
neoadjuvant ADT prior to 64 Gy EBRT [95].  By contrast, prostatectomy patients do not 
benefit from neoadjuvant ADT. Ten RCTs have compared RP ± neoadjuvant ADT (LHRH-
agonist, antiandrogen or TAB). No difference in survival was found [94]. 
Although the role of ADT adjuvant to RP in non-metastatic disease is not explored in 
RCTs, immediate ADT (orchiectomy or LHRH-agonist) in pN+ patients is shown to improve 
OS with a 46% relative risk reduction as compared to ADT given at detection of symptomatic 
local recurrence and/or distant metastases [96]. Moreover, there is substantial evidence from 
RCTs that endocrine treatment adjuvant to EBRT in locally advanced and/or lymph node 
positive prostate cancer improves survival as compared to EBRT alone. In 3 of these studies 
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an absolute OS benefit of 10-20% at was found in favour of adjuvant therapy [97-99], 
whereas an absolute CSS benefit of 6% was found in one study [100]. These studies are, 
however, heterogeneous with respect to radiation dose (65-70Gy), tumour stage as well as 
timing (started prior to, under or after local therapy), duration (6 months to indefinitely) and 
type (orchiectomy vs LHRH agonist + antiandrogen) of ADT. Moreover median follow-up 
ranged from 4.5 to more than 15 years. Nonetheless, there seems to be a clear interaction 
between local therapy and adjuvant ADT. A recent meta analysis which included the RT 
studies as well as the study on RP plus immediate vs. delayed ADT [96] estimated the relative 
risk reduction of death from any cause to be 31% in favour of adjuvant therapy [88]. In the 
Early Prostate Cancer Program, patients with M0 prostate cancer were randomized to receive 
a daily dose of antiandrogen (150 mg bicalutamide) or placebo in addition to standard care. A 
sub-group analysis demonstrated a 35% relative risk reduction of death from any cause in 
patients with locally advanced prostate cancer treated with RT and bicalutamide [101]. One 
RCT has examined short (6 months) vs. long (3 years) duration of ADT started 
simultaneously with EBRT. In this trial a small absolute OS benefit (3.8%) in favour of 3 
years ADT was found [102].  
Radical prostatectomy 
Patients with clinically localised prostate cancer and a life expectancy >10 years have been 
treated with surgery for decades [60] although only one published RCT has compared RP 
with observation alone (“watchful waiting”). The SPCG-4 study which included men with 
presumed organ confined prostate cancer (T1-T2b N0 M0) demonstrated a risk reduction of 
metastasis, cancer specific mortality as well as a 5% absolute reduction in over all mortality at 
10 years in favour of open radical retropubic prostatectomy (RRP) [103]. However, the 
overall mortality risk reduction was no longer statistically significant after an additional three 
years follow-up [104].  
In the past decade, minimal invasive techniques such as laparoscopic RP [105], and 
more recently robot-assisted laparoscopic RP [106], have been introduced. RCTs comparing 
 21
an absolute OS benefit of 10-20% at was found in favour of adjuvant therapy [97-99], 
whereas an absolute CSS benefit of 6% was found in one study [100]. These studies are, 
however, heterogeneous with respect to radiation dose (65-70Gy), tumour stage as well as 
timing (started prior to, under or after local therapy), duration (6 months to indefinitely) and 
type (orchiectomy vs LHRH agonist + antiandrogen) of ADT. Moreover median follow-up 
ranged from 4.5 to more than 15 years. Nonetheless, there seems to be a clear interaction 
between local therapy and adjuvant ADT. A recent meta analysis which included the RT 
studies as well as the study on RP plus immediate vs. delayed ADT [96] estimated the relative 
risk reduction of death from any cause to be 31% in favour of adjuvant therapy [88]. In the 
Early Prostate Cancer Program, patients with M0 prostate cancer were randomized to receive 
a daily dose of antiandrogen (150 mg bicalutamide) or placebo in addition to standard care. A 
sub-group analysis demonstrated a 35% relative risk reduction of death from any cause in 
patients with locally advanced prostate cancer treated with RT and bicalutamide [101]. One 
RCT has examined short (6 months) vs. long (3 years) duration of ADT started 
simultaneously with EBRT. In this trial a small absolute OS benefit (3.8%) in favour of 3 
years ADT was found [102].  
Radical prostatectomy 
Patients with clinically localised prostate cancer and a life expectancy >10 years have been 
treated with surgery for decades [60] although only one published RCT has compared RP 
with observation alone (“watchful waiting”). The SPCG-4 study which included men with 
presumed organ confined prostate cancer (T1-T2b N0 M0) demonstrated a risk reduction of 
metastasis, cancer specific mortality as well as a 5% absolute reduction in over all mortality at 
10 years in favour of open radical retropubic prostatectomy (RRP) [103]. However, the 
overall mortality risk reduction was no longer statistically significant after an additional three 
years follow-up [104].  
In the past decade, minimal invasive techniques such as laparoscopic RP [105], and 
more recently robot-assisted laparoscopic RP [106], have been introduced. RCTs comparing 
 21
an absolute OS benefit of 10-20% at was found in favour of adjuvant therapy [97-99], 
whereas an absolute CSS benefit of 6% was found in one study [100]. These studies are, 
however, heterogeneous with respect to radiation dose (65-70Gy), tumour stage as well as 
timing (started prior to, under or after local therapy), duration (6 months to indefinitely) and 
type (orchiectomy vs LHRH agonist + antiandrogen) of ADT. Moreover median follow-up 
ranged from 4.5 to more than 15 years. Nonetheless, there seems to be a clear interaction 
between local therapy and adjuvant ADT. A recent meta analysis which included the RT 
studies as well as the study on RP plus immediate vs. delayed ADT [96] estimated the relative 
risk reduction of death from any cause to be 31% in favour of adjuvant therapy [88]. In the 
Early Prostate Cancer Program, patients with M0 prostate cancer were randomized to receive 
a daily dose of antiandrogen (150 mg bicalutamide) or placebo in addition to standard care. A 
sub-group analysis demonstrated a 35% relative risk reduction of death from any cause in 
patients with locally advanced prostate cancer treated with RT and bicalutamide [101]. One 
RCT has examined short (6 months) vs. long (3 years) duration of ADT started 
simultaneously with EBRT. In this trial a small absolute OS benefit (3.8%) in favour of 3 
years ADT was found [102].  
Radical prostatectomy 
Patients with clinically localised prostate cancer and a life expectancy >10 years have been 
treated with surgery for decades [60] although only one published RCT has compared RP 
with observation alone (“watchful waiting”). The SPCG-4 study which included men with 
presumed organ confined prostate cancer (T1-T2b N0 M0) demonstrated a risk reduction of 
metastasis, cancer specific mortality as well as a 5% absolute reduction in over all mortality at 
10 years in favour of open radical retropubic prostatectomy (RRP) [103]. However, the 
overall mortality risk reduction was no longer statistically significant after an additional three 
years follow-up [104].  
In the past decade, minimal invasive techniques such as laparoscopic RP [105], and 
more recently robot-assisted laparoscopic RP [106], have been introduced. RCTs comparing 
 21
an absolute OS benefit of 10-20% at was found in favour of adjuvant therapy [97-99], 
whereas an absolute CSS benefit of 6% was found in one study [100]. These studies are, 
however, heterogeneous with respect to radiation dose (65-70Gy), tumour stage as well as 
timing (started prior to, under or after local therapy), duration (6 months to indefinitely) and 
type (orchiectomy vs LHRH agonist + antiandrogen) of ADT. Moreover median follow-up 
ranged from 4.5 to more than 15 years. Nonetheless, there seems to be a clear interaction 
between local therapy and adjuvant ADT. A recent meta analysis which included the RT 
studies as well as the study on RP plus immediate vs. delayed ADT [96] estimated the relative 
risk reduction of death from any cause to be 31% in favour of adjuvant therapy [88]. In the 
Early Prostate Cancer Program, patients with M0 prostate cancer were randomized to receive 
a daily dose of antiandrogen (150 mg bicalutamide) or placebo in addition to standard care. A 
sub-group analysis demonstrated a 35% relative risk reduction of death from any cause in 
patients with locally advanced prostate cancer treated with RT and bicalutamide [101]. One 
RCT has examined short (6 months) vs. long (3 years) duration of ADT started 
simultaneously with EBRT. In this trial a small absolute OS benefit (3.8%) in favour of 3 
years ADT was found [102].  
Radical prostatectomy 
Patients with clinically localised prostate cancer and a life expectancy >10 years have been 
treated with surgery for decades [60] although only one published RCT has compared RP 
with observation alone (“watchful waiting”). The SPCG-4 study which included men with 
presumed organ confined prostate cancer (T1-T2b N0 M0) demonstrated a risk reduction of 
metastasis, cancer specific mortality as well as a 5% absolute reduction in over all mortality at 
10 years in favour of open radical retropubic prostatectomy (RRP) [103]. However, the 
overall mortality risk reduction was no longer statistically significant after an additional three 
years follow-up [104].  
In the past decade, minimal invasive techniques such as laparoscopic RP [105], and 
more recently robot-assisted laparoscopic RP [106], have been introduced. RCTs comparing 
 22
the various RP techniques with respect to oncological outcome are, however, non-existent 
[107]. 
Radiotherapy
Several RCTs have shown that escalation of the EBRT dose from the traditionally used 64-70 
Gy to 74-79.2 Gy with conventional fraction doses (1.8 – 2.0 Gy) improves biochemical 
outcome (10-27% absolute risk reduction of biochemical recurrence) [108-111]. Although 
none of these studies demonstrated an OS benefit, there seems to be a clear dose-response 
relationship in radiotherapy for prostate cancer. In high dose-rate brachytherapy, radioactive 
iridium (192Ir) probes are temporarily implanted in the prostate gland, usually delivering 10-20 
Gy in 2-4 fractions combined with conventional fractionated 45-54 Gy EBRT [112]. In low 
dose-rate brachytherapy, permanent radioactive Iodine (125I) or Palladium (103Pd) implants are 
used, preferably in low-risk patients [113]. By both techniques, a normalized dose equivalent 
of 2 Gy per fraction of more than 100 Gy may be delivered safely [114, 115]. However the 
efficacy of brachytherapy is not compared with dose escalated EBRT in RCTs. 
 In hypofractionated EBRT, radiation doses biologically equivalent to those given with 
conventionally fractionated irradiation are delivered over a shorter period of time. Two RCTs 
have compared hypofractionationated with conventionally fractionated (2 Gy in 32-33 
fractions) EBRT. Equal survival was reported in both studies [116, 117].   
 Although the pelvic lymph nodes received 44-50 Gy irradiation in the RCTs that 
compared RT +/- long term ADT, [97, 99, 100, 102], the role of prophylactic pelvic lymph 
node irradiation is controversial. One large RCT demonstrated a PFS benefit of whole pelvic 
as compared to prostate only irradiation but no difference in OS. However, two other RCTs 
failed to demonstrate a survival benefit in favour of pelvic lymph node irradiation [118-120]. 
 Three RCTs have explored to role of adjuvant radiotherapy following RP in locally 
advanced prostate cancer. An improved biochemical DFS was found in two studies in which 
patients with pT3 and/or margin positive tumours were randomised to 60-64 Gy RT adjuvant 
or observation [121, 122]. In the Southwest Oncology Group (SWOG) trial number 8794, 
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patients with pT3N0M0 prostate cancer were randomized to receive either 60-64 Gy adjuvant 
EBRT or observation. At long-term follow up (median 12.7 and 12.5 years in the two groups, 
respectively) a 29% relative risk reduction of metastasis as well as an 11% absolute improved 
OS was found in favour of adjuvant RT [123].  
 Whether the observed survival benefit from combined EBRT and ADT as primary 
treatment in M0 disease was due to the ADT alone was until recently unresolved. This issue is 
addressed in study 2 in this thesis, and will be discussed in detail in subsequent sections. 
 
Surrogate measures of outcome in non metastatic prostate cancer  
Several surrogate outcome measures have been introduced to detect persistent cancer 
following therapy in asymptomatic patients at an early and potentially curable stage.  
Post-treatment PSA in outcome assessment  
Following RP, s-PSA should remain below the detection level as an indication of no residual 
cancer. Two consecutive s-PSA measurements of >0.2 ng/ml is a generally accepted 
definition of biochemical recurrence [60, 124]. Following RP, biochemical recurrence occurs 
in around one per cent in low-risk patients and in more than 60% high-risk patients [125-128]. 
In a retrospective study by Uchio et al, biochemical recurrence after RP was found to be a 
significant predictor of prostate cancer mortality with an absolute increased risk of 21% at 15 
years [129]. Moreover, Pound et al. reported in their retrospective study which included 1997 
men operated on with RP that an early biochemical recurrence (< 2 years vs. > 2 years) as 
well as a short PSADT (cut-off 10 months) was significant predictors of distant metastasis 
[81]. 
A detectable s-PSA level following curative RT does not necessarily imply treatment 
failure, as PSA may be produced in residual benign prostate tissue. Variations in post-RT s-
PSA levels not due to disease progression is most commonly observed the first two years after 
RT [130]. According to the 2006 American Society of Therapeutic Radiology (ASTRO) 
recommendation, PSA-recurrence post-RT is defined as a 2.0 ng/ml increase above a 
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previous nadir-value [131]. Dependent on radiation dose, biochemical recurrence following 
EBRT occurs in 16-35% [108-111]. Consistent with data on RP, biochemical recurrence after 
EBRT is found to be a significant predictor of prostate cancer mortality. In a retrospective 
study, patients with biochemical recurrence according to the ASTRO-definition were found to 
have a 41% higher absolute risk of dying from prostate cancer at 15 years as compared to 
patients without biochemical failure [129]. In another cohort study with retrospective design, 
patients with an early biochemical recurrence (<18 months) had a 5-year prostate cancer 
mortality of 36% as compared to 6% in late PSA-relapsing patients [132]. In addition, 
biochemical recurrence with a short PSADT is found to be an independent predictor of 
clinical recurrence and cancer specific mortality in several observational studies [132-134].  
 Biochemical progression in castration resistant prostate cancer is highly predictive of 
prostate cancer mortality, especially in patients with a short PSADT [135]. In a prospective 
study, patients with non-metastatic prostate cancer and biochemical progression on castration 
therapy only had a median metastasis-free survival of approximately 30 months. PSA velocity 
was an independent predictor of time to first bone metastasis, metastasis-free and overall 
survival [136]. On the other hand, the natural history of biochemical progression in non-
metastatic prostate cancer on antiandrogen monotherapy is poorly described in the literature 
[89, 90, 137].  
Histopathological outcome 
In RTCs, neoadjuvant ADT given prior to RP is shown to improve local control in terms of 
negative surgical margins, although no survival benefit was observed [138-141]. However, 
central pathology review of the prostatectomy specimens in a subgroup analysis of the 
European Organisation for Research and Treatment of Cancer (EORTC) trial 22911 (adjuvant 
RT vs. observation following RP in pT3 and/or margin positive cancer) demonstrated a 29% 
absolute improved biochemical DFS in favour adjuvant irradiation in patients with positive 
surgical margins. On the other hand, no benefit from RT was found in patients with margin 
negative disease [142].  Moreover, a positive surgical margin is shown to predict clinically 
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important outcomes such as local recurrence, distant metastasis and prostate cancer mortality 
[143, 144]. This includes one large population based cohort study of more than 65,000 
patients operated on with RP in which the incidence of positive surgical margins ranged 
from17-43% depending on pT-stage and to a lesser extent tumour grade. In the total study 
population, a 61% relative risk reduction of prostate cancer mortality was found in favour of 
negative margins [144]. In contrast, in the SPCG-4 randomized trial, positive margins which 
were found in 35% was not an independent predictor of prostate cancer mortality. 
Extracpsular tumour growth (pT3-stage) was, however, found in 46% of the RP-specimens 
and gave a 14-fold relative risk of prostate cancer death as compared to lower pT-stages. 
Moreover, patients with high-grade tumours (Gleason score > 8) had a more than 4 times 
increased relative risk of dying from prostate cancer as compared to patients with GS 7 
tumours [104]. The combination of locally advanced and histological aggressive disease 
seems to yield a particularly unfavourable prognosis in younger men. In a large population 
based cohort study which included more than 100,000 RP-patients aged 35-74 years, the 
youngest (age 34-44 years) men with pT3, Gleason score >8 tumours had an at least 5-fold 
relative risk of dying from prostate cancer as compared to their older counterparts [145]. 
Moreover, data from recently published observational studies suggest that length of positive 
margin is predictive of biochemical recurrence [146, 147], although this findings have not 
been confirmed in other studies [148, 149]. The prognostic value of tumour volume in RP-
specimens is also controversial. Whereas some studies report a high tumour volume to be 
predictive of an adverse clinical outcome, no association was found in other studies [150, 
151].  
There is substantial evidence of a dose-response relationship in EBRT for non-
metastatic cancer prostate cancer as assessed by posttreatment biopsy. A significantly reduced 
incidence of biopsy verified residual prostate cancer (RPC) following escalation of the 
radiation dose was demonstrated in a prospective observational study in the late 1990s [152]. 
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Moreover, ADT given neoadjuvant to EBRT was shown to improve local tumour control as 
assessed by posttreatment biopsy in a RCT [153].  
In retrospective studies, RPC after EBRT is found to be predictive of distant 
metastasis as well as prostate cancer mortality. In one of these studies, the 10 year distant 
metastasis free survival in patients with and without RPC was 61% and 77%, respectively 
[154]. Another retrospective study demonstrated an 11% absolute difference in 10 years CSS 
(96 vs. 85%) in favour of patients without RPC [155]. In a recently published RCT exploring 
the effect of two different neoadjuvant ADT schemes prior to EBRT in non-metastatic 
prostate cancer, biopsy verified RPC was found to be significantly predictive of biochemical 
DFS with an approximately 40% absolute difference in favour of negative biopsy [95]. 
However, RCP is not shown to predict clinical DFS, CSS or OS in prospective studies. 
Moreover, the incidence and clinical implications of biopsy verified RPC in patients treated 
with endocrine therapy alone is unknown. 
 
Side effects from diagnostic procedures and therapy 
Diagnostic procedures as well as therapy in non-metastatic prostate cancer are associated with 
considerable side effects which may affect QOL and even be fatal. Although there is a vast 
body of literature on this issue including retrospective and prospective observational studies, 
RCTs comparing different treatment modalities with main focus on side effects have been 
virtually non-existent. Comparisons of side effects from different treatment modalities are 
hampered by the methodological variability in data acquisition (different questionnaires), 
reporting (physician vs. patient reported), and definition of function as well patient 
characteristics in the published studies [107, 156-158]. 
  Widespread PSA measurement in asymptomatic men results in a considerable over-
diagnosis of “insignificant tumours” as well as false positives [34, 36], resulting in 
psychological distress as well as unnecessary and often repeated diagnostic procedures, 
treatment and follow-up [40, 159]. 
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Side effects from diagnostic procedures and therapy 
Diagnostic procedures as well as therapy in non-metastatic prostate cancer are associated with 
considerable side effects which may affect QOL and even be fatal. Although there is a vast 
body of literature on this issue including retrospective and prospective observational studies, 
RCTs comparing different treatment modalities with main focus on side effects have been 
virtually non-existent. Comparisons of side effects from different treatment modalities are 
hampered by the methodological variability in data acquisition (different questionnaires), 
reporting (physician vs. patient reported), and definition of function as well patient 
characteristics in the published studies [107, 156-158]. 
  Widespread PSA measurement in asymptomatic men results in a considerable over-
diagnosis of “insignificant tumours” as well as false positives [34, 36], resulting in 
psychological distress as well as unnecessary and often repeated diagnostic procedures, 
treatment and follow-up [40, 159]. 
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Transient hematuria, rectal bleeding and hematospermia as well as mild pain are 
frequent and usually self-limiting side effects in diagnostic prostate biopsy. Moderate to 
severe pain is reported in 11-30 % [160-163], whereas complications that require medical or 
surgical intervention such as major bleeding, urinary retention and complicated urinary tract 
infections are rare (<1-2%) in diagnostic biopsy [160, 164-166]. However, there are no 
published reports on posttreatment prostate biopsy complications. 
The most frequent complication to PLND is symptomatic pelvic lymphocele which is 
reported in 3-18%, depending on the extent of dissection [62, 63, 167].  Other complications 
such as thrombosis and pulmonary embolism, haematoma, wound infection and sepsis are 
reported in up to 6% [62]. 
The vast majority of patients on castration therapy experience loss of sexual function 
[168], and 80% report hot flashes [169]. Moreover, castration is associated with loss in bone-
mineral density, and in a large population-based study the number needed to harm with 
respect to bone fracture within 12 to 60 months from start of therapy was estimated to be 28 
and 16 for LHRH-agonist and orchiectomy, respectively [170]. Also, castration is 
significantly associated with an increase in total cholesterol and triglyceride serum levels 
[171]. In a population-based cohort study including more than 22,000 men with prostate 
cancer, patients on castration therapy for more than 1 year had a 20% higher relative risk of 
cardiovascular morbidity compared to untreated patients [172]. Furthermore, neoadjuvant 
TAB is reported to be associated with increased mortality in patients with a history of 
myocardial infarction or congestive heart failure due to coronary heart disease [173], although 
no difference in cardiovascular mortality was found in RCTs comparing long term adjuvant 
castration with no ADT in patients receiving EBRT [97, 174]. However, the risk of 
cardiovascular morbidity in patients treated with antiandrogens is unknown, whereas mineral 
density in patients on antiandrogen monotherapy was found to be maintained at 6 years in a 
prospective cohort study [175]. Moreover, bicalutamide was superior to castration with 
respect to maintained physical capacity and sexual interest in a RCT. However, gynecomastia 
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occurred in 50% of patients on bicalutamide and in <5% following castration. [89]. Although 
rarely severe, ADT is associated with elevations in aminotransferases, slight anaemia and 
diarrhoea [176, 177]. 
In patients operated on with RP, difference in functional outcome between open and 
minimally invasive procedures (laparoscopy) is not documented [107]. Anastomotic stricture 
is reported in less than 10% in prospective non-randomized studies [178, 179], whereas 
between 30 and 50% of patients report some degree of urinary incontinence at 3 months 
follow-up. However, successive improvement occurs in the majority, and 80-92% of patients 
are continent within one year [180-184]. In a RCT, intensive pelvic floor muscle training is 
shown to enhance urinary control [184]. The reported incidence of erectile dysfunction 
(partial or complete) varies considerably in the literature from less than 10% up to 100% 
[185]. The incidence depends on surgical technique, and is low in patients selected for nerve 
sparing procedures [186, 187].  Moreover, recovery frequently occurs within two years or 
more [188]. Postoperative inguinal hernia following open RP occurs in 12-20%, most 
frequently within the first two years. The risk seems to be higher in patients previously 
operated on with hernioplasty and in patients with postoperative wound infections [189-192]. 
The reported incidence of other rare, although potentially serious complications, such as rectal 
injury, unexpected bleeding and venous thomboembolism is around 1% or less [193], whereas 
the 30-day mortality is estimated to be 0.5% [194]. 
Following RT, symptoms of acute radiation cystitis and prostatitis with increased 
frequency, dysuria and incomplete emptying as well as proctitis (rectal discomfort and 
increased defecation frequency) are usually transient with gradual recovery within a few 
weeks. Recovery may, however, be prolonged in patients receiving brachytherapy [193, 195-
197].  Late radiation side effects develop over years due to gradual nerve damage and changes 
in the small vessels resulting in hypoxia, mucosal thinning and fibrosis as well as 
telangiectasia formation. The risk of late toxicity is dependent on several factors including 
total irradiation dose and volume [193, 197, 198]. In a retrospective study on late urinary and 
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intestinal side effects occurring within 24-56 months after irradiation for prostate cancer, 200 
patients were compared with an age-matched control population using a self-assessment 
questionnaire. In the patient group, 50% reported some kind of urinary problems as compared 
to of 25% the controls (urgency 42 vs. 19%; starting problems 33 vs. 22%; leakage 32 vs. 
11%). Intestinal problems in the patient and control groups were reported in 14 and 59%, 
respectively (mucus 38% vs. 4%; cramp 14% vs. 5%; leakage 27% vs. 2%; blood 36% vs. 
2%). However, 90% of the irradiated patients reported the problems to be minor [199]. 
Radiation to the penile bulb and neurovascular bundles may lead to erectile dysfunction 
caused by venous insufficiency and direct nerve damage. In a prospective cohort study, 286 
and 901 prostate cancer patients aged 55–74 years received EBRT without ADT and radical 
prostatectomy, respectively. Although potency declined in both groups, erectile dysfunction 
was more prevalent in the RP group at 5 years (79 vs. 64%). On the other hand, some 
recovery was observed in the RP group between 2 and 5 years follow-up, whereas the 
function continued to decline in the EBRT group [200]. In the EBRT dose-escalation RCTs, 
no or moderately increased late side effects was found in patients receiving the higher doses 
[108-111]. Radiation induced secondary cancer is a rare, although serious side effect. A 
population-based cohort study of nearly 18000 prostate cancer patients treated with EBRT 
(47%) and prostatectomy (53%) evaluated incident cases of cancer diagnosed 60 months or 
later after therapy. The incidence of pelvic malignity such as bladder and rectal cancer as well 
as lung cancer was significantly higher patients treated with EBRT. The absolute difference in 
risk of being diagnosed these malignancies was found to be 3.9, 2.4 and 5.2%, respectively 
[201]. 
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AIMS OF THE STUDIES 
The aim of this thesis is to evaluate outcomes following therapy and a diagnostic procedure in 
patients treated for non-metastatic prostate cancer in order to answer the following specified 
research questions: 
1. Histopathological outcome following RRP in terms of locally advanced (pT3) tumours 
and intra- and extra capsular tumour margins. Research questions: 
A) Is there evidence that histopathological outcome improves over time following 
the implementation of RRP? 
B) Does patient selection and/or surgical technique influence on the 
histopathological outcome? 
2. Clinical outcome (survival and side effects) in patients treated with either ADT alone 
or combined with EBRT. Research questions: 
A) Does the addition of EBRT to ADT improve survival? 
B) Does the addition of EBRT to ADT have an impact on therapy side effects? 
3. Histopathological outcome assessed by posttreatment biopsy in patients treated with 
either ADT alone or combined with EBRT. Research questions: 
A) Does the addition of EBRT to ADT improve local tumour control? 
B) Does residual prostate cancer in patients on ADT plus EBRT or ADT alone 
predict clinical outcome and survival? 
4. Clinical outcome in terms of patient-reported side effects from posttreatment prostate 
biopsy in patients treated with either ADT alone or combined with EBRT. Research 
questions: 
A) What is the incidence of posttreatment biopsy side effects? 
B) Are posttreatment prostate biopsy side effects increased in patients on ADT 
plus EBRT compared to side effects in patients on ADT alone?  
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MATERIAL AND METHODS  
 
Study 1 
 
Rationale 
The aim of study 1 was to evaluate the initial experience with open RRP at Trondheim 
University Hospital. When this study was initiated, the prognostic significance of pT-stage 
and surgical margins were not evaluated in prospective studies, although histopathological 
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Data on diagnosis and baseline characteristic (age, TNM-stage and s-PSA) were recorded 
from the patients’ medical records. The cT staging was made by performing digital rectal 
examination and TRUS, whereas a bone scan and chest X-ray was used to assess M-stage. 
 
Histopathological evaluation 
For microscopic evaluation, six to 10 transverse sections from each of the 167 RP specimens 
were randomly assigned for re-examination by one of two pathologists following a strictly 
defined protocol, without any knowledge of the clinical data or the original histopathology 
report. Tumour grade (Gleason score), pT stage and the tumour involvement of the surgical 
margins were recorded. Positive tumour margins were classified as either extra- or 
intracapsular. The site of positive tumour margins with respect to the prostate gland was 
recorded at the following locations: anterior, posterior, posterolateral, apex and base. 
 
Study 2 
 
Rationale 
For decades, both RT and ADT alone have been acceptable treatments for locally advanced 
prostate cancer. When this study was initiated, the effect of these treatment modalities were 
not compared in prospective trials, and the independent role of prostatic irradiation with 
respect to survival was controversial. To address this issue, the SPCG and the Swedish 
Association for Urological Oncology initiated the SPCG-7 study in 1995. The primary 
objective was to evaluate if CSS can be improved in patients treated with a combination of 
EBRT and ADT as compared to ADT alone. The secondary objectives were to evaluate time 
to biochemical progression, time to symptoms related to local progression, time to symptoms 
related to distant progression, and to evaluate side effects with special focus on sexual 
function, urinary and gastrointestinal morbidity. 
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 Design 
An open randomised prospective clinical trial with comparative parallel design. Eligible 
patients were randomised to receive three months with neoadjuvant TAB followed by either 
antiandrogen therapy alone or combined with EBRT (Figure 4). Stratification was according 
to study centre, cT-stage, and WHO tumour grade. 
 
Figure 4. Study design, SPCG-7. 
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Study population 
The inclusion criteria were histological verified prostate cancer cT3 (WHO tumour grade 1-3) 
N0M0 or cT1b-T2 (WHO tumour grade 2-3) N0M0, age 75 and a life expectancy of 10 
years.  All patients with a serum PSA value 11.0 ng/ml underwent a diagnostic PLND to 
select the eligible pN0 patients. Patients with a s-PSA value <10.9 ng/ml were defined as N0.  
The M0 status was established by bone scanning and chest X-ray. 
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Study treatment and follow-up  
Three months neoadjuvant TAB consisted of a LHRH agonist (leuprorelin 3.75 mg a month 
for 3 months or one 11.25 mg injection) combined with an oral antiandrogen (flutamide 250 
mg three times a day). After 3 months of TAB, flutamide was continued in all patients until 
progression or death. No change of treatment was recommended in case of biochemical 
progression only. The recommended treatment of local progression was optional: Surgical 
castration or treatment with a LHRH agonist, transurethral resection of the prostate (TUR-P) 
or palliative RT. In distant progression, castration well as discontinuation of the anti-andogen 
was recommended. 
A standard three-dimensional conformal EBRT technique was applied with a 
prescribed central dose of 50 Gy to the prostate and the seminal vesicles. A sequential boost 
of at least 20 Gy was added to the prostate, which received a total dose of minimum 70 Gy. A 
margin of 20 mm (15 mm in posterior direction) was added. If optimum immobilization could 
be achieved, the margins were reduced accordingly. Dose heterogeneity of 95–107% was 
allowed. To compensate for internal prostate movement and uncertainty in daily setup, a 
geometrical margin (2 cm) was established between the CT-verified prostate or seminal 
vesicles and the edge of the field. When invasion to the seminal vesicles was detected using 
palpation or TRUS-guided biopsy, 70 Gy was given to the prostate as well as the seminal 
vesicles. If more than half of the rectal cross-section received an accumulated dose higher 
than 50 Gy, the posterior margin was reduced. Pelvic lymph nodes were not intentionally 
irradiated. 
A clinical examination and assessment of PSA, liver function, and blood cell counts 
was done every 3 months for the first year and every 6 months thereafter. The ASTRO-
definition of PSA recurrence (increase in PSA >2 ng/ml above nadir) was used [131]. 
Adverse events concerning pain, use of analgesics, nausea/vomiting, breast tenderness, hot 
flushes, urinary problems, sexual function, bowel problems, were recorded by the treating 
physician at each visit (Appendix 1).  Patient-reported quality of life was assessed using the 
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European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 
questionnaire (Appendix 2) [209]. The questionnaires were filled out at baseline, at 3 and 6 
months, and thereafter at 1, 2, 4, 8, and 10 years after start of treatment. 
All included patients were linked to the nationwide population registries in Sweden, 
Norway, and Denmark (Feb 22, 2008) to ensure complete follow-up regarding survival.  
 
Study 3 
 
Rationale 
In 2001, the SPCG-7 study board initiated a side study:” Posttreatment prostatic 
biopsies after antiandrogen treatment with or without radiotherapy of locally advanced 
prostatic cancer”, abbreviated Biopsy side-study.  
  At that time, the clinical significance of post-radiotherapy RPC was controversial 
[210, 211], although there was some emerging evidence that RPC could predict biochemical 
outcome following EBRT [212]. The beneficial effect on local control following EBRT plus 
neoadjuvant ADT was recently demonstrated in a RCT [153], and a prospective observational 
study had demonstrated a dose-response relationship with respect to local control for EBRT 
[152]. However, the incidence and predictive value of RPC in posttreatment biopsies 
following long term ADT alone or combined with EBRT was not evaluated prospectively.  
 The primary objective was to evaluate the incidence of residual prostate cancer in 
post-treatment prostate biopsies in patients treated with either endocrine therapy alone or 
combined endocrine and radiotherapy. Secondary objectives were to assess clinical 
implications of residual cancer. 
 
Design 
Prospective design. Sub-group analysis of a RCT. 
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Study population 
The Biopsy side-study population constitute a sub-group of patients previously included in the 
SPCG-7 trial at 11 Norwegian and Swedish hospitals. Whereas all patients fulfilled the 
inclusion criteria of SPCG-7 trial at baseline and received protocol treatment, the Biopsy-side
study inclusion criteria were WHO performance-status 0-1 and no medical contra-indications 
for prostate biopsy.  
 
Biopsy procedure 
All patients were given prophylactic antibiotics according to local practice prior to the 
transrectal ultrasound guided biopsy procedure. At least two biopsies were taken from the 
primary lesion, followed by posterolateral sextant biopsies. 
 
Histopathological evaluation 
All prostate needle biopsies were fixed in neutral buffered 4% formaldehyde solution, 
dehydrated and separately embedded in paraffin. From all specimens 5 micron thick sections 
were cut and one section from each core stained with hematoxylin-eosin-saffron for 
histological examination performed by two pathologists without any knowledge of the clinical 
data or the original histopathological reports. Based on the results of microscopic evaluation, 
representative sections from each case were incubated with antiserum to high-molecular-
weight-cytokeratin (CKHMW) to distinguish residual tumour from benign glands with 
radiotherapy effect [213]. Gleason score was settled by agreement using the two most 
prevailing growth patterns. Each tumour-containing core was graded separately. Finally each 
case was given an overall score according to recent guidelines [52]. 
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Definition of events 
PSA-recurrence: A PSA-increase 2.0 ng/ml above nadir-value according to the 2006 
American Society of Therapeutic Radiology (ASTRO) recommendation [131].  
Local progression: Increasing urinary problems (frequency, urgency, obstruction) of such a 
magnitude that change of treatment was necessary.  
Distant recurrence: Metastases verified by X-ray, CT scan, bone scan, MRI or histological 
examination.  
Clinical recurrence: Either local progression, distant recurrence or both.  
The cause of death was classified into one of five categories: 1. Death from prostate cancer; 2. 
Death from other causes with prostate cancer significantly contributing; 3. Death from 
anticancer therapy; 4. Death from other causes without prostate cancer significantly 
contributing; 5. Death from unknown cause. Cancer-specific death was defined as items 1 and 
2. 
 
STUDY 4 
 
Rationale 
In 2001, RPC in posttreatment biopsy following RT had been used as a surrogate outcome 
measure following RT for decades [214], and histological evaluation of posttreatment prostate 
biopsies was recommended to select patients for salvage therapy [215, 216]. Although the 
side effects from diagnostic prostate biopsy were well known [160-163], local ADT effects as 
well as late radiation injury may theoretically have influenced on posttreatment biopsy 
complications [197, 217]. There were, however, no published reports on posttreatment 
prostate biopsy side effects. The objectives of study 4 were to estimate and compare 
incidences of posttreatment biopsy side effects in prostate cancer patients treated with ADT 
alone or combined with EBRT.   
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Design 
Prospective design. Sub-group analysis of a RCT. 
 
Study population 
The Biopsy side-study patients (study 3) were requested to complete a non-validated 
questionnaire concerning biopsy related side effects seven days after the biopsy procedure. 
Respondents to the questionnaire constitute the study population.  
 
Evaluation of side effects 
The intensity of biopsy related pain was graded by the patient using the following verbal 
rating scale [218]: 0-no pain; 1-slight pain (analgesics not necessary); 2-moderate pain 
(analgesics necessary); 3-severe pain. Post biopsy pain intensity experienced during the seven 
days follow-up period was graded on an identical scale. Experienced change in urinary flow 
(obstruction) in the seven days study period was graded on the following scale: 0-no change; 
1-slightly increased obstruction; 2-severely increased obstruction; 3-urinary retention. The 
occurrence of urinary tract infection, pyrexia and the use of antibiotics were recorded. The 
occurrence and duration (days) of hematuria and rectal bleeding were recorded as well as the 
experience of hematospermia. Furthermore, the patients were requested to record the reason 
for any contact with general practitioner or hospital, and to describe in their own words any 
other medical problem that occurred in the seven days period. 
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STATISTICAL CONSIDERATIONS 
 
Estimation of sample size 
Based on an assumed 65% 7-years CSS in patients on ADT alone, study 2 initially aimed to 
include 660 patients to detect a 10% difference between treatment groups (Į = 0.05, 1-ȕ = 
0.8). When 716 patients were included, an independent Data Safety Monitoring Committee 
found a lower overall mortality than expected in a blinded analysis (February, 2002), and the 
sample size was extended to 880 patients to achieve a total of 198 prostate cancer deaths at 7 
years. After 7.6 years median follow-up (February, 2008), 116 patients had died from prostate 
cancer. A new independent Data Safety Monitoring Committee blindly explored the power of 
the study. As the CSS was found to be much higher than expected (7-years OS was 90% 
compared with an assumed 70%) in the total study population, the committee concluded that 
the study had sufficient power and recommended that the results should be analyzed and 
published. 
 
Statistical analyses 
In general, categorical variables were compared using the Ȥ² or Fisher’s exact tests. 
Continuous variables were compared using the Student’s t-test. If not normally distributed, 
the Mann-Whitney U test was applied.  
In study 2, the EORTC QLQ-C30 questionnaire data were transformed linearly into a 
0-100 scale and analysed according to the EORTC recommendations [219]. The Wilcoxon 
rank-sum test was used to compare QOL scores within groups, whereas scores between 
groups were compared using the sign-rank test. In study 4, Pain intensity was graded 
according to the scale used in the EORTC QLQ-30 questionnaire, and the recommended 
linear transformation into a 0-100 scale was made to obtain a pain score in each case. 
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Moreover, all analyses in study 2 were made according to the intention to treat 
principle. Cumulative incidence of each endpoint was calculated, and the hypothesis that there 
was no difference between treatment groups was tested using Gray’s test. Differences in 
cumulative incidence with 95% confidence intervals (CIs) were used as measures of effect.  
In study 3, associations between biopsy status and time dependent outcomes were 
assessed in univariable analysis using the log-rank test and Kaplan-Meier curves of 
biochemical recurrence probability was estimated.  
The associations between potential predictive variables and time independent 
endpoints in terms of Odds ratio (OR) with a 95% CI were assessed in multivariable analysis 
using logistic regression models, whereas associations with time dependent endpoints in terms 
of Hazard ratio (HR) with a 95% CI were assessed in multivariable analysis using Cox 
proportional-hazards models. Only covariates that were considered clinically relevant were 
included in regression analysis. In study 2, the term relative risk, synonymous to HR, was 
used. Moreover, interaction between treatment group and the following variables: Age, PSA 
level and T-stage at diagnosis were tested by a Cox proportional-hazards model in study 2. In 
study 3 and 4, covariates with a p-value of 0.1 or less for an association with outcome in 
univariable analysis were included in the final regression models. As five events per variable 
is suggested to be sufficient in regression analysis [220], a maximum of two variables were 
included in the regression models in study 3 and 4 in case of 10 to 30 events. Otherwise, a 
maximum of one variable per 10 events was included.  
A two-sided p-value <0.05 was considered statistically significant in all the analyses. 
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RESULTS  
 
Study 1 
 
Patients 
The prostate cancer diagnosis was verified by biopsy in 152 (91%), TUR-P specimens in 12 
(7%) and cytology in 3 (2%) patients, respectively. Whereas 164 (98%) had organ confined 
tumours (cT-stage 1-2) at pre-operative staging, 3 (2%) patients had cT3 tumours. Mean pre-
operative PSA was 10.2 (range 1.6-39.2) ng/ml, and significantly higher in cohort I compared 
to cohorts II and III: 13.2, 9.0 and 8.5 ng/ml, respectively (p<0.05). 
 
Histopathology 
Locally advanced (pT3a-b) tumours were significantly more common in cohort I (44%) 
compared to cohorts II and III (20% in both cohorts), p<0.05.  
The proportion with positive tumour margins were higher in cohort I, compared to 
cohorts II and III (58, 30 and 13%, respectively), p<0.05. Moreover, positive intracapsular 
tumour margins (Figure 5) were found in 55% of the RRP specimens in cohort I, compared to 
25% in cohort II and 8.9% in cohort III, p<0.05, whereas pT2 tumours with positive margins 
in cohorts I-III was found in 57%, 26% and 8.9%, respectively, p<0.05.  
Low-grade tumours (Gleason score 4-6) were statistically significant more common in 
Cohort III (58.9%) compared to cohorts I (31.5%) and II (34%). 
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Figure 5. Intracapsular tumour margins in cohort I-III. 
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Study 2 
 
Patients  
Whereas a total of 880 patients were assessed for eligibility after written informed consent, 
875 met the inclusion criteria and were included in the study (figure 6). The treatment groups 
were well balanced with respect to clinical baseline characteristics and demographics (table 
4).  
 
 Figure 6. SPCG-7 trial profile [221] 
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 Table 4. Baseline characteristics of patients included in the SPCG-7 study [221]. 
 
 
Study therapy 
All patients allocated to the endocrine plus radiotherapy group received EBRT 
according to protocol with a median dose of 70 Gy with an interquartile range (IQR) of 69.5–
70.6 Gy. The flutamide dose was reduced in 35 (8%) in the endocrine and 58 (13.3%) patients 
in the endocrine plus radiotherapy group, whereas 77 (17.5%) in the endocrine and 
88 (20.2%) patients in the endocrine plus radiotherapy group had their treatment changed to 
bicalutamide. 
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Survival analysis 
No patient was lost from follow-up due to emigration. At a median follow-up of 7.6 years 
(range 0.2–11.9 years), a total of 224 patients had died of whom 116 patients died of prostate 
cancer.  
The cumulative 7-years cancer-specific mortality incidence was 9.9% (95% CI 7.1–
12.8%) in the endocrine and 6.3% (3.9–8.6%) in the endocrine plus radiotherapy group 
(difference 3.7%, 0.0–7.4%). At 10 years, the cumulative incidence for cancer-specific 
mortality increased to 23.9% in the endocrine group and to 11.9% in the endocrine plus 
radiotherapy group (difference 12.0%, 4.9–19.1%). The relative risk of cancer-specific death 
was 0.44 (0.30–0.66, p<0.0001) in favour of the endocrine plus radiotherapy group. 
 Moreover, the addition of EBRT to ADT yielded an absolute over all mortality 
difference of 3.6% (95% CI –1.7 to 8.8%) at 7 years and 9.8% (0.8–18.8%) at 10 years with a 
relative risk of overall death of 0.68 (0.52–0.89, p=0.004) in favour of the endocrine plus 
radiotherapy group. 
At 7 and 10 years, the cumulative incidence of PSA recurrence was 71.1% (95% CI 
66.3–75.9%) and 74.7% (69.6–79.8%) in the endocrine group, and 17.6% (13.6–21.5%) and 
25.9% (19.3–32.6%) in the endocrine plus radiotherapy group. The relative risk of PSA 
recurrence was 0.16 (0.12–0.20, p<0.0001) in favour of the endocrine plus radiotherapy 
group. 
No significant effect modification of the combined treatment according to T stage, 
PSA level at diagnosis, or age at inclusion was seen for any of the endpoints. 
 
Side effects and quality of life 
 As assessed by the treating physician at 5 years follow-up, significantly more patients 
in the endocrine plus radiotherapy group had urinary incontinence, urgency, urethral stricture, 
and erectile dysfunction compared to patients in the endocrine group, (table 5). 
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 Table 5. Proportion of patients reporting specific levels of distress or dysfunction as reported 
by treating doctor at baseline and 5 years after treatment start [221]. 
 
 
  
 
There was no difference in compliance to the EORTC QLQ-C30 questionnaire (table 
6) at baseline and during follow-up. The questionnaire was retuned by 85% in the endocrine 
and 89% in the endocrine plus radiotherapy group at 4 years. Social function was the only 
function scale whereas diarrhoea was the only symptom that differed significantly between 
the two groups. Mean social function score in the endocrine group was 80.7 compared to 76.2 
in the endocrine plus radiotherapy group (p=0.01), and moderate or severe diarrhoea were 
reported by 32 of 337 (9.5%) in the endocrine and 39 of 355 (11.6%) patients in the endocrine 
plus radiotherapy group, p=0.003.  
Emotional function was significantly improved at 4-year follow-up (mean score 85) 
compared with the baseline assessment (mean score 82) in the endocrine plus radiotherapy 
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group, p=0.006. Dyspnoea and fatigue were the only symptoms that increased significantly 
between baseline and 4-year follow-up in both groups (table 5). 
 
Table 6. Quality of life scores (EORTC QLQ-C30) in endocrine group and endocrine plus 
radiotherapy group[221] 
 
 
 
Study 3 
 
Patients 
The 11 participating hospitals recruited 47% (n = 415) of the SPCG-7 study population. Of 
these, 120 (29%) patients were successively enrolled in the Biopsy side-study and underwent 
posttreatment biopsies at a median of 45 months (range 30-97) follow-up.  Thus, the Biopsy
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side-study included 14% of the SPCG-7 study patients. Sixty-four patients were allocated to 
endocrine therapy alone and 56 patients to combined therapy. One patient allocated to 
endocrine therapy alone had PSA-recurrence six months after randomisation and started 
curative RT with a total dose of 70Gy 38 months prior to biopsy. Thus, of the included 
patients, 63 (53%) were in the endocrine and 57 (47%) were in the combined therapy group 
receiving a median radiation dose of 70Gy (range 70-78Gy). 
There were no significant differences in clinical baseline characteristics (age, s-PSA, 
cT-stage and WHO tumour grade) between the total SPCG-7 study population and the 120 
patients in the Biopsy side-study. Except for age (mean 67.1 vs. 64.9 years in patients on 
endocrine therapy alone in patients on combined therapy, respectively, p=0.047) there were 
no significant differences in baseline characteristics between therapy groups in the Biopsy 
side-study. 
 
Histopathology 
A median of 8 biopsy cores (range 2-10) were taken. No prostate tissue was found at biopsy 
in one patient in the endocrine and two patients in the combined therapy group. Consequently, 
biopsies from 117 patients (62 patients in the endocrine and 55 patients in the combined 
therapy group) were available for histological evaluation. Residual cancer was found in 66% 
(n = 41) and 22% (n = 12), respectively, p<0.0001. The majority of positive biopsies in the 
endocrine and all in the combined therapy group contained poorly differentiated (Gleason 
score > 8) cancer (Table 7).  
In logistic regression analysis, significant predictors of residual prostate cancer were: 
Endocrine therapy alone, OR 7.49 (3.18-17.7), p<0.0001, and baseline-PSA, OR 1.03 (1.00-
1.07), p=0.044. 
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Table 7. Biopsy results in 117 patients with locally advanced prostate cancer treated with 
endocrine therapy alone or combined endocrine and radical radiotherapy.  
 
 
Biopsy result 
 
 
Patients treated with 
endocrine therapy alone 
(n=62) 
Patients treated with 
combined endocrine and 
radiotherapy (n=55) 
p-value 
 
Residual cancer, n (%)  
 
41 
 
(66) 
 
12 
 
  (22) 
 
<0.001* 
Time to biopsy, months (range)  43 (32-81) 45 
 
(30-97) 
 
0.27† 
Median number of biopsy cores 
taken (range) 
7 (2-10) 8 (3-11) 0.40† 
 
Median number of tumour-
containing biopsy cores in 
patients with residual cancer, 
(range)  
 
3 (1-8) 4 (1-9) 0.45† 
Gleason score, median (range) 
 
8 (6-10) 8 (8-8)  
Gleason score 6, number (%) 
 
1 (2.4) 0   
Gleason score 7, number (%)  
 
7 (17) 0   
Gleason score 8, number (%) 
 
14 (34) 12 (100)  
Gleason score 9, number (%) 
 
15 (37) 0   
Gleason score 10, number (%) 
 
4 (9.8) 0   
Subgroups compared using *Ȥ² test, †Mann-Whitney U test. 
 
 
Survival analysis 
Median follow-up time for survival was 101.5 months with a range of 54 to 140 months and 
an inter quartile range (IQR) of 86.5 to 117.8 months, and 97 months (range 10-134,  IQR 
80.0-112.75) for other clinical events. Incidences of clinical events and univariable intergroup 
comparisons in patients with and without residual cancer are shown in Table 8. 
In multivariable Cox-regression analysis, factors significantly associated with PSA-
recurrence were: Residual cancer, HR 2.69 (1.45-4.99), p=0.002; Endocrine therapy alone HR 
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Patients 
Of the 120 Biopsy side-study patients, 109 (91%) returned the side effects questionnaire. The 
compliance to single questionnaire items varied from 94-100%. 
There were no significant differences in baseline characteristics (age, s-PSA, cT-stage and 
WHO tumour grade) between the total SPCG-7 study population and the 109 respondents, of 
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whom 57 (52%) patients received endocrine therapy alone, and 52 (48%) additional RT. A 
median of 8 biopsy cores (range 2-11, IQR 6-8) were obtained in both therapy groups. All 
patients received antibiotic prophylaxis, and 19% (n=21) were given periprostatic local 
anaesthesia. In the endocrine and combined therapy group, the mean age at biopsy was 71.5 
(range 56-83) years and 68.8 (range 51-80) years, respectively (difference 2.7, 95% CI 0.45-
4.91 years), p=0.019. 
 
Side effects 
The number of biopsy cores taken (less than eight cores vs. eight or more) and age at biopsy 
had no significant influence on the incidence of self-reported side effects. Moreover, therapy 
group had no significant influence on biopsy related pain (Table 9), change in urinary flow 
(Table 10), hematuria or hematospermia. The use of local anaesthesia had no significant 
impact on the incidence and degree of pain at biopsy.  No patient reported complete urinary 
retention (grade 3).  
Hematuria was reported in 26 of 56 patients (46%) in the endocrine therapy and in 18 
of 52 patients (35%) in the combined therapy group. The mean duration was 2.2 days (range 
1-7. Hematospermia was reported in two patients in each therapy group and unknown in 62 
(60%) of 108 patients. Ten of 56 patients (18%) on endocrine therapy alone reported rectal 
bleeding compared to 18 of 52 patients (35%) on combined therapy (p=0.047). The mean 
duration was 1.6 days (range 1-4) and 2.2 days (range 1-7), respectively, p=0.031. In logistic 
regression analysis, a trend towards a significant association between combined therapy and 
rectal bleeding was found, OR 2.4 (1.0-5.9), p=0.050.No patient had urinary tract infection. 
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Table 9. Intensity of pain during the post-treatment biopsy procedure reported by 108 patients. 
Except for mean score, the figures shown represent number of patients with percentages in 
parenthesis 
 
 
 
 
Therapy 
 
Pain (grade*) reported 
at biopsy 
 
Endocrine therapy alone
n = 57† 
 
Combined therapy 
n = 51‡ 
 
0 23 (40) 16 (31) 
1 32 (56) 30 (59) 
2 2 (4) 4 (8) 
3 0 1 (2) 
Mean score (SD) 21.1 (18.5) 26.8 (22.1) 
* 0: No pain, 1: Slight pain, 2: Moderate pain, 3: Severe pain. †11 patients (19%) 
received local anaesthesia. ‡10 patients (20%) received local anaesthesia. Abbreviation: 
SD = standard deviation. 
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Table10. Patient-reported subjective change in urinary flow during seven days follow-up after 
post-treatment biopsy in 103. The figures shown represent number of patients with 
percentages in parenthesis. 
 
  
Therapy 
Subjective change 
(grade*) in urinary flow 
 
Endocrine therapy  
n = 54 
 
 
Combined therapy  
n = 49 
 
0 44 (81) 38 (78) 
1 11 (19) 9 (18) 
2 0 2 (4) 
3 0 0 
*0: No change, 1: Slightly increased obstruction, 2: Severely increased obstruction, 3: Urinary retention 
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DISCUSSION 
 
Survival following therapy 
The principal finding in the SPCG-7 study (study 2) was that the addition of EBRT to ADT in 
locally advanced or histological aggressive prostate cancer significantly improved OS with 
acceptable side effects. The estimated absolute OS benefit of 9.8% at 10 years was driven by 
a 12% increased CSS in favour of the combined therapy. 
 However, the optimal local therapy in non-metastatic prostate cancer remains 
controversial. After a median of 8.2 years follow-up, Bill-Axelson et al. found a modestly 
reduced absolute 10-year over all mortality of 5% in favour of prostatectomy in the SPCG-4 
randomised study which compared open RRP with watchful waiting [103], whereas the 
difference was not statistically significant after an additional three years follow-up [104]. 
Although these results may seem inferior to that of study 2, the comparison may be severely 
biased by the fact the majority of the SPCG-4 study patients were diagnosed before the PSA-
era and may not be representative of currently treated patients. Recently, a long term follow-
up of the SWOG randomized trial number 8794 demonstrated an OS benefit from EBRT 
adjuvant to prostatectomy in high-risk (pT3 and/or positive surgical margin) patients [123]. In 
this study reported by Thompson et al., the estimated 8% absolute improved OS at 10 years 
was of the same magnitude as the 9.8% improvement found in study 2. Thus, both 
radiotherapy (if combined with ADT in locally advanced and/or histological aggressive 
disease) and prostatectomy (if followed by adjuvant therapy in high-risk patients) seems to be 
acceptable local therapies.  
Although the survival curves in study 2 started to separate after 4 years follow-up, the 
difference was not statistically significant at 7 years. A further separation occurred after 7 
years, and the difference in survival eventually became statistically significant at 10 years. 
Similar observations have been reported in other non-metastatic prostate cancer RCTs. The 
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reduced risk of metastasis and prostate cancer death found at a median follow-up of 6.2 years 
in the SPCG-4 study [222] translated into an OS benefit when the patients were followed for 
an additional three years [103]. In the SWOG 8794 randomized study on EBRT adjuvant to 
prostatectomy, no differenced in OS was found at 10.6 years median follow-up [223], 
whereas the OS benefit in favour of adjuvant EBRT was demonstrated at long term (median 
12.7 years) follow-up [123]. Two other RCTs evaluated the effect of EBRT adjuvant 
prostatectomy. With a median follow-up of 5 and 10.6 years, respectively, a benefit in terms 
of DFS was found for adjuvant irradiation, although there were no significant differences in 
OS [121, 122]. Thus, long term follow-up is needed to detect clinically important effects of 
radical therapy in non-metastatic prostate cancer. This reflects the long natural history of the 
disease [76], and radical therapy is most likely of little value in patients with a short life 
expectancy (<5 years). On the other hand, a life expectancy of 10 years, which was required 
in the SPCG-4 and 7 studies [222], may be a too strict criterion. 
The optimal scheme of ADT combined with EBRT in non-metastatic prostate cancer 
is still unresolved. Although several RCTs have demonstrated an OS benefit in favour of this 
combination over EBRT alone, these studies are heterogeneous with respect to the timing of 
ADT. Whereas D'Amico et al. gave TAB for six months initiated two months prior to EBRT 
[98], Bolla et al. started the 3 years a LHRH agonist treatment simultaneously with 
radiotherapy [224]. In the RCT reported by Granfors et al., ADT consisted of orchietomy 4-5 
weeks prior to EBRT [99]. Moreover, a sub-group analysis of the early prostate cancer 
program demonstrated an OS benefit from antiandrogen therapy if given in addition to 
radiotherapy in patients with locally advanced disease [101]. There is, however, evidence that 
the effect of adjuvant ADT depends on duration. Bolla et al. found that 3 years ADT (LHRH 
agonist initiated on the first day of irradiation) combined with EBRT yielded superior OS 
over 6 months adjuvant treatment [102].  The absolute OS benefit was, however, less than 
5%, and the effect of long term castration on survival should thus be weighed against side 
effects such as bone fractures due to loss in bone-mineral density, reduced sexual function and 
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cardiovascular disease [168, 170]. There is some evidence that antiandrogen therapy is 
superior to castration with regard to side effects [89, 175], whereas no difference in survival 
was found in a RCT comparing castration and antiandrogen monotherapy [89].  Withdrawal 
of LHRH agonists results in testosterone recovery within 3-4 months in the majority of 
patients on short term (<6 months) therapy [225]. In study 2, castration therapy was only 
given for three months, whereas long term ADT consisted of an antiandrogen. Most likely, the 
patients in study 2 benefited from long term ADT, although spared from the side effects of 
long term castration. 
 
Histopathological outcome; the importance of local tumour 
control 
Whereas the overall incidence of locally advanced (pT3) tumours found at histopathological 
examination in study 1 was 28%, the incidence was reduced from 52% in cohort I to 20% in 
cohorts II and III. The reported incidence of pT3-tumours ranges between 10 and almost 70% 
in previous and successive studies [104, 203, 226, 227]. However, the comparison between 
various patient series is hampered by the heterogeneity of preoperative risk factors such as 
cT-stage, Gleason score and s-PSA. Accordingly, the observed pT-stage migration in study 1 
was most likely due to a stricter preoperative patient selection. This is reflected by a 
significantly higher preoperative s-PSA in cohort I as compared to cohorts II and III as well as 
successively reduced proportion of palpable tumours (cT2-3) in the study period. A similar 
stage migration driven by preoperative patient selection was reported by Ung et al. in a study 
that included over 1000 RRP-patients which were divided into three  chronological cohorts 
[226]. 
 Positive tumour margins were found in 33% of the RRP-specimens in study 1, 
consistent with the incidence of 35% reported in the SPCG-4 randomised trial [104]. On the 
other hand, Eggelstone and Walsh reported positive margins in only 7% of their 100 first 
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patients operated on with nerve sparing RRP [228]. However, comparisons of tumour margin 
status reported in different patient series are most likely biased by differences in pre-operative 
risk factors. As for pT3 tumours, the proportions of RRP-specimens with positive tumour 
margins declined significantly in the study period from 58% in cohort I to 31% in cohort II 
and 13% in cohort III. Consistently, Ung et al. reported a successive reduction in positive 
tumour margins  in their three cohorts of RRP-patients (32, 26 and 14%, respectively)  [226].  
 The decline in positive tumour margins in study 1 may be explained by the observed 
pT-stage migration towards organ confined tumours (pT 2). However, the proportions of 
RRP-specimens with positive intracapsular margins also declined significantly in the study 
period (55, 25 and 9%, respectively), whereas the proportion of pT3 tumours (20%) was 
similar in cohorts II and III. This successive reduction in positive intracapsular margins was 
most likely due to an improved surgical technique, which is further illustrated by the 
successively reduced incidence of margin positive pT2-tumours in the three cohorts (57, 26 
and 9%, respectively). Guilloneau and Vallancien found 11% margin-positive pT2 tumours in 
patients operated on with laproscopic RP [203], whereas Salomon et al. found an incidence of 
19% margin-positive pT2 tumours following open RRP [202]. This excludes the margin-
positive pT3 tumours and is thus comparable to the results for cohort III in study 1.     
 Both the locally advanced and margin-positive tumours had a higher incidence of a 
Gleason score of >7 compared to the organ-confined and margin-negative tumours in study 1. 
As a high tumour grade has been shown to be a predictor of an unfavourable pathological 
tumour stage, this result is consistent with previous reports [66]. 
 The most important finding in study 1 was that the surgical technique seemed to 
improve significantly in the study period, which resulted in a more favourable 
histopathological outcome in terms of negative tumour margins. This study evaluated a single 
institutions initial experience with a new operative technique, and the results suggest that an 
adequate number of operations were needed to achieve the necessary experience with the 
operative procedure in order to improve cancer control. The importance of experience was 
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demonstrated in a retrospective cohort study by Vickers et al. published in 2007, in which 
PSA-recurrence rates in 7765 patients treated with RRP by 72 surgeons were evaluated. The 
surgeons experience was found to be significantly predictive of biochemical DFS, and the 
estimated learning curve was steep until a surgeon had completed approximately 250 
operations [229]. Vickers et al. also compared tumour margins in RRP-specimens from 
patients treated by inexperienced (10 previous RRP procedures) and experienced (250 
previous procedures) surgeons. A 15% absolute risk reduction of positive margins in favour 
of patients treated by experienced surgeons was found [230]. Moreover, a positive margin 
following prostatectomy was convincingly shown to be a negative predictor of CSS in a large 
population based study [144], and it is highly likely that the patients will benefit from the 
improved surgical technique demonstrated in study 1.   
 The principal finding in study 3 was that patients on endocrine therapy alone had a 
three times higher incidence of local residual prostate cancer compared to patients on 
combined therapy. Residual cancer was significantly associated with PSA- recurrence. 
Whereas 78% of patients treated with EBRT plus ADT had biopsy verified local tumour 
control, negative biopsies were found in only 33% of patients treated with ADT alone. The 
proportions mimicked almost exactly the final 10 years figures on PSA recurrence in the 
treatment arms of the SPCG-7 trial.  
 In prostate cancer patients treated with EBRT, previous studies have reported local 
tumour control rates assessed by posttreatment biopsies ranging from 40 to over 90% [152, 
155, 211, 212, 214, 231]. Comparisons of the different patient series are obviously biased, as 
the incidence of RPC in posttreatment biopsies depends on several factors. Tumour regression 
following RT occurs gradually, and a higher rate of positive and indeterminate biopsies 
showing treatment effect is obtained if taken earlier than two years of follow-up, whereas a 
significant proportion will eventually become negative if biopsy is repeated [153, 210, 212, 
214]. In a three armed RCT reported by Laverdiere et al., 64 Gy EBRT alone was compared 
with EBRT plus either 3 months neoadjuvant TAB or 3 months neoadjuvant, concomitant and 
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6 months adjuvant TAB. RPC in 24 months posttreatment biopsies was found in 65, 28 and 
5%, respectively, and the incidence was significantly reduced in patients who received ADT 
[153]. In the prospective non-randomized Memorial Sloan-Kettering Cancer Center dose-
escalation study, patients with T1c-T3 tumours underwent prostate biopsy at a median of 3.3 
years following EBRT with doses between 64.8 and 81 Gy in successive increments of 5.4 
Gy. As reported by Zelefsy et al., a radiation dose of 75.6Gy was inferior to 81Gy in terms of 
local control (positive biopsy in 48% vs. 7%) [152]. This dose-response relationship seems to 
be dependent on risk factors like clinical tumour stage, pre-treatment PSA and tumour grade, 
as high risk patients require significantly larger doses to achieve biopsy verified local control 
[232]. Notwithstanding these possible biases, the 78% biopsy-verified local control rate in 
patients on combined EBRT and ADT in study 3 is in accordance with the 76% negative 
posttreatment biopsies taken at minimum of 2.5 years follow-up in a subgroup of patients 
treated with ADT plus an EBRT dose of 70.2 Gy or less reported by Zelefsky et al. [155].
 Although not directly comparable [233], the tumours in study 3 were considerably less 
aggressive at diagnosis. Whereas more than 80% of the cancers initially were WHO grade I or 
II, the residual tumours were high-grade with a Gleason score >8 in all residual tumours in the 
combined and in 80% in the endocrine group. The shift towards a high-grade malignancy 
observed in this study may be caused by a gradual dedifferentiation over time, eradication of 
low-grade tumour elements, or a combination.  
 The association of residual tumour with PSA-recurrence probability observed in study 
3 corresponds with previous reports [95, 154, 155, 231], including one RCT in which Crook 
et al. randomly assigned patients to receive either 3 or 8 months ADT neoadjuvant to 64 Gy 
EBRT. In this study, 24 months preplanned posttreatment biopsies were taken, and an 
approximately 40% absolute difference in 7 years biochemical DFS was found in favour of 
negative biopsy [95]. Corresponding with the results of study 3, biopsy status was shown to 
be predictive of biochemical DFS in a multivariable analysis which included the following 
covariates: biopsy status, pretreatment PSA, tumour grade and cT-stage.  However, residual 
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cancer as well as an early PSA-recurrence is reported to be predictive of distant metastases 
and prostate cancer mortality in retrospective studies [132, 154, 155]. This finding was not 
confirmed in study 3, and the RCT conducted by Crook et al. also failed to demonstrate a 
significant association between RPC and clinical recurrence, CSS and OS in multivariable 
analysis.  A significant associations between biopsy verified RPC and these clinically 
important outcomes remains to be demonstrated prospectively, and an extended follow-up of 
patients in these studies may be required. However, a survival benefit from local irradiation 
was clearly demonstrated in the SPCG-7 trial, and the patients in the present study constitute a 
subgroup of the SPCG-7 study population with similar baseline prostate cancer risk-factors 
and clinical outcome. Most likely, post-treatment biopsies would be required from a 
substantially larger patient cohort to explore the influence of residual cancer on distant 
metastases and survival with sufficient statistical power.  
In patients unsuccessfully treated with radiotherapy for prostate cancer, eradication of 
the residual tumour may still be achieved with salvage prostatectomy, cryosurgery, 
brachytherapy or high intensity focused ultrasound (HIFU) [234-238]. However, these 
salvage therapies are associated with substantial morbidity, whereas cure is less likely in 
patients with histologically highly malignant (Gleason score > 9) residual tumours. Thus, 
posttreatment biopsies are recommended by several authors to select eligible patients [215, 
216, 237].  
 
Side effects 
In study 2, physician-assessed urinary and sexual problems (urethral strictures, urgency, 
incontinence and impotency) at 5 years follow-up were significantly increased in patients 
treated with combined ADT and EBRT as compared to patients on ADT alone. The 
differences between the two groups were, however small (range 2-8%). Whereas 
approximately 50% of the study patients were sexually active at baseline, impotency was 
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reported in the vast majority (89 vs. 81%, respectively) at 5 years. Urinary frequency >10 
times pr 24 h was the second most common problem at 5 years, although considerably less 
frequent (reported in 18%) and equally distributed in the two groups.  
The compliance to the EORTC QLQ-C30 questionnaire was high (85%). Consistent 
with a recent report, fatigue was increased in both groups [219]. The same trend was observed 
for dyspnoea, whereas the mean scores for diarrhoea at 4 years was significantly higher in 
patients on combined therapy as compared both with baseline (mean score difference 6.6) and 
with the mean score at 4 years in patients on endocrine therapy alone (difference 4.6). In 
accordance with a previous report [239], increased diarrhoea may possibly explain the 
reduced social function score of 4.5 at 4 years in patients on combined ADT and radiotherapy 
as compared to patients treated with ADT alone. The late toxicity observed in study 2 is 
consistent with several previous reports [89, 193, 197-199, 239]. All differences between the 
treatment groups were, however, small and of marginal clinical significance [240], and must 
be deemed acceptable considering the survival benefit achieved when EBRT is added to 
ADT. On the other hand, further improvement of local control as well as a maintained low 
level of serious side effects may be achieved by dose-escalation if image guided radiotherapy 
as well as intensity modulated radiotherapy techniques are applied [241, 242]. 
 The self-reported side effects were mild and self-limiting in the majority of patients 
who underwent posttreatment prostate biopsy. In accordance with reports on prostate biopsy 
side effects in previously untreated patients, the incidence of severe side effects was low, and 
not increased if more than eight biopsy cores were taken [164-166, 243].  
 More than 60 % of the patients reported biopsy related pain, whereas no more than 
10% required analgesics, and only one patient reported severe (grade 3) pain. The incidence 
of moderate to severe pain following diagnostic prostate biopsy is previously reported to be 
11-30 % [160, 161, 163, 243]. This study was not designed to evaluate the effect of local 
anaesthesia, and the use was infrequent and optional. Even though no significant effect on 
biopsy related pain was observed, local anaesthesia may still have been beneficial for some 
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patients. In addition, the low incidence of severe pain (grade 3) may be due to a reduced 
sensibility as endocrine therapy and radiotherapy reduce the prostate volume and cause 
fibrosis of the rectal wall [197, 198, 217]. 
 Although 20% of the patients reported decreased urinary flow, no patient reported 
urinary retention. These findings do not differ from those reported in patients undergoing 
diagnostic prostate biopsy, with a 0.7-1.6 % reported incidence of post biopsy urinary 
retention [160, 161, 165, 166, 244]. Urinary tract infection which may be complicated with 
pyrexia and sepsis has been reported in 0.3-11% following diagnostic prostate biopsy, even if 
antibiotic prophylaxis was used [160, 161, 164-166, 244]. On the other hand, a single dose of 
oral ciprofloxacin is shown to prevent infection following prostate biopsy in a randomised 
placebo controlled trial [245], and orally administered ciprofloxacin concentrates in the 
prostatic tissue [246]. In this study, all patients received antibiotic prophylaxis with 
Ciprofloxacin, and clinically urinary tract infections were not observed. Based on this result, 
two to three doses of ciprofloxacin, starting one hour prior to posttreatment biopsy, seems to 
be a safe regime for prevention of urinary tract infection. 
 Obviously, the low incidence of hematospermia observed in study 4 was due to a low 
degree of sexual activity in a senior study population on prostate cancer therapy.  
Corresponding with the results of the present study, the incidence of minor hematuria and 
rectal bleeding related to prostate biopsy in previously untreated patients is reported to be 14 -
74 % and 2-40%, respectively [160, 161, 165, 166, 244]. Although therapy induced prostate 
gland shrinkage and fibrosis may theoretically decrease the risk of prostate bleeding as 
compared to pretreatment biopsy, late radiation toxicity may lead to proctitis with ulceration 
and bleeding and thus a more vulnerable rectal mucosa [247, 248]. Study 4 showed a trend 
towards an increased risk of rectal bleeding in patients treated with radiotherapy. However, 
the clinical significance of this finding is limited because no patient had major rectal bleeding 
and the mean difference in duration was less than one day.  
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Limitations and strengths of the studies.  
 
Study 1  
A logistic regression model including cohorts and preoperative risk factors (tumour grade, cT-
stage and s-PSA) may have produced a more reliable estimate of the independent association 
between cohorts and tumour margins in study 1. However, selection biases other than an 
uneven distribution of these measurable preoperative risk factors may still be present in this 
retrospective study. For instance, the operations were performed by one of three surgeons 
whereas the skill of the individual surgeon may have influenced on histopathological outcome 
[230]. Furthermore, some patients with positive margins and/or pT3 tumors will not 
experience relapse [249], and clinical DFS and mortality were not evaluated in this study. 
Histopathological outcome as assessed in study 1 is, however, shown to be significant 
predictors of such clinically important outcomes in large population based studies [144, 145]. 
A major strength of the study is the histopathological re-examination of the RRP-
specimens which was blinded with respect to the clinical data and the original histopathology 
report. By this approach, the risk of a detection bias is minimal. The risk of selection bias may 
also have been reduced by the fact that the study included all consecutive patients operated on 
with open RRP in the study period. Moreover, only objectively measurable variables were 
analyzed. This eliminates recall bias, which is an inherent problem in retrospective studies. 
 
Study 2 
A suboptimal radiation dose of 70Gy was used, as the study was initiated before any of the 
dose-escalation RTCs were published [108-111]. The current EBRT standard dose of 78 Gy 
might increase the benefit from radiotherapy even further. This study was necessarily 
unblinded, which opens the possibility of detection biases, especially with regard to 
physician-assessed side effects. In general, physician-assessed side effects may be 
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problematic. Recently, Steinsvik et al. reported on discrepancies between patient and 
physician ratings of adverse events in the SPCG-7 trial. Although an acceptable accordance 
was generally found, physicians tended to over-report minor bowel problems after EBRT, 
whereas other symptoms, such as urinary problems, were usually under-reported [250]. 
Moreover, urinary and sexual problems are not directly addressed in the EORTC QLQ-C30 
questionnaire. Thus, the incidence of urogenital side effects was underestimated in study 2. 
This was demonstrated in a subsequent analysis of the SPCG-7 patients, in which Fransson et 
al. assessed urinary and bowel symptoms as well as sexual function using the validated 
prostate-cancer symptom scale (PCSS) self-assessment questionnaire [251].  At 4 years, 
significantly more patients in the combined therapy group reported moderate or severe urinary 
problems as compared to patients on endocrine therapy alone (18 vs. 12%) Also, bowel and 
sexual problems were more common in patients treated with EBRT. However the intergroup 
difference in symptom severity was generally small and considered clinically insignificant by 
the authors [247].  
In general, randomization reduces selection bias to a minimum. The RCT design and 
completeness of survival data constitutes the major strength of the SPCG-7 study. Moreover, 
the patient population was well characterized as all patients with a s-PSA 10.9 ng/ml 
underwent PLND to select the eligible pN0-patients, whereas all patients had negative chest 
X-rays and bone scans. In addition to cT3 tumours, histologically aggressive cT 1-2 tumours 
were eligible. Accordingly, the vast majority of the study population would currently be 
classified as intermediate or high-risk patients according to the risk-group classification 
proposed by D'Amico et al. [71], whereas patients in the low-risk group eligible for active 
surveillance were not included [78]. Thus, the SPCG-7 study population seems to be 
representative of current prostate cancer patients treated with combined ADT and EBRT, and 
the external validity of the study is most likely high.  
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Study 3 
The amount of remaining and biologically aggressive cancer may have been overestimated in 
study 3. In animal studies, cancer cells remaining after irradiation may not be functionally 
active because they do not proliferate even after testosterone stimulation [252]. In this study, 
cell proliferation was not examined. Although the morphology of the individual remaining 
cancer cells in study 3 was that of poorly differentiated tumours, Gleason score may be 
artificially upgraded and thus unreliable in posttreatment biopsies due to therapy induced 
gland shrinkage, especially following endocrine therapy [253]. However, a high Gleason 
score in prostate biopsies following radiotherapy is shown to strongly predict recurrence after 
salvage cryotherapy [215]. Furthermore, high-molecular-weight cytokeratin (CKHMW) 
staining was used to distinguish therapy-induced atypia in benign glands from malignancy 
[213]. Thus, the false-positive biopsy rate was most likely low. By contrast, the amount of 
residual cancer may be underestimated because a more extended number of biopsy cores may 
have detected additional small tumour foci [40]. The number of biopsies taken in study 3 is, 
however comparable with previous reports. Zelfsky et al. performed sextant biopsy  [155], 
whereas minimum sextant biopsy was taken by Crook et al [95]. Thus, a high false-negative 
biopsy rate seems unlikely. The number of patients examined with biopsy (n=117) was 
suboptimal with an inclusion rate of 29%. In comparison, Zelefsky et al. included 339 of 1773 
patients (19%) in a study reporting on posttreatment biopsy results following EBRT for 
prostate cancer [155], whereas Crook et al. obtained posttreatment biopsies from 205 of 378 
patients (54%) in their RCT [95]. Even though prostate cancer risk-factors were well balanced 
in the study population, intergroup-comparisons should be interpreted with caution because a 
low inclusion rate may yield a selection bias. In patients with residual cancer, median follow-
up to PSA-recurrence was 37 months compared to 65 months in patients without residual 
cancer, whereas the biopsies were performed at a median of 45 months. Consequently, PSA-
recurrence had occurred at the time of biopsy in 36% of patients with residual cancer and in 
only 4.7% with negative biopsy result. However, according to the written informed consent, 
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the biopsy result was not available for the treating physicians or the patients. Thus, it is 
unlikely that a selection bias has been introduced by an intention of allocating patients with 
PSA-recurrence and biopsy-verified residual cancer to salvage therapy.  In summary, these 
possible limitations are unlikely to affect the general conclusions. 
A major strength of the study is the prospective design with well balanced groups, 
which reduces the risk of selection bias. Moreover, a detection bias seems highly unlikely 
because the pathologist was blinded of which therapy the individual patients were allocated to 
and had no knowledge of any of the clinical data, whereas the number of biopsy cores 
obtained in patients with positive and negative biopsy was equal.  
 
Study 4 
Study 4 has some limitations. The self-assessment questionnaire used was not validated. 
However, to our knowledge, validated self-assessment questionnaires on prostate biopsy side 
effects have not been developed. Although the compliance to the questionnaire was high 
(91%), the true incidence of infrequently occurring serious complications in patients 
undergoing posttreatment prostate biopsy may have been underestimated due to a relatively 
small sample-size. For instance, no patient had rectal bleeding that required therapy, a 
complication which is reported to occur in less than 1% following diagnostic prostate biopsy 
[160, 165, 166]. Moreover, a comparison between pre- and posttreatment biopsy side effects 
was not planned. If patients who experienced major side effects of biopsy at diagnosis refused 
posttreatment biopsy, a selection bias is possible.  Pain intensity was assessed using a 4-point 
verbal rating scale, whereas a visual analogue or a numeric rating scale may have given a 
more reliable estimate. However, the validity of verbal rating scales in pain intensity 
assessment is well documented [218]. Although the questionnaire assessed clinically 
important change in urinary flow (severe reduced flow and retention) subjectively, 
uroflowmetry was not performed, and minor changes may have been underestimated.  
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Notwithstanding that the results of study 4 must be interpreted with care because of 
these limitations, the respondents seems to be representative of the SPCG-7 study population, 
and the patient-reported posttreatment biopsy side effects in study 4 most likely reflect those 
commonly seen in clinical practice. Posttreatment biopsy has been recommended to select 
patients with residual tumours who may take advantage from salvage therapy [215, 216]. In 
Norway, salvage HIFU has been offered to patients with locally radiorecurrent prostate cancer 
and no metastasis since 2006. A positive posttreatment biopsy taken at least 18 months after 
irradiation is a mandatory eligibility criterion [237]. To our knowledge, study 4 is the first to 
report posttreatment prostate biopsy side effects, and the results may be helpful in patient 
counselling. 
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CONCLUSIONS 
x As assessed by histopatholgical examination of open RRP-specimens, locally 
advanced prostate cancers and positive tumour margins were significantly reduced 
over time in the initial 5 years cohort of patients treated at Trondheim University 
Hospital. Reduced incidence of intracapsular tumour margins and margin positive pT2 
tumours over time imply that the surgical technique improved in the study period. 
x The addition of 70Gy EBRT to ADT significantly improved disease free, cancer 
specific and overall survival in patients with locally advanced or histologically 
aggressive non-metastatic prostate cancer with acceptable side effects. 
x The addition of 70 Gy EBRT to ADT in patients with locally advanced or 
histologically aggressive non-metastatic prostate cancer significantly improved local 
tumour control as assessed by posttreatment biopsy. Significantly more patients with 
histologically proven residual disease died of prostate cancer. In multivariable 
analysis, residual cancer was predictive of recurrence. 
x Posttreatment prostate biopsy can be performed safely with a low risk of major 
complications. Patients who receive combined endocrine therapy and EBRT may have 
a modestly increased risk of rectal bleeding as compared to patients on endocrine 
therapy alone.  
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ISSUES FOR FUTURE RESEARCH  
 
 
Although prostatectomy and radiotherapy are acceptable local therapies in non-metastatic 
prostate cancer, the optimal local therapy in is still to be defined as the efficacy of these 
modalities has not been compared in RCTs. However, several issues must be taken into 
consideration in future prostate cancer trials. Whereas active surveillance is acceptable in low-
risk patients [77-79], the optimal RP procedure (open RP vs. minimal invasive procedures 
such as robot-assisted RP) is still controversial [107]. The addition of ADT in high risk 
patients as well as dose-escalation beyond 72 Gy is recommended in the intermediate and 
high risk groups if EBRT is chosen, whereas the role of ADT combined with dose-escalated 
RT in intermediate risk patients is unclear [60]. Furthermore, at least 60Gy adjuvant EBRT 
should be offered patients with pT3 and/or margin positive tumours following prostatectomy 
[123]. Finally, chemotherapy (docetaxcel) has become standard therapy in castration resistant 
metastatic prostate cancer [254], and adjuvant docetaxcel after prostatectomy and EBRT is 
currently evaluated in the SPCG 12 and 13 randomized studies. Thus, future multimodal 
management of non-metastatic prostate cancer may include several treatment modalities, and 
to adequately design a RCT comparing the efficacy and side effects of prostatectomy and 
radiotherapy will certainly not be straightforward.  
Whether irradiation of the pelvic lymph nodes is necessary in high risk prostate cancer 
treated with radiotherapy is still controversial, as a PFS benefit was demonstrated in only one 
of several RCTs [118-120]. A study with sufficient power to demonstrate a CSS and OS 
benefit from pelvic lymph irradiation, if any, is warranted. Evaluation of side effects will be 
essential.  
Although not compared with EBRT in RCTs, dose-escalation may also be achieved 
with brachytherapy [113, 115]. Moreover, dose-escalation with hypofractionated  EBRT is 
shown to yield acceptable side effects and survival in non-randomised studies [255], and the 
efficacy and toxicity is currently evaluated in ongoing RCTs comparing conventional 
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fractionation and hypofractionation schemes. The dose-escalation strategies to be tested in 
future radiotherapy studies may thus imply conventionally fractionated and hypofractionated, 
EBRT, brachytherapy as well as combinations.   
Castration and antiandrogen monotherapy yields equal survival in M0 prostate cancer 
[89], and both therapies are shown to improve survival if combined with EBRT. Whereas 
several RCTs have shown the beneficial effect of castration in this setting [88], antiandrogen 
therapy (bicalutamide) was demonstrated to be superior to placebo in a subgroup analysis of a 
large randomized trial [101]. Although long term antiandrogen therapy was used in the 
SPCG-7 trial, RCTs comparing castration with antiandrogens in combination with irradiation 
for non-metastatic prostate cancer do not exist. The burden of evidence seems to lie on the 
antiandrogens, and a RCT with non-inferiority design appears to be appropriate way to 
compare antiandrogen therapy with castration in this setting. 
Although immediate castration improves OS in pN+ patients operated on with 
prostatectomy [96], the role of adjuvant ADT in lymph node-negative patients is unclear. 
Possibly, the beneficial effect of ADT obtained when given in addition to local radiation 
therapy may also be achieved following prostatectomy. This remains to be demonstrated in a 
randomized study. 
The predictive value of post radiation prostate biopsy is still controversial. Although 
study 3 as well as the prospective study conducted by Crook et al. demonstrated that a 
positive biopsy predicted biochemical recurrence [95], the association with metastasis and 
mortality remains to be shown prospectively. The predictive value of RPC with respect to 
these clinically important outcomes demonstrated in retrospective studies [155] remains 
unreliable because such studies may be severely biased. In future prospective radiotherapy 
studies, pre-planned posttreatment biopsies may resolve this issue if taken in a sufficient 
number of patients. This clarification is particularly important if posttreatment biopsies are 
used to select patients for post-radiation salvage therapies. Kattan et al. have developed a 
nomogram to predict treatment failure following EBRT [69], and recently Spiess et al. 
 70
fractionation and hypofractionation schemes. The dose-escalation strategies to be tested in 
future radiotherapy studies may thus imply conventionally fractionated and hypofractionated, 
EBRT, brachytherapy as well as combinations.   
Castration and antiandrogen monotherapy yields equal survival in M0 prostate cancer 
[89], and both therapies are shown to improve survival if combined with EBRT. Whereas 
several RCTs have shown the beneficial effect of castration in this setting [88], antiandrogen 
therapy (bicalutamide) was demonstrated to be superior to placebo in a subgroup analysis of a 
large randomized trial [101]. Although long term antiandrogen therapy was used in the 
SPCG-7 trial, RCTs comparing castration with antiandrogens in combination with irradiation 
for non-metastatic prostate cancer do not exist. The burden of evidence seems to lie on the 
antiandrogens, and a RCT with non-inferiority design appears to be appropriate way to 
compare antiandrogen therapy with castration in this setting. 
Although immediate castration improves OS in pN+ patients operated on with 
prostatectomy [96], the role of adjuvant ADT in lymph node-negative patients is unclear. 
Possibly, the beneficial effect of ADT obtained when given in addition to local radiation 
therapy may also be achieved following prostatectomy. This remains to be demonstrated in a 
randomized study. 
The predictive value of post radiation prostate biopsy is still controversial. Although 
study 3 as well as the prospective study conducted by Crook et al. demonstrated that a 
positive biopsy predicted biochemical recurrence [95], the association with metastasis and 
mortality remains to be shown prospectively. The predictive value of RPC with respect to 
these clinically important outcomes demonstrated in retrospective studies [155] remains 
unreliable because such studies may be severely biased. In future prospective radiotherapy 
studies, pre-planned posttreatment biopsies may resolve this issue if taken in a sufficient 
number of patients. This clarification is particularly important if posttreatment biopsies are 
used to select patients for post-radiation salvage therapies. Kattan et al. have developed a 
nomogram to predict treatment failure following EBRT [69], and recently Spiess et al. 
 70
fractionation and hypofractionation schemes. The dose-escalation strategies to be tested in 
future radiotherapy studies may thus imply conventionally fractionated and hypofractionated, 
EBRT, brachytherapy as well as combinations.   
Castration and antiandrogen monotherapy yields equal survival in M0 prostate cancer 
[89], and both therapies are shown to improve survival if combined with EBRT. Whereas 
several RCTs have shown the beneficial effect of castration in this setting [88], antiandrogen 
therapy (bicalutamide) was demonstrated to be superior to placebo in a subgroup analysis of a 
large randomized trial [101]. Although long term antiandrogen therapy was used in the 
SPCG-7 trial, RCTs comparing castration with antiandrogens in combination with irradiation 
for non-metastatic prostate cancer do not exist. The burden of evidence seems to lie on the 
antiandrogens, and a RCT with non-inferiority design appears to be appropriate way to 
compare antiandrogen therapy with castration in this setting. 
Although immediate castration improves OS in pN+ patients operated on with 
prostatectomy [96], the role of adjuvant ADT in lymph node-negative patients is unclear. 
Possibly, the beneficial effect of ADT obtained when given in addition to local radiation 
therapy may also be achieved following prostatectomy. This remains to be demonstrated in a 
randomized study. 
The predictive value of post radiation prostate biopsy is still controversial. Although 
study 3 as well as the prospective study conducted by Crook et al. demonstrated that a 
positive biopsy predicted biochemical recurrence [95], the association with metastasis and 
mortality remains to be shown prospectively. The predictive value of RPC with respect to 
these clinically important outcomes demonstrated in retrospective studies [155] remains 
unreliable because such studies may be severely biased. In future prospective radiotherapy 
studies, pre-planned posttreatment biopsies may resolve this issue if taken in a sufficient 
number of patients. This clarification is particularly important if posttreatment biopsies are 
used to select patients for post-radiation salvage therapies. Kattan et al. have developed a 
nomogram to predict treatment failure following EBRT [69], and recently Spiess et al. 
 70
fractionation and hypofractionation schemes. The dose-escalation strategies to be tested in 
future radiotherapy studies may thus imply conventionally fractionated and hypofractionated, 
EBRT, brachytherapy as well as combinations.   
Castration and antiandrogen monotherapy yields equal survival in M0 prostate cancer 
[89], and both therapies are shown to improve survival if combined with EBRT. Whereas 
several RCTs have shown the beneficial effect of castration in this setting [88], antiandrogen 
therapy (bicalutamide) was demonstrated to be superior to placebo in a subgroup analysis of a 
large randomized trial [101]. Although long term antiandrogen therapy was used in the 
SPCG-7 trial, RCTs comparing castration with antiandrogens in combination with irradiation 
for non-metastatic prostate cancer do not exist. The burden of evidence seems to lie on the 
antiandrogens, and a RCT with non-inferiority design appears to be appropriate way to 
compare antiandrogen therapy with castration in this setting. 
Although immediate castration improves OS in pN+ patients operated on with 
prostatectomy [96], the role of adjuvant ADT in lymph node-negative patients is unclear. 
Possibly, the beneficial effect of ADT obtained when given in addition to local radiation 
therapy may also be achieved following prostatectomy. This remains to be demonstrated in a 
randomized study. 
The predictive value of post radiation prostate biopsy is still controversial. Although 
study 3 as well as the prospective study conducted by Crook et al. demonstrated that a 
positive biopsy predicted biochemical recurrence [95], the association with metastasis and 
mortality remains to be shown prospectively. The predictive value of RPC with respect to 
these clinically important outcomes demonstrated in retrospective studies [155] remains 
unreliable because such studies may be severely biased. In future prospective radiotherapy 
studies, pre-planned posttreatment biopsies may resolve this issue if taken in a sufficient 
number of patients. This clarification is particularly important if posttreatment biopsies are 
used to select patients for post-radiation salvage therapies. Kattan et al. have developed a 
nomogram to predict treatment failure following EBRT [69], and recently Spiess et al. 
 71
presented a pretreatment nomogram to predict biochemical failure following salvage 
cryotherapy in patients with post-EBRT relapse [256]. Predictor variables included in these 
nomograms were cT-stage, pretreatment s-PSA, pretreatment biopsy Gleason score as well as 
radiation dose and the use of ADT. In a phase I/II study, a high Gleason score in post-EBRT 
biopsy verified residual tumour was shown to be a predictor of recurrence following salvage 
cryotherapy [215]. Thus, the addition of posttreatment biopsy status might possibly increase 
the predictive value of pre-salvavage treatment nomograms. Such nomograms should be 
evaluated in prospective studies.  
Study 4 suggests that posttreatment prostate biopsy can be performed with a low risk 
of serious complications. However, the sample-size was relatively small, and this finding 
should be verified in a larger cohort in order to estimate the true incidence of rare and serious 
complications using validated self-assessment questionnaires as well as objective methods 
such as flowmetry. Moreover, the efficacy of local anaesthesia and antibiotic prophylaxis 
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RESIDUAL PROSTATE CANCER IN PATIENTS TREATEDWITH ENDOCRINE
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Purpose: The Scandinavian Prostate Cancer Group-7 randomized trial demonstrated a survival beneﬁt of com-
bined endocrine therapy and external-beam radiotherapy over endocrine therapy alone in patients with high-
risk prostate cancer. In a subset of the study population, the incidence and clinical implications of residual prostate
cancer in posttreatment prostate biopsy specimens was evaluated.
Methods andMaterials: Biopsy specimens were obtained from120 of 875men in the Scandinavian Prostate Cancer
Group-7 study.
Results: Biopsies were performed at median of 45 months follow-up. In 63 patients receiving endocrine treatment
only and 57 patients receiving combined treatment, residual cancer was found in 66% (n = 41) and 22% (n = 12),
respectively (p < 0.0001). The vast majority of residual tumors were poorly differentiated (Gleason score$8). En-
docrine therapy alone was predictive of residual prostate cancer: odds ratio 7.49 (3.18–17.7), p < 0.0001. In patients
with positive vs. negative biopsy the incidences of clinical events were as follows: biochemical recurrence 74% vs.
27% (p < 0.0001), local progression 26% vs. 4.7% (p = 0.002), distant recurrence 17% vs. 9.4% (p = 0.27), clinical
recurrence 36% vs. 13% (p = 0.006), cancer-speciﬁc death 19% vs. 9.7% (p = 0.025). In multivariable analysis, bio-
chemical recurrence was signiﬁcantly associated with residual cancer: hazard ratio 2.69 (1.45–4.99), p = 0.002, and
endocrine therapy alone hazard ratio 3.45 (1.80–6.62), p < 0.0001.
Conclusions: Radiotherapy combined with hormones improved local tumor control in comparison with endocrine
therapy alone. Residual prostate cancer was signiﬁcantly associated with serum prostate-speciﬁc antigen recur-
rence, local tumor progression, clinical recurrence, and cancer-speciﬁc death in univariable analysis. Residual can-
cer was predictive of prostate-speciﬁc antigen recurrence in multivariable analysis.  2010 Elsevier Inc.
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INTRODUCTION
In locally advanced prostate cancer, antiandrogen monother-
apy is equally efﬁcient to luteinising-hormone releasing
hormone agonist therapy (1), and survival is improved if
external-beam radiotherapy (EBRT) is combined with endo-
crine therapy (2–5). Randomized trials have shown that
dose-escalated radiation therapy decrease recurrence rates,
especially in patients with unfavourable clinical tumor stage,
pretreatment serum prostate-speciﬁc antigen (PSA), and
tumor grade (6–8). To explore the role of EBRT in locally
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CLINICAL INVESTIGATION
RESIDUAL PROSTATE CANCER IN PATIENTS TREATEDWITH ENDOCRINE
THERAPY WITH ORWITHOUT RADICAL RADIOTHERAPY: A SIDE STUDY OF THE
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Purpose: The Scandinavian Prostate Cancer Group-7 randomized trial demonstrated a survival beneﬁt of com-
bined endocrine therapy and external-beam radiotherapy over endocrine therapy alone in patients with high-
risk prostate cancer. In a subset of the study population, the incidence and clinical implications of residual prostate
cancer in posttreatment prostate biopsy specimens was evaluated.
Methods andMaterials: Biopsy specimens were obtained from120 of 875men in the Scandinavian Prostate Cancer
Group-7 study.
Results: Biopsies were performed at median of 45 months follow-up. In 63 patients receiving endocrine treatment
only and 57 patients receiving combined treatment, residual cancer was found in 66% (n = 41) and 22% (n = 12),
respectively (p < 0.0001). The vast majority of residual tumors were poorly differentiated (Gleason score$8). En-
docrine therapy alone was predictive of residual prostate cancer: odds ratio 7.49 (3.18–17.7), p < 0.0001. In patients
with positive vs. negative biopsy the incidences of clinical events were as follows: biochemical recurrence 74% vs.
27% (p < 0.0001), local progression 26% vs. 4.7% (p = 0.002), distant recurrence 17% vs. 9.4% (p = 0.27), clinical
recurrence 36% vs. 13% (p = 0.006), cancer-speciﬁc death 19% vs. 9.7% (p = 0.025). In multivariable analysis, bio-
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Conclusions: Radiotherapy combined with hormones improved local tumor control in comparison with endocrine
therapy alone. Residual prostate cancer was signiﬁcantly associated with serum prostate-speciﬁc antigen recur-
rence, local tumor progression, clinical recurrence, and cancer-speciﬁc death in univariable analysis. Residual can-
cer was predictive of prostate-speciﬁc antigen recurrence in multivariable analysis.  2010 Elsevier Inc.
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advanced prostate cancer, the Scandinavian Prostate Cancer
Group (SPCG) initiated the SPCG-7 trial in 1995 in which
patients were randomized to endocrine therapy either alone
or combined with EBRT. Combined therapy improved over-
all survival and reduced the10-year cancer-speciﬁc mortality
by 50% (9).
Variations in serumPSA levels thatmaybemisinterpreted as
treatment failure (PSA bouncing) are commonly observed the
ﬁrst 2 years of follow-up in patients successfully treated with
radiotherapy (10). The PSA recurrence deﬁnition is thus based
on an increasing PSA above the nadir value (11). Whereas
a PSA recurrence does not distinguish between local and
distant failure, biopsy-veriﬁed residual prostate cancer
enhances the risk of PSA recurrence, metastatic disease, and
prostate cancer mortality (12–15). Moreover, the residual
cancer incidence in patients treated with radiotherapy is
dependent on radiation dose (15, 16), and the addition of
endocrine therapy reduces the incidence in comparison with
EBRT alone (15, 17). However, the incidence and clinical
signiﬁcance of residual cancer in patients with locally
advanced tumors treated with endocrine therapy alone is
unknown.
The primary aim of this prospective study was to evaluate
the incidence of residual prostate cancer in posttreatment
prostate biopsy specimens in patients treated with either
endocrine therapy alone or combined endocrine and radio-
therapy in the SPCG-7 trial. Secondary objectives were to
assess the clinical implications of residual cancer.
METHODS AND MATERIALS
Patients
Locally advanced or local aggressive tumors were included in the
SPCG-7 study (9). Patients were randomly assigned to receive either
endocrine therapy alone or endocrine therapy plus EBRT. A total of
875 patients from Norway, Sweden, and Denmark recruited at 47
centers met the inclusion criteria and were randomized from Febru-
ary 1996 until December 2002. The present biopsy side-study aimed
to include all consecutive patients at 11 of the 47 hospitals at approx-
imately 30 to 42 months of follow-up. Posttreatment prostate biop-
sies were performed in patients with World Health Organisation
(WHO) performance status 01 unless there were medical contraindi-
cations. Before inclusion, all participants received oral and written
information and gave their written informed consent. The study
was approved by the Regional Committee for Medical and Health
Research Ethics of Middle-Norway, conducted according to the
Declaration of Helsinki, and is registered as a Current Controlled
Trials study (registration number ISRCTN76301727).
Study therapy
After randomization, all patients were given 3 months of neoad-
juvant total androgen blockade (TAB) with antiandrogen therapy
(ﬂutamide 250 mg three times daily) plus leuproline 11.25 mg sub-
cutaneously, followed by the same ﬂutamide dose continuously. In
case of PSA recurrence only, no change of treatment was recom-
mended. Local progression was optionally treated with medical or
surgical castration, transurethral resection of the prostate, or pallia-
tive radiotherapy. If metastases were diagnosed, castration was
added, and discontinuation of the antiandrogen was recommended
on further progression. In patients with unacceptable side effects
of ﬂutamide, the drug was stopped and then restarted with gradually
increasing doses to at least 500 mg daily. If the side effects recurred,
the antiandrogen therapy was changed to bicalutamide 150 mg
daily. After three months of TAB, patients allocated to combined
therapy received a minimum of 70 Gy conformal EBRT with
a dose of 2 Gy per fraction (9).
Follow-up
Clinical examination and assessment of serum PSA was made in
all patients every 3 months the ﬁrst year and every 6 months there-
after. Follow-up concluded by the end of February 2008 or on the
date of death. Survival status was controlled against the nationwide
population registries in Sweden and Norway. No patient was lost
from follow-up as a result of emigration.
Deﬁnition of clinical events
PSA recurrence. A PSA increase$2.0 ng/mL above nadir value
according to the 2006 American Society for Therapeutic Radiology
and Oncology recommendation (11).
Local progression. Increasing urinary problems (frequency,
urgency, obstruction) of such a magnitude that change of treatment
was necessary.
Distant recurrence. Metastases veriﬁed by X-ray, computed
tomography, bone scan, magnetic resonance imaging, or histologic
examination.
Clinical recurrence. Local progression, distant recurrence, or
both.
The cause of death was classiﬁed into one of ﬁve categories: (1)
death from prostate cancer, (2) death from other causes with prostate
cancer signiﬁcantly contributing, (3) death from anticancer therapy,
(4) death from other causes without prostate cancer signiﬁcantly
contributing, and (5) death from unknown cause. Cancer-speciﬁc
death was deﬁned as items 1 and 2.
Prostate biopsy procedure
All patients were given prophylactic antibiotics according to local
practice before the transrectal ultrasound-guided biopsy procedure.
At least two biopsy specimens were taken from the primary lesion,
followed by posterolateral sextant biopsies.
Histologic examination
All prostate needle biopsy specimens were ﬁxed in neutral
buffered 4% formaldehyde solution, dehydrated, and separately
embedded in parafﬁn. From all specimens, sections 5 mm thick
were cut, and one section from each core was stained with
hematoxylin-eosin-saffron for histologic examination performed
by two pathologists (OAH and TV) who had no knowledge of the
clinical data or the original histopathologic reports. On the basis
of the results of microscopic evaluation, representative sections
from each case were incubated with antiserum to high-molecular-
weight cytokeratin to distinguish residual tumor from benign glands
with radiotherapy effect (18). Gleason score was settled by agree-
ment using the two most prevailing growth patterns. Each tumor-
containing core was graded separately. Finally, each case was given
an overall score according to recent guidelines (19).
Statistics
Categoric variables were compared using the chi-square or Fisher’s
exact tests. Continuous variables were compared using the Student’s t
test. If the distribution was not normal, the Mann-WhitneyU test was
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applied. The association between residual cancer and therapy group,
and baseline prostate cancer risk factors (serum PSA,WHO grade III,
clinical stage T3, and seminal vesicle tumor involvement) was
assessed in univariable analysis. Variables with a p value of #0.1
were evaluated simultaneously in a logistic regression model. Odds
ratio (OR) with a 95% conﬁdence interval (CI) was used as effect
measure. The association between clinical events and residual cancer
was assessed using the log-rank test. Kaplan-Meier curves of freedom
from PSA recurrence probability were estimated in patients with and
without residual cancer. Furthermore, the inﬂuence of therapy
group and baseline prostate cancer risk factors on clinical events
was assessed in univariable analysis. Variables with a p value #0.1
were analyzed simultaneously with the biopsy result using a Cox
proportional-hazards model. Hazard ratio (HR) with a 95% CI was
used as effect measure.
Given that ﬁve events per variable is suggested to be sufﬁcient in
regression analysis (20), a maximum of two variables were included
in the regression models in the case of 10 to 30 events. Otherwise,
a maximum of one variable per 10 events was included. A two-
sided p value <0.05 was considered statistically signiﬁcant.
RESULTS
Study population
Eleven Norwegian and Swedish hospitals participated in
the biopsy study. Of 875 patients included in the SPCG-7
trial, these hospitals recruited 415 (47%) patients. Posttreat-
ment prostate biopsy was performed in 120 (29%) patients
in these hospitals. Sixty-four patients were allocated to endo-
crine therapy alone and 56 patients to combined therapy. One
patient allocated to endocrine therapy alone had PSA recur-
rence 6 months after randomization and started curative
radiotherapy with a total dose of 70 Gy 38 months before bi-
opsy. Thus, of the included patients, 63 (53%) were in the en-
docrine group and 57 (47%) were in the combined therapy
group receiving a median radiation dose of 70 Gy (range
70–78 Gy). Three patients received more than 70 Gy.
All patients completed neoadjuvant TAB. In the endocrine
therapy group, 25 patients had the ﬂutamide dose modiﬁed in
the follow-up. In 10 of these patients the antiandrogen was
later changed to bicalutamide 150 mg. The corresponding
ﬁgures in the combined therapy group were 21 and 8 patients.
Additionally, the antiandrogen was changed to bicalutamide
without ﬂutamide dose modiﬁcations in 1 patient in the
combined therapy group.
Median follow-up time for survival was 101.5 months
(range, 54–140 months) and an inter quartile range (IQR)
of 86.5 to 117.8 months, and 97 months (range, 10–134;
IQR, 80.0–112.75) for other clinical events.
There were no statistically signiﬁcant differences in
clinical baseline characteristics between the total SPCG-7
study population and the 120 patients in the biopsy study
(Table 1). Except for age, there were no signiﬁcant differ-
ences in baseline characteristics between therapy groups in
the biopsy study (Table 2).
Biopsy result
A median of 8 biopsy cores (range, 2–10) were taken at
a median of 45 months (range, 30–97 months) follow-up.
The biopsy specimens from 1 patient in the endocrine group
and 2 patients in the combined therapy group contained no
prostate tissue. Consequently, biopsy specimens from 117
patients (62 patients in the endocrine group and 55 patients
in the combined therapy group) were available for histologic
evaluation. In 62 patients receiving endocrine treatment only
and 55 patients receiving combined treatment, residual can-
cer was found in 66% (n = 41) and 22% (n = 12), respectively
(p < 0.0001). The majority of positive biopsy specimens in
the endocrine group and all in the combined therapy group
contained poorly differentiated (Gleason score $8) cancer
(Table 3). There was no signiﬁcant difference in baseline
prostate cancer risk factors in patients with and without resid-
ual cancer (Table 4). In logistic regression analysis, signiﬁ-
cant predictors of residual prostate cancer were as follows:
endocrine therapy alone, OR 7.49 (3.18–17.7), p < 0.0001,
and baseline PSA, OR 1.03 (1.00–1.07), p = 0.044.
Clinical events
Incidences of clinical events and univariable intergroup
comparisons in patients with and without residual cancer
are shown in Table 5.
PSA recurrence
The median nadir PSA value in the study population was
0.1 ng/mL (IQR 0.1-0.1), and the level was not signiﬁcantly
inﬂuenced by biopsy-proven residual cancer. Moreover, the
48% incidence (n = 56) of PSA recurrence observed in this
study was not signiﬁcantly different from the 41% (n =
362) incidence in the total SPCG-7 study population. The
estimated Kaplan-Meier curves of freedom from PSA recur-
rence probability in patients with and without residual cancer
are shown in Fig. 1. In Cox regression analysis, factors signif-
icantly associated with PSA recurrence were as follows: re-
sidual cancer, HR 2.69 (1.45–4.99), p = 0.002; endocrine
Table 1. Baseline characteristics of 875 men enrolled in the
SPCG-7 study and of 120 patients who underwent
posttreatment prostate biopsy
Characteristic
SPCG-7
study
Posttreatment
prostate biopsy
Age (y), mean (SD) 65.8 (5.4) 66.1 (6.1)
Median PSA, ng/mL (IQR) 16 (9–27) 15.5 (8–26.75)
Tumor stage, n (%)
T1b 3 (0.3) 0
T1c 16 (1.8) 4 (3.3)
T2 169 (19.3) 18 (15)
T3 682 (77.9) 98 (81.7)
Unknown 5 (0.6) 0
Seminal vesicle
involvement, n (%)
203 (23.2) 24 (20)
WHO grade, n (%)
I 131 (17) 25 (20.8)
II 572 (65.4) 71 (59.2)
III 164 (18.7) 23 (19.2)
Unknown 8 (0.9) 1 (0.8)
Abbreviations: SD = standard deviation; PSA = prostate-speciﬁc
antigen; IQR = interquartile range.
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applied. The association between residual cancer and therapy group,
and baseline prostate cancer risk factors (serum PSA,WHO grade III,
clinical stage T3, and seminal vesicle tumor involvement) was
assessed in univariable analysis. Variables with a p value of #0.1
were evaluated simultaneously in a logistic regression model. Odds
ratio (OR) with a 95% conﬁdence interval (CI) was used as effect
measure. The association between clinical events and residual cancer
was assessed using the log-rank test. Kaplan-Meier curves of freedom
from PSA recurrence probability were estimated in patients with and
without residual cancer. Furthermore, the inﬂuence of therapy
group and baseline prostate cancer risk factors on clinical events
was assessed in univariable analysis. Variables with a p value #0.1
were analyzed simultaneously with the biopsy result using a Cox
proportional-hazards model. Hazard ratio (HR) with a 95% CI was
used as effect measure.
Given that ﬁve events per variable is suggested to be sufﬁcient in
regression analysis (20), a maximum of two variables were included
in the regression models in the case of 10 to 30 events. Otherwise,
a maximum of one variable per 10 events was included. A two-
sided p value <0.05 was considered statistically signiﬁcant.
RESULTS
Study population
Eleven Norwegian and Swedish hospitals participated in
the biopsy study. Of 875 patients included in the SPCG-7
trial, these hospitals recruited 415 (47%) patients. Posttreat-
ment prostate biopsy was performed in 120 (29%) patients
in these hospitals. Sixty-four patients were allocated to endo-
crine therapy alone and 56 patients to combined therapy. One
patient allocated to endocrine therapy alone had PSA recur-
rence 6 months after randomization and started curative
radiotherapy with a total dose of 70 Gy 38 months before bi-
opsy. Thus, of the included patients, 63 (53%) were in the en-
docrine group and 57 (47%) were in the combined therapy
group receiving a median radiation dose of 70 Gy (range
70–78 Gy). Three patients received more than 70 Gy.
All patients completed neoadjuvant TAB. In the endocrine
therapy group, 25 patients had the ﬂutamide dose modiﬁed in
the follow-up. In 10 of these patients the antiandrogen was
later changed to bicalutamide 150 mg. The corresponding
ﬁgures in the combined therapy group were 21 and 8 patients.
Additionally, the antiandrogen was changed to bicalutamide
without ﬂutamide dose modiﬁcations in 1 patient in the
combined therapy group.
Median follow-up time for survival was 101.5 months
(range, 54–140 months) and an inter quartile range (IQR)
of 86.5 to 117.8 months, and 97 months (range, 10–134;
IQR, 80.0–112.75) for other clinical events.
There were no statistically signiﬁcant differences in
clinical baseline characteristics between the total SPCG-7
study population and the 120 patients in the biopsy study
(Table 1). Except for age, there were no signiﬁcant differ-
ences in baseline characteristics between therapy groups in
the biopsy study (Table 2).
Biopsy result
A median of 8 biopsy cores (range, 2–10) were taken at
a median of 45 months (range, 30–97 months) follow-up.
The biopsy specimens from 1 patient in the endocrine group
and 2 patients in the combined therapy group contained no
prostate tissue. Consequently, biopsy specimens from 117
patients (62 patients in the endocrine group and 55 patients
in the combined therapy group) were available for histologic
evaluation. In 62 patients receiving endocrine treatment only
and 55 patients receiving combined treatment, residual can-
cer was found in 66% (n = 41) and 22% (n = 12), respectively
(p < 0.0001). The majority of positive biopsy specimens in
the endocrine group and all in the combined therapy group
contained poorly differentiated (Gleason score $8) cancer
(Table 3). There was no signiﬁcant difference in baseline
prostate cancer risk factors in patients with and without resid-
ual cancer (Table 4). In logistic regression analysis, signiﬁ-
cant predictors of residual prostate cancer were as follows:
endocrine therapy alone, OR 7.49 (3.18–17.7), p < 0.0001,
and baseline PSA, OR 1.03 (1.00–1.07), p = 0.044.
Clinical events
Incidences of clinical events and univariable intergroup
comparisons in patients with and without residual cancer
are shown in Table 5.
PSA recurrence
The median nadir PSA value in the study population was
0.1 ng/mL (IQR 0.1-0.1), and the level was not signiﬁcantly
inﬂuenced by biopsy-proven residual cancer. Moreover, the
48% incidence (n = 56) of PSA recurrence observed in this
study was not signiﬁcantly different from the 41% (n =
362) incidence in the total SPCG-7 study population. The
estimated Kaplan-Meier curves of freedom from PSA recur-
rence probability in patients with and without residual cancer
are shown in Fig. 1. In Cox regression analysis, factors signif-
icantly associated with PSA recurrence were as follows: re-
sidual cancer, HR 2.69 (1.45–4.99), p = 0.002; endocrine
Table 1. Baseline characteristics of 875 men enrolled in the
SPCG-7 study and of 120 patients who underwent
posttreatment prostate biopsy
Characteristic
SPCG-7
study
Posttreatment
prostate biopsy
Age (y), mean (SD) 65.8 (5.4) 66.1 (6.1)
Median PSA, ng/mL (IQR) 16 (9–27) 15.5 (8–26.75)
Tumor stage, n (%)
T1b 3 (0.3) 0
T1c 16 (1.8) 4 (3.3)
T2 169 (19.3) 18 (15)
T3 682 (77.9) 98 (81.7)
Unknown 5 (0.6) 0
Seminal vesicle
involvement, n (%)
203 (23.2) 24 (20)
WHO grade, n (%)
I 131 (17) 25 (20.8)
II 572 (65.4) 71 (59.2)
III 164 (18.7) 23 (19.2)
Unknown 8 (0.9) 1 (0.8)
Abbreviations: SD = standard deviation; PSA = prostate-speciﬁc
antigen; IQR = interquartile range.
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applied. The association between residual cancer and therapy group,
and baseline prostate cancer risk factors (serum PSA,WHO grade III,
clinical stage T3, and seminal vesicle tumor involvement) was
assessed in univariable analysis. Variables with a p value of #0.1
were evaluated simultaneously in a logistic regression model. Odds
ratio (OR) with a 95% conﬁdence interval (CI) was used as effect
measure. The association between clinical events and residual cancer
was assessed using the log-rank test. Kaplan-Meier curves of freedom
from PSA recurrence probability were estimated in patients with and
without residual cancer. Furthermore, the inﬂuence of therapy
group and baseline prostate cancer risk factors on clinical events
was assessed in univariable analysis. Variables with a p value #0.1
were analyzed simultaneously with the biopsy result using a Cox
proportional-hazards model. Hazard ratio (HR) with a 95% CI was
used as effect measure.
Given that ﬁve events per variable is suggested to be sufﬁcient in
regression analysis (20), a maximum of two variables were included
in the regression models in the case of 10 to 30 events. Otherwise,
a maximum of one variable per 10 events was included. A two-
sided p value <0.05 was considered statistically signiﬁcant.
RESULTS
Study population
Eleven Norwegian and Swedish hospitals participated in
the biopsy study. Of 875 patients included in the SPCG-7
trial, these hospitals recruited 415 (47%) patients. Posttreat-
ment prostate biopsy was performed in 120 (29%) patients
in these hospitals. Sixty-four patients were allocated to endo-
crine therapy alone and 56 patients to combined therapy. One
patient allocated to endocrine therapy alone had PSA recur-
rence 6 months after randomization and started curative
radiotherapy with a total dose of 70 Gy 38 months before bi-
opsy. Thus, of the included patients, 63 (53%) were in the en-
docrine group and 57 (47%) were in the combined therapy
group receiving a median radiation dose of 70 Gy (range
70–78 Gy). Three patients received more than 70 Gy.
All patients completed neoadjuvant TAB. In the endocrine
therapy group, 25 patients had the ﬂutamide dose modiﬁed in
the follow-up. In 10 of these patients the antiandrogen was
later changed to bicalutamide 150 mg. The corresponding
ﬁgures in the combined therapy group were 21 and 8 patients.
Additionally, the antiandrogen was changed to bicalutamide
without ﬂutamide dose modiﬁcations in 1 patient in the
combined therapy group.
Median follow-up time for survival was 101.5 months
(range, 54–140 months) and an inter quartile range (IQR)
of 86.5 to 117.8 months, and 97 months (range, 10–134;
IQR, 80.0–112.75) for other clinical events.
There were no statistically signiﬁcant differences in
clinical baseline characteristics between the total SPCG-7
study population and the 120 patients in the biopsy study
(Table 1). Except for age, there were no signiﬁcant differ-
ences in baseline characteristics between therapy groups in
the biopsy study (Table 2).
Biopsy result
A median of 8 biopsy cores (range, 2–10) were taken at
a median of 45 months (range, 30–97 months) follow-up.
The biopsy specimens from 1 patient in the endocrine group
and 2 patients in the combined therapy group contained no
prostate tissue. Consequently, biopsy specimens from 117
patients (62 patients in the endocrine group and 55 patients
in the combined therapy group) were available for histologic
evaluation. In 62 patients receiving endocrine treatment only
and 55 patients receiving combined treatment, residual can-
cer was found in 66% (n = 41) and 22% (n = 12), respectively
(p < 0.0001). The majority of positive biopsy specimens in
the endocrine group and all in the combined therapy group
contained poorly differentiated (Gleason score $8) cancer
(Table 3). There was no signiﬁcant difference in baseline
prostate cancer risk factors in patients with and without resid-
ual cancer (Table 4). In logistic regression analysis, signiﬁ-
cant predictors of residual prostate cancer were as follows:
endocrine therapy alone, OR 7.49 (3.18–17.7), p < 0.0001,
and baseline PSA, OR 1.03 (1.00–1.07), p = 0.044.
Clinical events
Incidences of clinical events and univariable intergroup
comparisons in patients with and without residual cancer
are shown in Table 5.
PSA recurrence
The median nadir PSA value in the study population was
0.1 ng/mL (IQR 0.1-0.1), and the level was not signiﬁcantly
inﬂuenced by biopsy-proven residual cancer. Moreover, the
48% incidence (n = 56) of PSA recurrence observed in this
study was not signiﬁcantly different from the 41% (n =
362) incidence in the total SPCG-7 study population. The
estimated Kaplan-Meier curves of freedom from PSA recur-
rence probability in patients with and without residual cancer
are shown in Fig. 1. In Cox regression analysis, factors signif-
icantly associated with PSA recurrence were as follows: re-
sidual cancer, HR 2.69 (1.45–4.99), p = 0.002; endocrine
Table 1. Baseline characteristics of 875 men enrolled in the
SPCG-7 study and of 120 patients who underwent
posttreatment prostate biopsy
Characteristic
SPCG-7
study
Posttreatment
prostate biopsy
Age (y), mean (SD) 65.8 (5.4) 66.1 (6.1)
Median PSA, ng/mL (IQR) 16 (9–27) 15.5 (8–26.75)
Tumor stage, n (%)
T1b 3 (0.3) 0
T1c 16 (1.8) 4 (3.3)
T2 169 (19.3) 18 (15)
T3 682 (77.9) 98 (81.7)
Unknown 5 (0.6) 0
Seminal vesicle
involvement, n (%)
203 (23.2) 24 (20)
WHO grade, n (%)
I 131 (17) 25 (20.8)
II 572 (65.4) 71 (59.2)
III 164 (18.7) 23 (19.2)
Unknown 8 (0.9) 1 (0.8)
Abbreviations: SD = standard deviation; PSA = prostate-speciﬁc
antigen; IQR = interquartile range.
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applied. The association between residual cancer and therapy group,
and baseline prostate cancer risk factors (serum PSA,WHO grade III,
clinical stage T3, and seminal vesicle tumor involvement) was
assessed in univariable analysis. Variables with a p value of #0.1
were evaluated simultaneously in a logistic regression model. Odds
ratio (OR) with a 95% conﬁdence interval (CI) was used as effect
measure. The association between clinical events and residual cancer
was assessed using the log-rank test. Kaplan-Meier curves of freedom
from PSA recurrence probability were estimated in patients with and
without residual cancer. Furthermore, the inﬂuence of therapy
group and baseline prostate cancer risk factors on clinical events
was assessed in univariable analysis. Variables with a p value #0.1
were analyzed simultaneously with the biopsy result using a Cox
proportional-hazards model. Hazard ratio (HR) with a 95% CI was
used as effect measure.
Given that ﬁve events per variable is suggested to be sufﬁcient in
regression analysis (20), a maximum of two variables were included
in the regression models in the case of 10 to 30 events. Otherwise,
a maximum of one variable per 10 events was included. A two-
sided p value <0.05 was considered statistically signiﬁcant.
RESULTS
Study population
Eleven Norwegian and Swedish hospitals participated in
the biopsy study. Of 875 patients included in the SPCG-7
trial, these hospitals recruited 415 (47%) patients. Posttreat-
ment prostate biopsy was performed in 120 (29%) patients
in these hospitals. Sixty-four patients were allocated to endo-
crine therapy alone and 56 patients to combined therapy. One
patient allocated to endocrine therapy alone had PSA recur-
rence 6 months after randomization and started curative
radiotherapy with a total dose of 70 Gy 38 months before bi-
opsy. Thus, of the included patients, 63 (53%) were in the en-
docrine group and 57 (47%) were in the combined therapy
group receiving a median radiation dose of 70 Gy (range
70–78 Gy). Three patients received more than 70 Gy.
All patients completed neoadjuvant TAB. In the endocrine
therapy group, 25 patients had the ﬂutamide dose modiﬁed in
the follow-up. In 10 of these patients the antiandrogen was
later changed to bicalutamide 150 mg. The corresponding
ﬁgures in the combined therapy group were 21 and 8 patients.
Additionally, the antiandrogen was changed to bicalutamide
without ﬂutamide dose modiﬁcations in 1 patient in the
combined therapy group.
Median follow-up time for survival was 101.5 months
(range, 54–140 months) and an inter quartile range (IQR)
of 86.5 to 117.8 months, and 97 months (range, 10–134;
IQR, 80.0–112.75) for other clinical events.
There were no statistically signiﬁcant differences in
clinical baseline characteristics between the total SPCG-7
study population and the 120 patients in the biopsy study
(Table 1). Except for age, there were no signiﬁcant differ-
ences in baseline characteristics between therapy groups in
the biopsy study (Table 2).
Biopsy result
A median of 8 biopsy cores (range, 2–10) were taken at
a median of 45 months (range, 30–97 months) follow-up.
The biopsy specimens from 1 patient in the endocrine group
and 2 patients in the combined therapy group contained no
prostate tissue. Consequently, biopsy specimens from 117
patients (62 patients in the endocrine group and 55 patients
in the combined therapy group) were available for histologic
evaluation. In 62 patients receiving endocrine treatment only
and 55 patients receiving combined treatment, residual can-
cer was found in 66% (n = 41) and 22% (n = 12), respectively
(p < 0.0001). The majority of positive biopsy specimens in
the endocrine group and all in the combined therapy group
contained poorly differentiated (Gleason score $8) cancer
(Table 3). There was no signiﬁcant difference in baseline
prostate cancer risk factors in patients with and without resid-
ual cancer (Table 4). In logistic regression analysis, signiﬁ-
cant predictors of residual prostate cancer were as follows:
endocrine therapy alone, OR 7.49 (3.18–17.7), p < 0.0001,
and baseline PSA, OR 1.03 (1.00–1.07), p = 0.044.
Clinical events
Incidences of clinical events and univariable intergroup
comparisons in patients with and without residual cancer
are shown in Table 5.
PSA recurrence
The median nadir PSA value in the study population was
0.1 ng/mL (IQR 0.1-0.1), and the level was not signiﬁcantly
inﬂuenced by biopsy-proven residual cancer. Moreover, the
48% incidence (n = 56) of PSA recurrence observed in this
study was not signiﬁcantly different from the 41% (n =
362) incidence in the total SPCG-7 study population. The
estimated Kaplan-Meier curves of freedom from PSA recur-
rence probability in patients with and without residual cancer
are shown in Fig. 1. In Cox regression analysis, factors signif-
icantly associated with PSA recurrence were as follows: re-
sidual cancer, HR 2.69 (1.45–4.99), p = 0.002; endocrine
Table 1. Baseline characteristics of 875 men enrolled in the
SPCG-7 study and of 120 patients who underwent
posttreatment prostate biopsy
Characteristic
SPCG-7
study
Posttreatment
prostate biopsy
Age (y), mean (SD) 65.8 (5.4) 66.1 (6.1)
Median PSA, ng/mL (IQR) 16 (9–27) 15.5 (8–26.75)
Tumor stage, n (%)
T1b 3 (0.3) 0
T1c 16 (1.8) 4 (3.3)
T2 169 (19.3) 18 (15)
T3 682 (77.9) 98 (81.7)
Unknown 5 (0.6) 0
Seminal vesicle
involvement, n (%)
203 (23.2) 24 (20)
WHO grade, n (%)
I 131 (17) 25 (20.8)
II 572 (65.4) 71 (59.2)
III 164 (18.7) 23 (19.2)
Unknown 8 (0.9) 1 (0.8)
Abbreviations: SD = standard deviation; PSA = prostate-speciﬁc
antigen; IQR = interquartile range.
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therapy alone, HR 3.45 (1.80–6.62), p < 0.0005; baseline
serum PSA level, HR 1.02 (1.00–1.04), p = 0.014.
Local progression
Two patients with biopsy-veriﬁed residual cancer in the
endocrine therapy group had local progression with rising
PSA, but not yet PSA recurrence according to the American
Society for Therapeutic Radiology and Oncology deﬁnition.
All other patients with local progression had PSA recurrence.
Local progression was found in 3 patients without residual
cancer, of whom all had PSA progression and 1 was later
diagnosed with metastasis. Although Cox regression analysis
showed no statistically signiﬁcant association between resid-
ual cancer and local progression, a signiﬁcant association
with endocrine therapy alone was found: HR 11.6 (1.38–
97.2), p = 0.024.
Distant recurrence
All patients with distant recurrence had PSA recurrence,
among whom 5 patients also had local progression. Although
patients with residual cancer more often had distant recur-
rence (17 vs. 9.4%), the difference was not statistically
signiﬁcant (Table 5).
Clinical recurrence
In patients with residual cancer (n = 63), clinical recur-
rence was more common than in patients without residual
tumor (p = 0.006) (Table 5). However, in Cox regression
analysis, only endocrine therapy alone was signiﬁcantly
associated with clinical recurrence: HR 3.86 (1.30–11.5),
p = 0.015.
Mortality
At the cutoff point of follow-up, 26 patients had died.
Whereas 13 patients died of other causes than prostate cancer,
the incidence of cancer-speciﬁc death was 11% (n = 13),
compared with 13% (n = 362) in the total SPCG-7 study pop-
ulation (p = 0.5). Of patients with residual cancer, 5 died of
prostate cancer and 5 died of other causes with prostate can-
cer signiﬁcantly contributing. The corresponding ﬁgures in
patients without residual cancer were 2 patients and 1 patient,
respectively. Although cancer-speciﬁc death occurred more
frequently (p = 0.025) in patients with residual cancer
(Table 5), no signiﬁcant association was found when residual
tumor and therapy group were evaluated simultaneously in
Cox regression analysis.
DISCUSSION
The principal ﬁnding in this study was that patients receiv-
ing endocrine therapy alone had a three times higher inci-
dence of local residual prostate cancer than did patients
Table 3. Biopsy results in 117 patients with locally advanced
prostate cancer treated with endocrine therapy alone or
combined endocrine and radical radiotherapy
Biopsy
result
Endocrine
therapy
alone (n = 62)
Combined endocrine
and radiotherapy
(n = 55) p value
Residual cancer, n (%) 41 (66) 12 (22) <0.001*
Time to biopsy, mo
(range)
43 (32–81) 45 (30–97) 0.27y
Median number
of biopsy cores
taken (range)
7 (2–10) 8 (3–11) 0.40y
Median number
of tumor-containing
biopsy
cores in patients
with residual cancer
(range)
3 (1–8) 4 (1–9) 0.45y
Gleason score,
median (range)
8 (6–10) 8 (8–8)
Gleason score 6, n (%) 1 (2.4) 0
Gleason score 7, n (%) 7 (17) 0
Gleason score 8, n (%) 14 (34) 12 (100)
Gleason score 9, n (%) 15 (37) 0
Gleason score 10, n (%) 4 (9.8) 0
* Chi-square test.
y Mann-Whitney U test.
Table 2. Baseline characteristics of 120 men enrolled in the
SPCG-7 study who underwent posttreatment prostate biopsy
Characteristic
Endocrine
therapy alone
Combined endocrine
and radiotherapy pvalue
Included
patients, n
63 57
No prostate
tissue, n
2 1
Analyzed
patients, n
62 55
Age (y), mean
(SD)
67.1 (5.7) 64.9 (6.4) 0.047*
Median PSA,
ng/mL (IQR)
14.5 (8–26.8) 16.5 (8–26.8) 0.94y
Tumor stage, n
(%)
0.21z
T1c 2 (3.2) 2 (3.5)
T2 13 (20.6) 5 (8.8)
T3 48 (76.2) 49 (87.7)
Seminal vesicle
involvement,
n (%)
9 (14.3) 15 (26.3) 0.11x
Unknown, n
(%)
1 (1.6) 0
WHO grade, n
(%)
0.49x
I 16 (25.4) 9 (15.8)
II 36 (57.1) 35 (61.4)
III 11 (17.5) 12 (21.1)
Unknown, n
(%)
0 1 (1.8)
Abbreviations: SD = standard deviation; PSA = prostate-speciﬁc
antigen; IQR = interquartile range; WHO =World Health Organiza-
tion.
* Student’s t test.
y Mann-Whitney U test.
z Fisher’s exact test.
x Chi-square test.
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therapy alone, HR 3.45 (1.80–6.62), p < 0.0005; baseline
serum PSA level, HR 1.02 (1.00–1.04), p = 0.014.
Local progression
Two patients with biopsy-veriﬁed residual cancer in the
endocrine therapy group had local progression with rising
PSA, but not yet PSA recurrence according to the American
Society for Therapeutic Radiology and Oncology deﬁnition.
All other patients with local progression had PSA recurrence.
Local progression was found in 3 patients without residual
cancer, of whom all had PSA progression and 1 was later
diagnosed with metastasis. Although Cox regression analysis
showed no statistically signiﬁcant association between resid-
ual cancer and local progression, a signiﬁcant association
with endocrine therapy alone was found: HR 11.6 (1.38–
97.2), p = 0.024.
Distant recurrence
All patients with distant recurrence had PSA recurrence,
among whom 5 patients also had local progression. Although
patients with residual cancer more often had distant recur-
rence (17 vs. 9.4%), the difference was not statistically
signiﬁcant (Table 5).
Clinical recurrence
In patients with residual cancer (n = 63), clinical recur-
rence was more common than in patients without residual
tumor (p = 0.006) (Table 5). However, in Cox regression
analysis, only endocrine therapy alone was signiﬁcantly
associated with clinical recurrence: HR 3.86 (1.30–11.5),
p = 0.015.
Mortality
At the cutoff point of follow-up, 26 patients had died.
Whereas 13 patients died of other causes than prostate cancer,
the incidence of cancer-speciﬁc death was 11% (n = 13),
compared with 13% (n = 362) in the total SPCG-7 study pop-
ulation (p = 0.5). Of patients with residual cancer, 5 died of
prostate cancer and 5 died of other causes with prostate can-
cer signiﬁcantly contributing. The corresponding ﬁgures in
patients without residual cancer were 2 patients and 1 patient,
respectively. Although cancer-speciﬁc death occurred more
frequently (p = 0.025) in patients with residual cancer
(Table 5), no signiﬁcant association was found when residual
tumor and therapy group were evaluated simultaneously in
Cox regression analysis.
DISCUSSION
The principal ﬁnding in this study was that patients receiv-
ing endocrine therapy alone had a three times higher inci-
dence of local residual prostate cancer than did patients
Table 3. Biopsy results in 117 patients with locally advanced
prostate cancer treated with endocrine therapy alone or
combined endocrine and radical radiotherapy
Biopsy
result
Endocrine
therapy
alone (n = 62)
Combined endocrine
and radiotherapy
(n = 55) p value
Residual cancer, n (%) 41 (66) 12 (22) <0.001*
Time to biopsy, mo
(range)
43 (32–81) 45 (30–97) 0.27y
Median number
of biopsy cores
taken (range)
7 (2–10) 8 (3–11) 0.40y
Median number
of tumor-containing
biopsy
cores in patients
with residual cancer
(range)
3 (1–8) 4 (1–9) 0.45y
Gleason score,
median (range)
8 (6–10) 8 (8–8)
Gleason score 6, n (%) 1 (2.4) 0
Gleason score 7, n (%) 7 (17) 0
Gleason score 8, n (%) 14 (34) 12 (100)
Gleason score 9, n (%) 15 (37) 0
Gleason score 10, n (%) 4 (9.8) 0
* Chi-square test.
y Mann-Whitney U test.
Table 2. Baseline characteristics of 120 men enrolled in the
SPCG-7 study who underwent posttreatment prostate biopsy
Characteristic
Endocrine
therapy alone
Combined endocrine
and radiotherapy pvalue
Included
patients, n
63 57
No prostate
tissue, n
2 1
Analyzed
patients, n
62 55
Age (y), mean
(SD)
67.1 (5.7) 64.9 (6.4) 0.047*
Median PSA,
ng/mL (IQR)
14.5 (8–26.8) 16.5 (8–26.8) 0.94y
Tumor stage, n
(%)
0.21z
T1c 2 (3.2) 2 (3.5)
T2 13 (20.6) 5 (8.8)
T3 48 (76.2) 49 (87.7)
Seminal vesicle
involvement,
n (%)
9 (14.3) 15 (26.3) 0.11x
Unknown, n
(%)
1 (1.6) 0
WHO grade, n
(%)
0.49x
I 16 (25.4) 9 (15.8)
II 36 (57.1) 35 (61.4)
III 11 (17.5) 12 (21.1)
Unknown, n
(%)
0 1 (1.8)
Abbreviations: SD = standard deviation; PSA = prostate-speciﬁc
antigen; IQR = interquartile range; WHO =World Health Organiza-
tion.
* Student’s t test.
y Mann-Whitney U test.
z Fisher’s exact test.
x Chi-square test.
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therapy alone, HR 3.45 (1.80–6.62), p < 0.0005; baseline
serum PSA level, HR 1.02 (1.00–1.04), p = 0.014.
Local progression
Two patients with biopsy-veriﬁed residual cancer in the
endocrine therapy group had local progression with rising
PSA, but not yet PSA recurrence according to the American
Society for Therapeutic Radiology and Oncology deﬁnition.
All other patients with local progression had PSA recurrence.
Local progression was found in 3 patients without residual
cancer, of whom all had PSA progression and 1 was later
diagnosed with metastasis. Although Cox regression analysis
showed no statistically signiﬁcant association between resid-
ual cancer and local progression, a signiﬁcant association
with endocrine therapy alone was found: HR 11.6 (1.38–
97.2), p = 0.024.
Distant recurrence
All patients with distant recurrence had PSA recurrence,
among whom 5 patients also had local progression. Although
patients with residual cancer more often had distant recur-
rence (17 vs. 9.4%), the difference was not statistically
signiﬁcant (Table 5).
Clinical recurrence
In patients with residual cancer (n = 63), clinical recur-
rence was more common than in patients without residual
tumor (p = 0.006) (Table 5). However, in Cox regression
analysis, only endocrine therapy alone was signiﬁcantly
associated with clinical recurrence: HR 3.86 (1.30–11.5),
p = 0.015.
Mortality
At the cutoff point of follow-up, 26 patients had died.
Whereas 13 patients died of other causes than prostate cancer,
the incidence of cancer-speciﬁc death was 11% (n = 13),
compared with 13% (n = 362) in the total SPCG-7 study pop-
ulation (p = 0.5). Of patients with residual cancer, 5 died of
prostate cancer and 5 died of other causes with prostate can-
cer signiﬁcantly contributing. The corresponding ﬁgures in
patients without residual cancer were 2 patients and 1 patient,
respectively. Although cancer-speciﬁc death occurred more
frequently (p = 0.025) in patients with residual cancer
(Table 5), no signiﬁcant association was found when residual
tumor and therapy group were evaluated simultaneously in
Cox regression analysis.
DISCUSSION
The principal ﬁnding in this study was that patients receiv-
ing endocrine therapy alone had a three times higher inci-
dence of local residual prostate cancer than did patients
Table 3. Biopsy results in 117 patients with locally advanced
prostate cancer treated with endocrine therapy alone or
combined endocrine and radical radiotherapy
Biopsy
result
Endocrine
therapy
alone (n = 62)
Combined endocrine
and radiotherapy
(n = 55) p value
Residual cancer, n (%) 41 (66) 12 (22) <0.001*
Time to biopsy, mo
(range)
43 (32–81) 45 (30–97) 0.27y
Median number
of biopsy cores
taken (range)
7 (2–10) 8 (3–11) 0.40y
Median number
of tumor-containing
biopsy
cores in patients
with residual cancer
(range)
3 (1–8) 4 (1–9) 0.45y
Gleason score,
median (range)
8 (6–10) 8 (8–8)
Gleason score 6, n (%) 1 (2.4) 0
Gleason score 7, n (%) 7 (17) 0
Gleason score 8, n (%) 14 (34) 12 (100)
Gleason score 9, n (%) 15 (37) 0
Gleason score 10, n (%) 4 (9.8) 0
* Chi-square test.
y Mann-Whitney U test.
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therapy alone, HR 3.45 (1.80–6.62), p < 0.0005; baseline
serum PSA level, HR 1.02 (1.00–1.04), p = 0.014.
Local progression
Two patients with biopsy-veriﬁed residual cancer in the
endocrine therapy group had local progression with rising
PSA, but not yet PSA recurrence according to the American
Society for Therapeutic Radiology and Oncology deﬁnition.
All other patients with local progression had PSA recurrence.
Local progression was found in 3 patients without residual
cancer, of whom all had PSA progression and 1 was later
diagnosed with metastasis. Although Cox regression analysis
showed no statistically signiﬁcant association between resid-
ual cancer and local progression, a signiﬁcant association
with endocrine therapy alone was found: HR 11.6 (1.38–
97.2), p = 0.024.
Distant recurrence
All patients with distant recurrence had PSA recurrence,
among whom 5 patients also had local progression. Although
patients with residual cancer more often had distant recur-
rence (17 vs. 9.4%), the difference was not statistically
signiﬁcant (Table 5).
Clinical recurrence
In patients with residual cancer (n = 63), clinical recur-
rence was more common than in patients without residual
tumor (p = 0.006) (Table 5). However, in Cox regression
analysis, only endocrine therapy alone was signiﬁcantly
associated with clinical recurrence: HR 3.86 (1.30–11.5),
p = 0.015.
Mortality
At the cutoff point of follow-up, 26 patients had died.
Whereas 13 patients died of other causes than prostate cancer,
the incidence of cancer-speciﬁc death was 11% (n = 13),
compared with 13% (n = 362) in the total SPCG-7 study pop-
ulation (p = 0.5). Of patients with residual cancer, 5 died of
prostate cancer and 5 died of other causes with prostate can-
cer signiﬁcantly contributing. The corresponding ﬁgures in
patients without residual cancer were 2 patients and 1 patient,
respectively. Although cancer-speciﬁc death occurred more
frequently (p = 0.025) in patients with residual cancer
(Table 5), no signiﬁcant association was found when residual
tumor and therapy group were evaluated simultaneously in
Cox regression analysis.
DISCUSSION
The principal ﬁnding in this study was that patients receiv-
ing endocrine therapy alone had a three times higher inci-
dence of local residual prostate cancer than did patients
Table 3. Biopsy results in 117 patients with locally advanced
prostate cancer treated with endocrine therapy alone or
combined endocrine and radical radiotherapy
Biopsy
result
Endocrine
therapy
alone (n = 62)
Combined endocrine
and radiotherapy
(n = 55) p value
Residual cancer, n (%) 41 (66) 12 (22) <0.001*
Time to biopsy, mo
(range)
43 (32–81) 45 (30–97) 0.27y
Median number
of biopsy cores
taken (range)
7 (2–10) 8 (3–11) 0.40y
Median number
of tumor-containing
biopsy
cores in patients
with residual cancer
(range)
3 (1–8) 4 (1–9) 0.45y
Gleason score,
median (range)
8 (6–10) 8 (8–8)
Gleason score 6, n (%) 1 (2.4) 0
Gleason score 7, n (%) 7 (17) 0
Gleason score 8, n (%) 14 (34) 12 (100)
Gleason score 9, n (%) 15 (37) 0
Gleason score 10, n (%) 4 (9.8) 0
* Chi-square test.
y Mann-Whitney U test.
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receiving combined therapy (Table 3). Residual cancer was
signiﬁcantly associated with PSA recurrence. The propor-
tions mimicked almost exactly the ﬁnal 10-year ﬁgures on
PSA recurrence in the treatment arms of the SPCG-7 trial (9).
The biopsy-veriﬁed local control rate in the combined
therapy group was 78%. Previous studies have reported local
tumor control assessed by posttreatment biopsy in 40–80% of
patients receiving 70 Gy or less (12, 13, 15, 21, 22). The
residual prostate cancer incidence is, however, reduced if
EBRT is combined with endocrine therapy, indicating
a radiosensitizing effect (15, 17, 23). In accordance with
the present study results, Zelefsky et al. reported a local
control rate of 76% in patients treated with a radiation dose
of 70.2 Gy or less combined with endocrine therapy (15).
In contrast, biopsy-veriﬁed local control was achieved in
only 33% of patients treated with endocrine therapy alone
in the present study. Although radiotherapy constitutes an
essential therapeutic element, this ﬁnding illustrates the
additive effect of endocrine therapy.
Tumor regression after radiotherapy occurs gradually, and
a higher rate of positive and indeterminate biopsy specimens
showing treatment effect is obtained if specimens are taken
earlier than 2 years of follow-up. A signiﬁcant proportion
will eventually become negative if biopsy is repeated (13,
21, 24). In contrast to previous ﬁndings, inconclusive
biopsy specimens were not observed in this study with
a median of 42 months follow-up from radiotherapy to
biopsy.
Although not directly comparable (25), the tumors were
considerably less aggressive at diagnosis, inasmuch as
more than 80% of the cancers initially were WHO grade
I or II. The shift toward high-grade malignancy (Table 3)
observed in this study may be caused by a gradual dediffer-
entiation over time, eradication of low-grade tumor elements,
or a combination of both.
The association of residual tumor with PSA recurrence
observed in this study corresponds with previous reports
(12, 14, 15). However, residual cancer and early PSA
recurrence are reported to be predictive of distant
metastases and prostate cancer mortality (15, 26). Although
study patients with residual cancer had earlier PSA
recurrence than did patients with negative biopsy
specimens, residual cancer had no inﬂuence on other
clinical endpoints in multivariable analysis. Nevertheless,
a survival beneﬁt in favor of combined therapy was clearly
demonstrated in the SPCG-7 trial (9), and the patients in
the present study constitute a subset of the SPCG-7 study
population with similar baseline prostate cancer risk factors
and clinical outcome. Most likely, posttreatment biopsies
would be required in a substantially larger cohort to explore
the inﬂuence of residual cancer on distant metastases and
survival with sufﬁcient statistical power.
In patients unsuccessfully treated with radiotherapy,
eradication of the residual tumor may still be achieved with
cryosurgery, salvage prostatectomy, or high-intensity
focused ultrasound (27–29). However, the optimal salvage
therapy is unknown, and randomized trials comparing
available treatment modalities are warranted. Posttreatment
prostate biopsy may be useful to select eligible patients.
The study has some possible limitations. The amount of
remaining and biologically aggressive cancer may be overes-
timated. In animal studies, cancer cells remaining after
Table 5. Clinical events in 117 patients with positive and
negative posttreatment biopsy performed at a median of
45 months follow-up
Clinical event, n (%)
With residual
cancer
(n = 53)
Without residual
cancer
(n = 64) p value
PSA recurrence* 39 (74) 17 (27) <0.001k
Time from
randomization to
PSA recurrence,
mo (IQR)
37 (13–59) 65 (39.5–69) 0.03**
PSA recurrence at biopsy 19 (36) 3 (4.7) <0.001yy
Local progression# 14 (26) 3 (4.7) 0.002k
Distant recurrencez 9 (17) 6 (9.4) 0.27k
Clinical recurrencex 19 (36) 8 (13) 0.006k
Cancer-speciﬁc death{ 10 (19) 3 (4.7) 0.025k
Abbreviations: PSA = prostate-speciﬁc antigen; IQR = interquar-
tile range.
Except for time to PSA recurrence, the values shown represent
number of patients with percentages in parentheses.
* PSA increase of 2 ng/mL or more above nadir value.
# Increasing urinary frequency, urgency, or obstruction of such
a magnitude that change of treatment was necessary. 12 patients
had PSA recurrence.
x Either local progression, distant recurrence, or both.
z Metastases veriﬁed radiologically or histologically All patients
had PSA recurrence.
{ Death from prostate cancer or other causes with prostate cancer
signiﬁcantly contributing.
k Log-rank test.
** Mann-Whitney U test.
yy Chi-square test.
Table 4. Baseline prostate cancer risk factors in 117 patients
with and without local residual prostate cancer
Characteristic
With residual
prostate cancer
(n = 53)
Without residual
prostate cancer
(n = 64) p value
Median PSA, ng/mL (IQR)13 (7–25.8) 16 (9.5–29) 0.11*
Tumor stage, n (%) 0.70y
T1c 2 (3.8) 1 (1.6)
T2 9 (17) 9 (14)
T3 42 (79) 54 (84)
Seminal vesicle
involvement, n (%)
7 (13) 17 (27) 0.11z
Unknown, n (%) 0 1 (1.6)
WHO grade, n (%) 0.81z
I 10 (19) 15 (23)
II 33 (62) 36 (56)
III 10 (19) 12 (19)
Unknown, n (%) 0 1 (1.6)
Abbreviations: PSA = prostate-speciﬁc antigen; IQR = interquar-
tile range.
* Mann-Whitney U test.
y Fisher’s exact test.
z Chi-square test.
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receiving combined therapy (Table 3). Residual cancer was
signiﬁcantly associated with PSA recurrence. The propor-
tions mimicked almost exactly the ﬁnal 10-year ﬁgures on
PSA recurrence in the treatment arms of the SPCG-7 trial (9).
The biopsy-veriﬁed local control rate in the combined
therapy group was 78%. Previous studies have reported local
tumor control assessed by posttreatment biopsy in 40–80% of
patients receiving 70 Gy or less (12, 13, 15, 21, 22). The
residual prostate cancer incidence is, however, reduced if
EBRT is combined with endocrine therapy, indicating
a radiosensitizing effect (15, 17, 23). In accordance with
the present study results, Zelefsky et al. reported a local
control rate of 76% in patients treated with a radiation dose
of 70.2 Gy or less combined with endocrine therapy (15).
In contrast, biopsy-veriﬁed local control was achieved in
only 33% of patients treated with endocrine therapy alone
in the present study. Although radiotherapy constitutes an
essential therapeutic element, this ﬁnding illustrates the
additive effect of endocrine therapy.
Tumor regression after radiotherapy occurs gradually, and
a higher rate of positive and indeterminate biopsy specimens
showing treatment effect is obtained if specimens are taken
earlier than 2 years of follow-up. A signiﬁcant proportion
will eventually become negative if biopsy is repeated (13,
21, 24). In contrast to previous ﬁndings, inconclusive
biopsy specimens were not observed in this study with
a median of 42 months follow-up from radiotherapy to
biopsy.
Although not directly comparable (25), the tumors were
considerably less aggressive at diagnosis, inasmuch as
more than 80% of the cancers initially were WHO grade
I or II. The shift toward high-grade malignancy (Table 3)
observed in this study may be caused by a gradual dediffer-
entiation over time, eradication of low-grade tumor elements,
or a combination of both.
The association of residual tumor with PSA recurrence
observed in this study corresponds with previous reports
(12, 14, 15). However, residual cancer and early PSA
recurrence are reported to be predictive of distant
metastases and prostate cancer mortality (15, 26). Although
study patients with residual cancer had earlier PSA
recurrence than did patients with negative biopsy
specimens, residual cancer had no inﬂuence on other
clinical endpoints in multivariable analysis. Nevertheless,
a survival beneﬁt in favor of combined therapy was clearly
demonstrated in the SPCG-7 trial (9), and the patients in
the present study constitute a subset of the SPCG-7 study
population with similar baseline prostate cancer risk factors
and clinical outcome. Most likely, posttreatment biopsies
would be required in a substantially larger cohort to explore
the inﬂuence of residual cancer on distant metastases and
survival with sufﬁcient statistical power.
In patients unsuccessfully treated with radiotherapy,
eradication of the residual tumor may still be achieved with
cryosurgery, salvage prostatectomy, or high-intensity
focused ultrasound (27–29). However, the optimal salvage
therapy is unknown, and randomized trials comparing
available treatment modalities are warranted. Posttreatment
prostate biopsy may be useful to select eligible patients.
The study has some possible limitations. The amount of
remaining and biologically aggressive cancer may be overes-
timated. In animal studies, cancer cells remaining after
Table 5. Clinical events in 117 patients with positive and
negative posttreatment biopsy performed at a median of
45 months follow-up
Clinical event, n (%)
With residual
cancer
(n = 53)
Without residual
cancer
(n = 64) p value
PSA recurrence* 39 (74) 17 (27) <0.001k
Time from
randomization to
PSA recurrence,
mo (IQR)
37 (13–59) 65 (39.5–69) 0.03**
PSA recurrence at biopsy 19 (36) 3 (4.7) <0.001yy
Local progression# 14 (26) 3 (4.7) 0.002k
Distant recurrencez 9 (17) 6 (9.4) 0.27k
Clinical recurrencex 19 (36) 8 (13) 0.006k
Cancer-speciﬁc death{ 10 (19) 3 (4.7) 0.025k
Abbreviations: PSA = prostate-speciﬁc antigen; IQR = interquar-
tile range.
Except for time to PSA recurrence, the values shown represent
number of patients with percentages in parentheses.
* PSA increase of 2 ng/mL or more above nadir value.
# Increasing urinary frequency, urgency, or obstruction of such
a magnitude that change of treatment was necessary. 12 patients
had PSA recurrence.
x Either local progression, distant recurrence, or both.
z Metastases veriﬁed radiologically or histologically All patients
had PSA recurrence.
{ Death from prostate cancer or other causes with prostate cancer
signiﬁcantly contributing.
k Log-rank test.
** Mann-Whitney U test.
yy Chi-square test.
Table 4. Baseline prostate cancer risk factors in 117 patients
with and without local residual prostate cancer
Characteristic
With residual
prostate cancer
(n = 53)
Without residual
prostate cancer
(n = 64) p value
Median PSA, ng/mL (IQR)13 (7–25.8) 16 (9.5–29) 0.11*
Tumor stage, n (%) 0.70y
T1c 2 (3.8) 1 (1.6)
T2 9 (17) 9 (14)
T3 42 (79) 54 (84)
Seminal vesicle
involvement, n (%)
7 (13) 17 (27) 0.11z
Unknown, n (%) 0 1 (1.6)
WHO grade, n (%) 0.81z
I 10 (19) 15 (23)
II 33 (62) 36 (56)
III 10 (19) 12 (19)
Unknown, n (%) 0 1 (1.6)
Abbreviations: PSA = prostate-speciﬁc antigen; IQR = interquar-
tile range.
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receiving combined therapy (Table 3). Residual cancer was
signiﬁcantly associated with PSA recurrence. The propor-
tions mimicked almost exactly the ﬁnal 10-year ﬁgures on
PSA recurrence in the treatment arms of the SPCG-7 trial (9).
The biopsy-veriﬁed local control rate in the combined
therapy group was 78%. Previous studies have reported local
tumor control assessed by posttreatment biopsy in 40–80% of
patients receiving 70 Gy or less (12, 13, 15, 21, 22). The
residual prostate cancer incidence is, however, reduced if
EBRT is combined with endocrine therapy, indicating
a radiosensitizing effect (15, 17, 23). In accordance with
the present study results, Zelefsky et al. reported a local
control rate of 76% in patients treated with a radiation dose
of 70.2 Gy or less combined with endocrine therapy (15).
In contrast, biopsy-veriﬁed local control was achieved in
only 33% of patients treated with endocrine therapy alone
in the present study. Although radiotherapy constitutes an
essential therapeutic element, this ﬁnding illustrates the
additive effect of endocrine therapy.
Tumor regression after radiotherapy occurs gradually, and
a higher rate of positive and indeterminate biopsy specimens
showing treatment effect is obtained if specimens are taken
earlier than 2 years of follow-up. A signiﬁcant proportion
will eventually become negative if biopsy is repeated (13,
21, 24). In contrast to previous ﬁndings, inconclusive
biopsy specimens were not observed in this study with
a median of 42 months follow-up from radiotherapy to
biopsy.
Although not directly comparable (25), the tumors were
considerably less aggressive at diagnosis, inasmuch as
more than 80% of the cancers initially were WHO grade
I or II. The shift toward high-grade malignancy (Table 3)
observed in this study may be caused by a gradual dediffer-
entiation over time, eradication of low-grade tumor elements,
or a combination of both.
The association of residual tumor with PSA recurrence
observed in this study corresponds with previous reports
(12, 14, 15). However, residual cancer and early PSA
recurrence are reported to be predictive of distant
metastases and prostate cancer mortality (15, 26). Although
study patients with residual cancer had earlier PSA
recurrence than did patients with negative biopsy
specimens, residual cancer had no inﬂuence on other
clinical endpoints in multivariable analysis. Nevertheless,
a survival beneﬁt in favor of combined therapy was clearly
demonstrated in the SPCG-7 trial (9), and the patients in
the present study constitute a subset of the SPCG-7 study
population with similar baseline prostate cancer risk factors
and clinical outcome. Most likely, posttreatment biopsies
would be required in a substantially larger cohort to explore
the inﬂuence of residual cancer on distant metastases and
survival with sufﬁcient statistical power.
In patients unsuccessfully treated with radiotherapy,
eradication of the residual tumor may still be achieved with
cryosurgery, salvage prostatectomy, or high-intensity
focused ultrasound (27–29). However, the optimal salvage
therapy is unknown, and randomized trials comparing
available treatment modalities are warranted. Posttreatment
prostate biopsy may be useful to select eligible patients.
The study has some possible limitations. The amount of
remaining and biologically aggressive cancer may be overes-
timated. In animal studies, cancer cells remaining after
Table 5. Clinical events in 117 patients with positive and
negative posttreatment biopsy performed at a median of
45 months follow-up
Clinical event, n (%)
With residual
cancer
(n = 53)
Without residual
cancer
(n = 64) p value
PSA recurrence* 39 (74) 17 (27) <0.001k
Time from
randomization to
PSA recurrence,
mo (IQR)
37 (13–59) 65 (39.5–69) 0.03**
PSA recurrence at biopsy 19 (36) 3 (4.7) <0.001yy
Local progression# 14 (26) 3 (4.7) 0.002k
Distant recurrencez 9 (17) 6 (9.4) 0.27k
Clinical recurrencex 19 (36) 8 (13) 0.006k
Cancer-speciﬁc death{ 10 (19) 3 (4.7) 0.025k
Abbreviations: PSA = prostate-speciﬁc antigen; IQR = interquar-
tile range.
Except for time to PSA recurrence, the values shown represent
number of patients with percentages in parentheses.
* PSA increase of 2 ng/mL or more above nadir value.
# Increasing urinary frequency, urgency, or obstruction of such
a magnitude that change of treatment was necessary. 12 patients
had PSA recurrence.
x Either local progression, distant recurrence, or both.
z Metastases veriﬁed radiologically or histologically All patients
had PSA recurrence.
{ Death from prostate cancer or other causes with prostate cancer
signiﬁcantly contributing.
k Log-rank test.
** Mann-Whitney U test.
yy Chi-square test.
Table 4. Baseline prostate cancer risk factors in 117 patients
with and without local residual prostate cancer
Characteristic
With residual
prostate cancer
(n = 53)
Without residual
prostate cancer
(n = 64) p value
Median PSA, ng/mL (IQR)13 (7–25.8) 16 (9.5–29) 0.11*
Tumor stage, n (%) 0.70y
T1c 2 (3.8) 1 (1.6)
T2 9 (17) 9 (14)
T3 42 (79) 54 (84)
Seminal vesicle
involvement, n (%)
7 (13) 17 (27) 0.11z
Unknown, n (%) 0 1 (1.6)
WHO grade, n (%) 0.81z
I 10 (19) 15 (23)
II 33 (62) 36 (56)
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receiving combined therapy (Table 3). Residual cancer was
signiﬁcantly associated with PSA recurrence. The propor-
tions mimicked almost exactly the ﬁnal 10-year ﬁgures on
PSA recurrence in the treatment arms of the SPCG-7 trial (9).
The biopsy-veriﬁed local control rate in the combined
therapy group was 78%. Previous studies have reported local
tumor control assessed by posttreatment biopsy in 40–80% of
patients receiving 70 Gy or less (12, 13, 15, 21, 22). The
residual prostate cancer incidence is, however, reduced if
EBRT is combined with endocrine therapy, indicating
a radiosensitizing effect (15, 17, 23). In accordance with
the present study results, Zelefsky et al. reported a local
control rate of 76% in patients treated with a radiation dose
of 70.2 Gy or less combined with endocrine therapy (15).
In contrast, biopsy-veriﬁed local control was achieved in
only 33% of patients treated with endocrine therapy alone
in the present study. Although radiotherapy constitutes an
essential therapeutic element, this ﬁnding illustrates the
additive effect of endocrine therapy.
Tumor regression after radiotherapy occurs gradually, and
a higher rate of positive and indeterminate biopsy specimens
showing treatment effect is obtained if specimens are taken
earlier than 2 years of follow-up. A signiﬁcant proportion
will eventually become negative if biopsy is repeated (13,
21, 24). In contrast to previous ﬁndings, inconclusive
biopsy specimens were not observed in this study with
a median of 42 months follow-up from radiotherapy to
biopsy.
Although not directly comparable (25), the tumors were
considerably less aggressive at diagnosis, inasmuch as
more than 80% of the cancers initially were WHO grade
I or II. The shift toward high-grade malignancy (Table 3)
observed in this study may be caused by a gradual dediffer-
entiation over time, eradication of low-grade tumor elements,
or a combination of both.
The association of residual tumor with PSA recurrence
observed in this study corresponds with previous reports
(12, 14, 15). However, residual cancer and early PSA
recurrence are reported to be predictive of distant
metastases and prostate cancer mortality (15, 26). Although
study patients with residual cancer had earlier PSA
recurrence than did patients with negative biopsy
specimens, residual cancer had no inﬂuence on other
clinical endpoints in multivariable analysis. Nevertheless,
a survival beneﬁt in favor of combined therapy was clearly
demonstrated in the SPCG-7 trial (9), and the patients in
the present study constitute a subset of the SPCG-7 study
population with similar baseline prostate cancer risk factors
and clinical outcome. Most likely, posttreatment biopsies
would be required in a substantially larger cohort to explore
the inﬂuence of residual cancer on distant metastases and
survival with sufﬁcient statistical power.
In patients unsuccessfully treated with radiotherapy,
eradication of the residual tumor may still be achieved with
cryosurgery, salvage prostatectomy, or high-intensity
focused ultrasound (27–29). However, the optimal salvage
therapy is unknown, and randomized trials comparing
available treatment modalities are warranted. Posttreatment
prostate biopsy may be useful to select eligible patients.
The study has some possible limitations. The amount of
remaining and biologically aggressive cancer may be overes-
timated. In animal studies, cancer cells remaining after
Table 5. Clinical events in 117 patients with positive and
negative posttreatment biopsy performed at a median of
45 months follow-up
Clinical event, n (%)
With residual
cancer
(n = 53)
Without residual
cancer
(n = 64) p value
PSA recurrence* 39 (74) 17 (27) <0.001k
Time from
randomization to
PSA recurrence,
mo (IQR)
37 (13–59) 65 (39.5–69) 0.03**
PSA recurrence at biopsy 19 (36) 3 (4.7) <0.001yy
Local progression# 14 (26) 3 (4.7) 0.002k
Distant recurrencez 9 (17) 6 (9.4) 0.27k
Clinical recurrencex 19 (36) 8 (13) 0.006k
Cancer-speciﬁc death{ 10 (19) 3 (4.7) 0.025k
Abbreviations: PSA = prostate-speciﬁc antigen; IQR = interquar-
tile range.
Except for time to PSA recurrence, the values shown represent
number of patients with percentages in parentheses.
* PSA increase of 2 ng/mL or more above nadir value.
# Increasing urinary frequency, urgency, or obstruction of such
a magnitude that change of treatment was necessary. 12 patients
had PSA recurrence.
x Either local progression, distant recurrence, or both.
z Metastases veriﬁed radiologically or histologically All patients
had PSA recurrence.
{ Death from prostate cancer or other causes with prostate cancer
signiﬁcantly contributing.
k Log-rank test.
** Mann-Whitney U test.
yy Chi-square test.
Table 4. Baseline prostate cancer risk factors in 117 patients
with and without local residual prostate cancer
Characteristic
With residual
prostate cancer
(n = 53)
Without residual
prostate cancer
(n = 64) p value
Median PSA, ng/mL (IQR)13 (7–25.8) 16 (9.5–29) 0.11*
Tumor stage, n (%) 0.70y
T1c 2 (3.8) 1 (1.6)
T2 9 (17) 9 (14)
T3 42 (79) 54 (84)
Seminal vesicle
involvement, n (%)
7 (13) 17 (27) 0.11z
Unknown, n (%) 0 1 (1.6)
WHO grade, n (%) 0.81z
I 10 (19) 15 (23)
II 33 (62) 36 (56)
III 10 (19) 12 (19)
Unknown, n (%) 0 1 (1.6)
Abbreviations: PSA = prostate-speciﬁc antigen; IQR = interquar-
tile range.
* Mann-Whitney U test.
y Fisher’s exact test.
z Chi-square test.
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irradiation may not be functionally active because they do not
proliferate even after testosterone stimulation (30). In this
study, cell proliferation was not examined. Moreover, Glea-
son scores may be artiﬁcially upgraded and thus unreliable in
posttreatment biopsy specimens because of therapy-induced
gland shrinkage, especially after endocrine therapy (31).
The morphology of the individual remaining cancer cells
(Table 3) was, however, that of poorly differentiated tumors
(Gleason score $8 in all residual tumors in the combined
group and in 80% in the endocrine group). Furthermore,
high-molecular-weight cytokeratin staining was used to
distinguish therapy-induced atypia in benign glands from
malignancy (18). Thus, the false-positive biopsy rate was
most likely low.
By contrast, the amount of residual cancer may be under-
estimated because a more extended number of biopsy cores
may have detected additional small tumor foci (32, 33).
However, the number of biopsy cores obtained in patients
with positive and negative biopsy results was equal.
Moreover, the pathologist was blinded to which therapy the
individual patients were allocated to. Thus, a high false-
negative biopsy rate seems unlikely, as does detection bias.
The 70-Gy radiation dose used is suboptimal. Dose escala-
tion is necessary to improve local control and clinical
outcome (6–8, 15, 16, 34), and today 78 Gy is mostly used
in Scandinavian EBRT.
A suboptimal number of patients was examined with
biopsy. The inclusion rate was 29%. In comparison, Zelefsky
et al. included 339 of 1773 patients (19%) in a study report-
ing on posttreatment biopsy results after EBRT for prostate
cancer (15). Even though prostate cancer risk factors were
well balanced in the study population, intergroup compari-
sons should be interpreted with caution because a low
inclusion rate may yield a selection bias.
Timing of posttreatment biopsy. In patients with residual
cancer, the median follow-up to PSA recurrence was
37 months, compared with 65 months in patients without
residual cancer, whereas the biopsies were performed at
a median of 45 months. Consequently, PSA recurrence had
occurred at the time of biopsy in 36% of patients with resid-
ual cancer and in only 4.7% with negative biopsy results.
However, according to the written informed consent, the
biopsy result was not available for the treating physicians
or the patients. Thus, it is unlikely that a selection bias
was introduced by an intent to allocate patientswith PSA recur-
rence and biopsy-veriﬁed residual cancer to salvage therapy.
In summary, these possible limitations are unlikely to
affect the general conclusions.
In conclusion, combined therapy with EBRT and antian-
drogen gave a superior biopsy-veriﬁed local tumor control
in comparison with endocrine therapy alone. The vast major-
ity of residual tumors were poorly differentiated. Residual
prostate cancer was signiﬁcantly associated with serum
PSA recurrence, local tumor progression, clinical recurrence,
and cancer-speciﬁc death in univariable analysis. Multivari-
able analysis showed that residual cancer was predictive of
PSA recurrence.
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Figure 1. Cumulative probability of freedom from prostate-speciﬁc
antigen (PSA) recurrence in biopsy-positive and -negative prostate
cancer patients treated with endocrine therapy alone or in combina-
tion with radiotherapy.
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irradiation may not be functionally active because they do not
proliferate even after testosterone stimulation (30). In this
study, cell proliferation was not examined. Moreover, Glea-
son scores may be artiﬁcially upgraded and thus unreliable in
posttreatment biopsy specimens because of therapy-induced
gland shrinkage, especially after endocrine therapy (31).
The morphology of the individual remaining cancer cells
(Table 3) was, however, that of poorly differentiated tumors
(Gleason score $8 in all residual tumors in the combined
group and in 80% in the endocrine group). Furthermore,
high-molecular-weight cytokeratin staining was used to
distinguish therapy-induced atypia in benign glands from
malignancy (18). Thus, the false-positive biopsy rate was
most likely low.
By contrast, the amount of residual cancer may be under-
estimated because a more extended number of biopsy cores
may have detected additional small tumor foci (32, 33).
However, the number of biopsy cores obtained in patients
with positive and negative biopsy results was equal.
Moreover, the pathologist was blinded to which therapy the
individual patients were allocated to. Thus, a high false-
negative biopsy rate seems unlikely, as does detection bias.
The 70-Gy radiation dose used is suboptimal. Dose escala-
tion is necessary to improve local control and clinical
outcome (6–8, 15, 16, 34), and today 78 Gy is mostly used
in Scandinavian EBRT.
A suboptimal number of patients was examined with
biopsy. The inclusion rate was 29%. In comparison, Zelefsky
et al. included 339 of 1773 patients (19%) in a study report-
ing on posttreatment biopsy results after EBRT for prostate
cancer (15). Even though prostate cancer risk factors were
well balanced in the study population, intergroup compari-
sons should be interpreted with caution because a low
inclusion rate may yield a selection bias.
Timing of posttreatment biopsy. In patients with residual
cancer, the median follow-up to PSA recurrence was
37 months, compared with 65 months in patients without
residual cancer, whereas the biopsies were performed at
a median of 45 months. Consequently, PSA recurrence had
occurred at the time of biopsy in 36% of patients with resid-
ual cancer and in only 4.7% with negative biopsy results.
However, according to the written informed consent, the
biopsy result was not available for the treating physicians
or the patients. Thus, it is unlikely that a selection bias
was introduced by an intent to allocate patientswith PSA recur-
rence and biopsy-veriﬁed residual cancer to salvage therapy.
In summary, these possible limitations are unlikely to
affect the general conclusions.
In conclusion, combined therapy with EBRT and antian-
drogen gave a superior biopsy-veriﬁed local tumor control
in comparison with endocrine therapy alone. The vast major-
ity of residual tumors were poorly differentiated. Residual
prostate cancer was signiﬁcantly associated with serum
PSA recurrence, local tumor progression, clinical recurrence,
and cancer-speciﬁc death in univariable analysis. Multivari-
able analysis showed that residual cancer was predictive of
PSA recurrence.
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Figure 1. Cumulative probability of freedom from prostate-speciﬁc
antigen (PSA) recurrence in biopsy-positive and -negative prostate
cancer patients treated with endocrine therapy alone or in combina-
tion with radiotherapy.
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irradiation may not be functionally active because they do not
proliferate even after testosterone stimulation (30). In this
study, cell proliferation was not examined. Moreover, Glea-
son scores may be artiﬁcially upgraded and thus unreliable in
posttreatment biopsy specimens because of therapy-induced
gland shrinkage, especially after endocrine therapy (31).
The morphology of the individual remaining cancer cells
(Table 3) was, however, that of poorly differentiated tumors
(Gleason score $8 in all residual tumors in the combined
group and in 80% in the endocrine group). Furthermore,
high-molecular-weight cytokeratin staining was used to
distinguish therapy-induced atypia in benign glands from
malignancy (18). Thus, the false-positive biopsy rate was
most likely low.
By contrast, the amount of residual cancer may be under-
estimated because a more extended number of biopsy cores
may have detected additional small tumor foci (32, 33).
However, the number of biopsy cores obtained in patients
with positive and negative biopsy results was equal.
Moreover, the pathologist was blinded to which therapy the
individual patients were allocated to. Thus, a high false-
negative biopsy rate seems unlikely, as does detection bias.
The 70-Gy radiation dose used is suboptimal. Dose escala-
tion is necessary to improve local control and clinical
outcome (6–8, 15, 16, 34), and today 78 Gy is mostly used
in Scandinavian EBRT.
A suboptimal number of patients was examined with
biopsy. The inclusion rate was 29%. In comparison, Zelefsky
et al. included 339 of 1773 patients (19%) in a study report-
ing on posttreatment biopsy results after EBRT for prostate
cancer (15). Even though prostate cancer risk factors were
well balanced in the study population, intergroup compari-
sons should be interpreted with caution because a low
inclusion rate may yield a selection bias.
Timing of posttreatment biopsy. In patients with residual
cancer, the median follow-up to PSA recurrence was
37 months, compared with 65 months in patients without
residual cancer, whereas the biopsies were performed at
a median of 45 months. Consequently, PSA recurrence had
occurred at the time of biopsy in 36% of patients with resid-
ual cancer and in only 4.7% with negative biopsy results.
However, according to the written informed consent, the
biopsy result was not available for the treating physicians
or the patients. Thus, it is unlikely that a selection bias
was introduced by an intent to allocate patientswith PSA recur-
rence and biopsy-veriﬁed residual cancer to salvage therapy.
In summary, these possible limitations are unlikely to
affect the general conclusions.
In conclusion, combined therapy with EBRT and antian-
drogen gave a superior biopsy-veriﬁed local tumor control
in comparison with endocrine therapy alone. The vast major-
ity of residual tumors were poorly differentiated. Residual
prostate cancer was signiﬁcantly associated with serum
PSA recurrence, local tumor progression, clinical recurrence,
and cancer-speciﬁc death in univariable analysis. Multivari-
able analysis showed that residual cancer was predictive of
PSA recurrence.
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irradiation may not be functionally active because they do not
proliferate even after testosterone stimulation (30). In this
study, cell proliferation was not examined. Moreover, Glea-
son scores may be artiﬁcially upgraded and thus unreliable in
posttreatment biopsy specimens because of therapy-induced
gland shrinkage, especially after endocrine therapy (31).
The morphology of the individual remaining cancer cells
(Table 3) was, however, that of poorly differentiated tumors
(Gleason score $8 in all residual tumors in the combined
group and in 80% in the endocrine group). Furthermore,
high-molecular-weight cytokeratin staining was used to
distinguish therapy-induced atypia in benign glands from
malignancy (18). Thus, the false-positive biopsy rate was
most likely low.
By contrast, the amount of residual cancer may be under-
estimated because a more extended number of biopsy cores
may have detected additional small tumor foci (32, 33).
However, the number of biopsy cores obtained in patients
with positive and negative biopsy results was equal.
Moreover, the pathologist was blinded to which therapy the
individual patients were allocated to. Thus, a high false-
negative biopsy rate seems unlikely, as does detection bias.
The 70-Gy radiation dose used is suboptimal. Dose escala-
tion is necessary to improve local control and clinical
outcome (6–8, 15, 16, 34), and today 78 Gy is mostly used
in Scandinavian EBRT.
A suboptimal number of patients was examined with
biopsy. The inclusion rate was 29%. In comparison, Zelefsky
et al. included 339 of 1773 patients (19%) in a study report-
ing on posttreatment biopsy results after EBRT for prostate
cancer (15). Even though prostate cancer risk factors were
well balanced in the study population, intergroup compari-
sons should be interpreted with caution because a low
inclusion rate may yield a selection bias.
Timing of posttreatment biopsy. In patients with residual
cancer, the median follow-up to PSA recurrence was
37 months, compared with 65 months in patients without
residual cancer, whereas the biopsies were performed at
a median of 45 months. Consequently, PSA recurrence had
occurred at the time of biopsy in 36% of patients with resid-
ual cancer and in only 4.7% with negative biopsy results.
However, according to the written informed consent, the
biopsy result was not available for the treating physicians
or the patients. Thus, it is unlikely that a selection bias
was introduced by an intent to allocate patientswith PSA recur-
rence and biopsy-veriﬁed residual cancer to salvage therapy.
In summary, these possible limitations are unlikely to
affect the general conclusions.
In conclusion, combined therapy with EBRT and antian-
drogen gave a superior biopsy-veriﬁed local tumor control
in comparison with endocrine therapy alone. The vast major-
ity of residual tumors were poorly differentiated. Residual
prostate cancer was signiﬁcantly associated with serum
PSA recurrence, local tumor progression, clinical recurrence,
and cancer-speciﬁc death in univariable analysis. Multivari-
able analysis showed that residual cancer was predictive of
PSA recurrence.
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Abstract
Objectives:  Posttreatment prostate biopsy side effects were evaluated in locally advanced prostate 
cancer patients on endocrine therapy alone or combined with radiotherapy in the SPCG-7 
randomised trial.  
Materials and Methods: 120 patients underwent transrectal, ultrasound-guided biopsy, and were 
requested to complete a questionnaire on side effects occurring within 7 days follow-up.
Results: The questionnaire was returned by 109 (91%) patients (endocrine therapy only 52%, 
combined therapy 48%). Therapy group had no significant influence on pain, urinary flow, 
hematuria or hematospermia. Pain at biopsy was reported in 63% (mild: 57%, moderate: 5.6%, 
severe: one patient), pain at follow-up in 31% (mild: 27%, moderate: four patients). Hematuria 
(mean duration 2.2 days) was reported in 41%, and reduced urinary flow in 20% (mild: 18%, 
severe: four patients, no patient had urinary retention). Hematospermia was scarce. No patient 
reported urinary tract infection. Rectal bleeding occurred in 18 % in the endocrine and 35 % in 
the combined therapy group (p=0.047) with a mean duration of 1.6 vs. 2.2 days, respectively, 
p=0.031. In logistic regression analysis, a trend towards increased rectal bleeding was found in 
patients on combined therapy (odds ratio 2.4, p=0.050).
Conclusions: Patient-reported posttreatment prostate biopsy side effects were mild and self-
limiting. 
Key words: Endocrine therapy; Posttreatment biopsy; Prostate cancer; Radiotherapy; Side effects. 
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Introduction
Biopsy verified residual prostate cancer in patients treated with endocrine therapy and 
radical external beam radiotherapy (EBRT) is a predictor of biochemical and clinical relapse 
as well as cancer related mortality (1-3). Eradication of unsuccessfully treated local tumours 
is, however, possible with cryosurgery, salvage prostatectomy or high intensity focused 
ultrasound. Although histological evaluation of posttreatment prostate biopsies is used to 
select patients for salvage therapy (4-6), there are no published reports on posttreatment 
prostate biopsy complications.  
On the other hand, hematuria, rectal bleeding and hematospermia as well as mild 
discomfort and pain are frequent and usually self-limiting side effects in diagnostic prostate 
biopsy, whereas the incidence of major bleeding, urinary retention and urinary tract infections 
is low (7-10). Antibiotic prophylaxis prevents bacteriuria following prostate biopsy and is 
commonly used (11-13). Local anaesthesia may be applied to reduce pain (14-16).  
Although prostate cancer has been treated with endocrine therapy and curative 
radiotherapy for decades, the role of EBRT was controversial until the results of the 
Scandinavian Prostate Cancer Group (SPCG) 7 study were published recently. This trial, in 
which patients with locally advanced or aggressive non-metastatic prostate cancer were 
randomised to receive either endocrine therapy alone or combined with EBRT, demonstrated 
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Materials and methods 
The SPCG-7 study inclusion criteria and study population is described previously (17).
All the 875 included patients received three months total androgen blockade (TAB) with three 
monthly injections of an LHRH agonist (Leuprorelin) combined with an antiandrogen 
(Flutamide 250 mg three times per day), followed by the same dose of antiandrogen 
continuously. EBRT to the prostate with a minimum dose of 70 Gy in 35 fractions was started 
after the three months TAB in patients randomised to combined therapy. Eleven of 47 
hospitals participated in the present side study which aimed to include all consecutive patients 
at approximately 30-42 months from randomization. Patients with World Health Organisation 
(WHO) performance status 0-1 and no medical contraindications to biopsy underwent TRUS-
guided posttreatment prostate biopsies. All patients received antibiotic prophylaxis with three 
doses of 500 mg ciprofloxacin. The first dose was taken one hour ahead of the biopsy 
procedure. The use of local anaesthesia was optional dependent on local practice. All patients 
were requested to complete a non-validated questionnaire concerning biopsy related side 
effects seven days after the biopsy procedure. 
All participants received oral and written information about the study and gave their 
written informed consent before inclusion. The study was approved by The Regional 
Committee for Medical and Health Research Ethics of Middle-Norway on the 15th of August 
2000 (ref: 112-2000) and conducted according to the Helsinki Declaration of 1975, as revised 
in 1983.
Collection of side effect data 
The intensity of biopsy related pain was graded by the patient according to the 
following verbal rating scale (19): 0-no pain; 1-slight pain (analgesics not necessary); 2-
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moderate pain (analgesics necessary); 3-severe pain. Post biopsy pain experienced during the 
seven days follow-up period was graded on an identical scale.
Experienced change in urinary flow (obstruction) in the seven days study period was 
graded on the following scale: 0-no change; 1-slightly increased obstruction; 2-severely 
increased obstruction; 3-urinary retention.
The occurrence of urinary tract infection, pyrexia and the use of antibiotics was 
recorded.  
The occurrence and duration (days) of hematuria and rectal bleeding was recorded as 
well as the experience of hematospermia.  
Furthermore, the patients were requested to record the reason for any contact with 
general practitioner or hospital, and to describe in their own words any other medical problem 
that occurred in the seven days period. 
Statistical analyses
Categorical variables were compared using Pearson’s Chi-square or Fisher’s exact tests. 
Continuous variables were compared using the Students T-test. If not normally distributed, the 
Mann Whitney U-test was used. Pain intensity was graded according to the scale used in the 
European Organization for Research and Treatment of Cancer (EORTC) QLQ-30 
questionnaire, and the recommended linear transformation into a 0-100 scale was made to 
obtain a pain score in each case (20). Furthermore, biopsy related side effects (pain, urinary 
obstruction and bleeding complications) were transformed into dichotomous variables. The 
associations between these dichotomous variables and therapy group, age at biopsy and 
number of biopsy cores taken (less than eight vs. eight or more) were first assessed in 
univariable logistic regression. Variables with a p-value of <0.1 for an association were 
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included in a multivariable logistic regression model. Odds ratio with a 95% confidence 
interval (CI) was used as effect measure.  
A two-sided p-value <0.05 was considered statistically significant. 
Results
The participating hospitals recruited 415 (47%) of the SPCG-7 trial patients of which 
120 (29%) patients accepted inclusion in the biopsy study. The 109 (91%) patients who 
returned the questionnaire constitute the study population in which the compliance to single 
questionnaire items varied from 94-100%. There were no significant differences in baseline 
characteristics at randomisation between the total SPCG-7 study population and the 109 
respondents (Table I), of whom 57 (52%) patients received endocrine therapy alone, and 52 
(48%) additional radiotherapy.
The biopsies were performed between March 2001 and October 2005 at median of 44 
months with a range of 30-97 and an inter-quartile range (IQR) of 37-60 months from start of 
treatment. A median of 8 biopsy cores (range 2-11, IQR 6-8) were obtained in both therapy 
groups. All patients received antibiotic prophylaxis, and 19% (n=21) were given periprostatic 
local anaesthesia. In the endocrine and combined therapy group, the mean age at biopsy was 
71.5 (range 56-83) years and 68.8 (range 51-80) years, respectively (difference 2.7, 95% CI 
0.45-4.91 years), p=0.019. 
  The number of biopsy cores taken and age at biopsy had no significant influence on 
the incidence of self-reported side effects. Moreover, therapy group was not associated with 
biopsy related pain, change in urinary flow, hematuria or hematospermia. The use of local 
anaesthesia had no significant impact on the incidence and intensity of pain at biopsy. 
Pain during the biopsy procedure was reported in 69 (64%) patients (Table II), and 33 
(31%) patients reported pain during follow-up (Table III). 
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Change in urinary flow was reported in 21 (20%) patients (Table IV). No patient 
reported complete urinary retention (grade 3). 
 Hematuria was reported in 26 of 56 patients (46%) in the endocrine therapy and in 18 
of 52 patients (35%) in the combined therapy group with a mean duration of 2.2 days (range 
1-7).  In one patient on combined therapy with persistent hematuria at completion of the 
questionnaire, seven days duration was recorded. 
Hematospermia was reported in two patients in each therapy group and unknown in 62 
(60%) of 108 patients.
Ten of 56 patients (18%) on endocrine therapy alone reported rectal bleeding 
compared to 18 of 52 patients (35%) on combined therapy (p=0.047, Pearson’s Chi squared 
test), whereas the mean duration in patients who bled was 1.6 days (range 1-4) and 2.2 days 
(range 1-7), respectively (p=0.031, Mann-Whitney U-test). In logistic regression analysis, a 
trend towards a significant association between combined therapy and rectal bleeding was 
found, OR 2.4 (1.0-5.9), p=0.050. 
No patient had urinary tract infection. Only the patient with grade 3 pain was admitted 
to hospital. Additionally, one patient contacted his general practitioner because of hematuria, 
and one of reasons not related to the biopsy procedure. No patient required therapeutic 
intervention due to bleeding complications in the study period. 
Discussion
The self-reported side effects were mild and self-limiting in the majority of patients 
who underwent posttreatment prostate biopsy. In accordance with reports on prostate biopsy 
side effects in previously untreated patients, the incidence of severe side effects was low, and 
not increased if more than eight biopsy cores were taken (8-10, 21).  
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This study has some limitations. Although the compliance to the side effect 
questionnaire was high (91%), the true incidence of infrequently occurring serious 
complications in patients undergoing posttreatment prostate biopsy may have been 
underestimated due to a relatively small sample-size. For instance, no patient had rectal 
bleeding that required therapy, a complication which is reported to occur in less than 1% 
following diagnostic prostate biopsy (7, 9, 10). Moreover, a comparison between pre- and 
posttreatment biopsy side effects was not planned. If patients who experienced major side 
effects of biopsy at diagnosis refused posttreatment biopsy, a selection bias is possible.  Pain 
intensity was assessed using a 4-point verbal rating scale, whereas a visual analogue or a 
numeric rating scale may have given a more reliable estimate. However, the validity of verbal 
rating scales in pain intensity assessment is well documented (19). Although the questionnaire 
assessed clinically important change in urinary flow (severe reduced flow and retention) 
subjectively, uroflowmetry was not performed, and minor changes may have been 
underestimated. Despite these limitations, the patient-reported side effects in the present study 
most likely reflect those commonly seen in clinical practice, and the respondents seems to be 
representative of the SPCG-7 study patients (Table I). 
More than 60 % of the patients reported biopsy related pain, whereas no more than 
10% required analgesics, and only one patient reported severe (grade 3) pain (Table II). The 
incidence of moderate to severe pain following diagnostic prostate biopsy is previously 
reported to be 11-30 % (7, 12, 22, 23), corresponding with the 12% incidence in the present 
study (Table 2). This study was not designed to evaluate the effect of local anaesthesia, and 
the use was infrequent and optional. Even though no significant effect on biopsy related pain 
was observed, local anaesthesia may still have been beneficial for some patients. In addition, 
the low incidence of severe pain (grade 3) may be due to a reduced sensibility as endocrine 
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therapy and radiotherapy reduce the prostate volume and cause fibrosis of the rectal wall (24-
26).
Although 20% of the patients reported decreased urinary flow (Table III), no patient 
reported urinary retention. These findings do not differ from those reported in patients 
undergoing diagnostic prostate biopsy, with a 0.7-1.6 % reported incidence of post biopsy 
urinary retention (7, 9, 10, 12, 13). 
 Corresponding with the results of the present study, the incidence of minor 
hematuria and rectal bleeding related to prostate biopsy in previously untreated patients is
reported to be 14 -74 % and 2-40%, respectively (7-9, 12, 13). Although therapy induced 
prostate gland shrinkage and fibrosis may theoretically decrease the risk of prostate bleeding 
as compared to pretreatment biopsy, late radiation toxicity may lead to proctitis with 
ulceration and bleeding and thus a more vulnerable rectal mucosa (27, 28). Our study showed 
a trend towards an increased risk of rectal bleeding in patients treated with radiotherapy.
Hematospermia was only reported by four patients and unknown in the majority (60%) 
even though the compliance to this questionnaire-item was high (99%). In comparison, a 10% 
incidence was reported during seven days follow-up after prostate biopsy in 1051 untreated 
patients (7). Obviously, the low incidence observed in the present study was due to a low 
degree of sexual activity in our senior study population on prostate cancer therapy. 
Urinary tract infection which may be complicated with pyrexia and sepsis has been 
reported in 0.3-11% following diagnostic prostate biopsy, even if antibiotic prophylaxis was 
used (7-13). On the other hand, a single dose of oral ciprofloxacin is shown to prevent 
infection following prostate biopsy in a randomised placebo controlled trial (11), and orally 
administered ciprofloxacin concentrates in the prostatic tissue (29). In this study, all patients 
received antibiotic prophylaxis with Ciprofloxacin, and clinically urinary tract infections were 
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not observed. Based on this result, two to three doses of ciprofloxacin, starting one hour prior 
to posttreatment biopsy, seems to be a safe regime for prevention of urinary tract infection.
 Notwithstanding that the results of small sample-size studies must be interpreted 
with care, our main conclusion is that post treatment prostate biopsy can be performed safely 
with a low risk of major complications. Patients who receive combined endocrine therapy and 
EBRT may, however, have a modest increased risk of rectal bleeding as compared to patients 
on endocrine therapy alone. In Norway, posttreatment biopsy is mandatory to select patients 
with residual tumours who may take advantage from salvage therapy (4). To our knowledge 
this is the first study that report on side effects of this procedure, and our results may be 
helpful in patient counselling. 
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Table I. Baseline characteristics of the 875 men enrolled in the SPCG-7 study and of the 109 
patients who responded to the posttreatment prostate biopsy side effects questionnaire.
Characteristic Patients enrolled in the SPCG-
7 study 
Patients who underwent post 
treatment prostate biopsy 
Age in years, mean (SD) 65.8 (5.4) 66.1 (5.9) 
Median PSA in ng/ml (IQR) 16 (9-27) 16 (8-27) 
Tumour stage, number (%) 
T1b 3 (0.3) 0
T1c 16 (1.8) 4 (3.7) 
T2 169 (19.3) 16 (14.7) 
T3 682 (77.9) 89 (81.7) 
Unknown 5 (0.6) 0
Seminal vesicle involvement, number (%) 203 (23.2) 22 (20) 
WHO grade, number (%) 
I 131 (17) 24 (22) 
II 572 (65.4) 64 (58.7) 
III 164 (18.7) 20 (18.3) 
Unknown 8 (0.9) 1 (0.9) 
Abbreviations: SD = Standard deviation, IQR = Inter quartile range, PSA = Prostate specific antigen 
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Table II. Intensity of pain during the post-treatment biopsy procedure reported by 108 prostate 
cancer treated patients treated with either endocrine therapy alone or combined with external 
beam radiotherapy. Except for mean score, the figures shown represent number of patients 
with percentages in parenthesis. 
Therapy
Pain (grade¹) reported at 
biopsy
Endocrine therapy alone 
n = 57²
Combined therapy 
n = 51³
0 23 (40) 16 (31) 
1 32 (56) 30 (59) 
2 2 (4) 4 (8) 
3 0 1 (2)
Mean score (SD) 21.1 (18.5) 26.8 (22.1) 
¹ 0: No pain, 1: Slight pain, 2: Moderate pain, 3: Severe pain. ²11 patients (19%) received 
local anaesthesia. ³10 patients (20%) received local anaesthesia. Abbreviation: SD = standard 
deviation
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Table III. Intensity of pain during 7 days follow-up after post-treatment biopsy procedure 
reported in 106 patients with locally advanced prostate cancer treated with either endocrine 
therapy alone or combined with external beam radiotherapy. Except for mean score, the the 
figures shown represent number of patients with percentages in parenthesis. 
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Table IV. 
Subjective change in urinary flow during seven days follow-up after post-treatment biopsy in 
103 patients with locally advanced prostate cancer treated with either endocrine therapy alone 
or combined with external beam radiotherapy. The figures shown represent number of 
patients with percentages in parenthesis. 
Therapy
Subjective change (grade¹) 
in urinary flow 
Endocrine therapy
n = 54 
Combined therapy  
n = 49 
0 44 (81) 38 (78) 
1 11 (19) 9 (18) 
2 0 2 (4)
3 0 0
¹0: No change, 1: Slightly increased obstruction, 2: Severely increased obstruction, 3: Urinary 
retention 
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Grading of physician-assessed side effects in study 2 
Items Grading scale 
0 1 2 3 4 5
Pain intensity None Mild Moderate Severe Intolerable
Use of 
analgesics 
None Non-opioids 
occationally
Non-opioids 
regularly 
Opioids 
occationally
Opioids 
regularly 
100% increased 
opioid dose or 
epidural
administration 
Nausea/vomiting  None Nausea Transient 
vomiting 
Vomiting 
requiring
therapy 
Intractable 
vomiting 
Hot flushes None 1-3 times per 
day
4-10 times per 
day
>10 times per 
day
Daytime urinary 
frequency¹  
<5 6-8 9-12 >12
Nighttime 
urinary 
frequency¹ 
0-1 2 3 >4
Urinary 
incontinence¹ 
None Slight, do not 
use diper 
Moderate, use 
diper
Total 
incontinence
Macroscopic 
haematuria¹ 
No Yes
Urinary 
urgency¹ 
No Yes
Uretral 
stricture¹,²
No Yes
Bladder
obstruction¹ 
No Yes
Diarrhoea None <2/day >2/day Requiering 
therapy 
Haemorrhagic, 
dehydration
Other intestinal 
symptoms
None Increased 
frequency or 
rectal
discomfort not 
requiring
therapy.  
Sometimes 
mucus and/or 
blood
Diarrhoea (>5 
stools/day) 
requiring
parasymptholytic 
drugs. 
Sometimes 
medication with 
Imodium or 
Pred-clysma
Problems in 
daily routines. 
Continued 
medication with 
Imodium or 
repeated
Cortison 
treatments
More extensive 
bleedings 
necessitating
investigation or 
transfusions 
Problems 
demanding
surgical 
intervention (for 
example
colostomy, 
perforation,
fistula) 
Erection Normal Not enough for 
intercourse
None 
Sexual activity Last week Last month Last year Not last year 
¹During the last two weeks. ²Evaluated with cystoscopy. 
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